













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 




Investigation of the role of hepatic 




















Submitted for the degree of Doctor of Philosophy 




Declaration of Authorship 
 
I declare that the work presented within this thesis was carried out by myself 
during the course of my PhD. It has not been submitted for any other degree or 
qualification. Where I have included the work of others, the sources of 
















     
Declaration of Authorship ....................................................................................... 2 
List of Figures ......................................................................................................... 6 
Acknowledgements .................................................................................................. 9 
Abstract ................................................................................................................... 10 
Lay summary .......................................................................................................... 11 
Publications and presentations arising from this thesis .................................... 13 
Abbreviations .......................................................................................................... 14 
Chapter 1: Introduction .......................................................................................... 18 
1.1 Clinical consequences of hepatic fibrosis: chronic liver disease .................... 18 
1.2 Clinical consequences of fibrosis: hepatocellular carcinoma ......................... 20 
1.3 Acute liver failure: clinical perspective ............................................................ 24 
Chapter 2: Hepatocellular carcinoma and hepatic stellate cells ........................ 31 
2.1.1 The role of the microenvironment in HCC ................................................. 31 
2.1.2 HSC, the extracellular matrix and myofibroblast phenotype in fibrosis ........ 32 
2.1.3 The role of HSC in HCC .............................................................................. 33 
2.2 Modelling HCC ............................................................................................... 46 
2.3 Hypothesis and aims .................................................................................... 46 
2.4 Characterisation of HSC infiltration and collagen deposition in HCC .......... 47 
2.4.1 Materials and methods ................................................................................ 47 
2.4.2 General immunohistochemistry protocol with formalin-fixed, paraffin-
embedded sections .............................................................................................. 47 
Immunohistochemistry on human and mouse HCC specimens ........................... 48 
2.4.3 Microscopy and digital image analysis ........................................................ 48 
2.5 HSC infiltration and collagen deposition in human HCC .............................. 50 
2.6 Discussion ...................................................................................................... 52 
Chapter 3: The role of αv integrins during hepatocarcinogenesis .................... 55 
3.1 The integrin family and TGF-β signalling ........................................................ 55 
3.2 Targeted αv integrin depletion on HSC in HCC .............................................. 62 
3.3 Hypothesis and aims ...................................................................................... 66 
3.4 DEN model of murine hepatocarcinogenesis ................................................. 66 
3.5 Targeted αv integrin depletion on HSC in a mouse model of HCC ................ 69 
3.6 Targeted αv integrin depletion on hepatocytes in HCC .................................. 71 
3.7 Discussion ...................................................................................................... 73 
Chapter 4: HSC and acute liver injury .................................................................. 77 
 
4 
4.1 Introduction ..................................................................................................... 77 
4.2.1 Modelling acute liver injury .......................................................................... 81 
4.2.2 Paracetamol model of acute liver injury ....................................................... 81 
4.2.3 FAS model ................................................................................................... 83 
4.2.4 Acute carbon tetrachloride ........................................................................... 84 
4.3 Hypothesis ...................................................................................................... 84 
4.4 Aims ................................................................................................................ 84 
4.5 Materials and methods ................................................................................... 84 
4.6 Targeted αv integrin depletion on HSC in a mouse model of paracetamol-
induced acute liver injury ...................................................................................... 92 
4.7 Pharmacological αv integrin blockade in a mouse model of paracetamol-
induced acute liver injury ...................................................................................... 97 
4.8 Targeted αv integrin depletion on hepatocytes in a mouse model of 
paracetamol-induced acute liver injury ................................................................. 98 
4.9 Targeted β8 integrin depletion on HSC in a mouse model of paracetamol-
induced acute liver injury .................................................................................... 100 
4.10 Targeted β8 integrin depletion on hepatocytes in a mouse model of 
paracetamol-induced acute liver injury ............................................................... 100 
4.11 Targeted αv integrin depletion on LSEC in a mouse model of paracetamol-
induced acute liver injury .................................................................................... 105 
4.12 Summary of Chapter 4 acute liver injury experiments ................................ 107 
4.13 Discussion .................................................................................................. 108 
Chapter 5: Intravital imaging of the liver ............................................................ 111 
5.1.1 Intravital microscopy: excitation fluorescence and label-free techniques .. 111 
5.1.2 Development of IVM of the liver ................................................................ 118 
5.1.3 Application of IVM to the study of liver injury, carcinogenesis and repair .. 118 
5.2 Hypothesis and aims .................................................................................... 132 
5.3 Methods ........................................................................................................ 133 
5.4 Results .......................................................................................................... 141 
5.5 Discussion .................................................................................................... 163 
Chapter 6: Intravital imaging of paracetamol-induced acute liver injury ........ 166 
6.1 Introduction ................................................................................................... 166 
6.3 Materials and methods ................................................................................. 166 
6.3 Characterisation of injury and inflammatory infiltrate following paracetamol 
administration, with and without abdominal window ........................................... 170 
 
5 
6.4 Characterisation of quiescent and activated HSC and neutrophil infiltrate 
following paracetamol-induced acute liver injury in animals with an AIW, and non-
operated controls ................................................................................................ 174 
6.5 Sequential daily imaging of paracetamol-induced acute liver injury ............. 177 
6.6 Discussion ...................................................................................................... 186 
Final discussion ................................................................................................... 188 
This research project began with an investigation into the role of αv integrins in a 
mouse model of HCC. It is proposed that loss of αv integrins on HSC or hepatocytes 
does not affect hepatocarcinogenesis in the DEN mouse model of HCC. This was an 
unexpected finding, but perhaps reflects the complexity of TGF-β effects in 
tumourigenesis. Evaluation in a cirrhotic model of HCC would complement these 
experiments. ........................................................................................................... 188 





List of Figures 
Chapter 2 
Figure 2.1 Crosstalk between HSC and HCC          41 
Figure 2.2 Therapeutic approaches to targeting HSC         45 
Figure 2.3 HSC infiltration and collagen deposition in human HCC        50 
 
Chapter 3 
Figure 3.1 The integrin family of cell adhesion molecules         56 
Figure 3.2 TGF-β activation by αv integrins           56 
Figure 3.3 Schematic diagram of cell-specific Cre-recombinase        64 
Figure 3.4 Induction of hepatocarcinogenesis: DEN injection        67 
Figure 3.5 Confirmation of αv integrin loss           68 
Figure 3.6 Targeted αv integrin depletion on HSC during hepatocarcinogenesis         70 
Figure 3.7 Targeted αv integrin depletion on hepatocytes during  
hepatocarcinogenesis              72 
 
Chapter 4 
Figure 4.1 Paracetamol metabolism            88 
Figure 4.2 Paracetamol administration and harvesting protocol        89 
Figure 4.3 CWHM 12 simulated plasma concentrations (uM)        90 
Figure 4.4 CWHM 12 simulated plasma concentrations after repeated injections  
(uM)                           91
    
Figure 4.5 Targeted αv integrin depletion on HSC during paracetamol-induced acute 
liver injury (1)               93 
Figure 4.6 Targeted αv integrin depletion on HSC during paracetamol-induced acute liver 
injury (2)               94 
Figure 4.7 Targeted αv integrin depletion on HSC during paracetamol-induced acute liver 
injury (3)               96 
Figure 4.8 Small molecule inhibition of αv integrins during paracetamol-induced acute 
liver injury               97 
Figure 4.9 Targeted αv integrin depletion on hepatocytes during paracetamol-induced 
acute liver injury              99 
Figure 4.10 Targeted β8 integrin depletion on HSC during paracetamol-induced acute 
liver injury             101 
 
7 
Figure 4.11 Targeted β8 integrin depletion on HSC during paracetamol-induced acute 
liver injury (2)             102 
Figure 4.12 Confirmation of β8 integrin loss on hepatocytes      103 
Figure 4.13 Targeted β8 integrin depletion on hepatocytes during paracetamol-induced 
acute liver injury             104 
Figure 4.14 Targeted αv integrin loss on LSEC during paracetamol-induced acute liver 
injury              106 
 
Chapter 5 
Figure 5.1 Jablonski diagram                      112 
Figure 5.2 Principles of confocal and two-photon microscopy      113 
Figure 5.3 CARS energy diagram          117 
Figure 5.4 Abdominal imaging windows         135 
Figure 5.5 Abdominal imaging windows surgical technique       138 
Figure 5.6 Multiphoton microscope and IVM equipment       140 
Figure 5.7 Uninjured PDGFRβCre+/-;mTmG liver ex vivo       142 
Figure 5.8 Timelapse IVM of uninjured PDGFRβCre+/-;mTmG      144 
Figure 5.9 CCL4–injured PDGFRβCre+/-;mTmG ex vivo       145 
Figure 5.10 Intravital imaging of CCL4-injured PDGFRβCre+/-;mTmG mice     146 
Figure 5.11 Jo-2 antibody-injured PDGFRβCre+/-;mTmG liver ex vivo     148 
Figure 5.12 Timelapse IVM of Jo-2 antibody-injured PDGFRβCre+/-;mTmG liver       150 
Figure 5.13 PDGFRβCre+/-;Ai14 liver ex vivo        152 
Figure 5.14 IVM of PDGFRβCre+/-;Ai14 mouse under terminal anaesthesia    153 
Figure 5.15 IVM of uninjured PDGFRβCre+/-;Ai14 liver capsule      154 
Figure 5.16 IVM of Jo-2 antibody-injured PDGFRβCre+/-;Ai14 liver      155 
Figure 5.17 Serial imaging of CCL4-injured MacGreen liver       157 
Figure 5.18 MP microscopy of DEN-induced HCC ex vivo       159 
Figure 5.19 IVM of DEN-induced HCC under terminal anaesthesia                 161 
 
Chapter 6 
Figure 6.1 Schematic of AIW implantation, paracetamol administration, and sequential 
imaging             168 
Figure 6.2 Paracetamol-induced acute liver injury with and without an AIW in situ    170 
Figure 6.3 The hepatic regenerative response following paracetamol-induced acute liver 
injury, with and without an AIW in situ         172 
 
8 
Figure 6.4 PDGFRβ staining positivity following paracetamol-induced acute liver injury, 
with and without an AIW in situ          174 
Figure 6.5 GR1 staining positivity following paracetamol-induced acute liver injury, with 
and without an AIW in situ           175 
Figure 6.6 Paracetamol-injured and uninjured Cdh5Cre+/-;Ai14 liver ex vivo    177 
Figure 6.7 Serial IVM of Cdh5Cre+/-;Ai14 mouse at baseline and 24 hours post-
paracetamol, under anaesthesia          178 
Figure 6.8 Timelapse IVM of Cdh5Cre+/-;Ai14 mouse 24 hours post-paracetamol    180 
Figure 6.9 Serial IVM of Cdh5+/-Ai14;PDGFRβ-BAC-eGFP mouse, performed under 
anaesthesia, before and after paracetamol-induced acute liver injury     182 
Figure 6.10 Serial IVM of Cdh5+/-;mTmG mouse, under anaesthesia, following 
paracetamol-induced acute liver injury         184 
 
List of Tables 
Table 1 Summary of antibodies used            48 
Table 2 Effects of αv integrin inhibition in pre-clinical models of fibrosis       60 
Table 3 Cre drivers that may be used to target HSC/myofibroblasts        65 







I would like to thank the many people who have contributed to the work presented in this 
thesis. Firstly, I would like to thank my principal supervisor, Neil Henderson, for endless 
support, encouragement and mentorship. I would also like to thank John Iredale, for 
academic mentorship and his assistance in securing a CRUK Clinical Research Training 
Fellowship.  
Special thanks are due to Kylie Conroy, who was tirelessly patient with me in teaching 
laboratory techniques, and who, together with Stephen Greenhalgh, worked closely with 
me on developing the intravital imaging parts of the project. Thanks are also due to Mhairi 
Donnelly, who contributed to immunohistochemistry, and to the other members of the 
Henderson group, who always offered help and advice, and have been a pleasure to 
work with.  
Dr Timothy Kendall kindly provided help with histological identification of hepatocellular 
carcinoma, and image analysis. Furthermore, Rebecca Aucott helped with learning 
immunohistochemistry and was extremely supportive throughout my PhD, in her role as 
laboratory manager.  
I would also like to thank David Griggs, one of our US collaborators, who provided 
compound CWHM12 for integrin inhibitor experiments, and assisted with 
pharmacokinetic modelling.  
I am heavily indebted to our CRUK collaborators Martin Lee and Alan Serrels, whose 
expertise with intravital imaging and the custom-built multiphoton microscope was 
invaluable. Similarly, I would like to thank Margaret Frame, David Cameron, and CRUK 
for funding my research.  
I wish to express my gratitude to all the technicians in the animal units, and specifically 
to Jon Henderson, who is an enormous asset to the Henderson group, and whose 
kindness, diligence and meticulous colony management was immensely appreciated. 
Thanks also to Ken Simpson, for managing the Project Licence, and for offering welcome 
advice regarding paracetamol experiments.  
 
Finally, I would like to thank my gastroenterology colleagues, friends, family, and 






Introduction: Hepatic stellate cells (HSC) and myofibroblasts may be relevant stromal 
drivers of human hepatocellular carcinoma (HCC). It was hypothesised that targeted 
inhibition of αv integrin-mediated TGF-β activation, by HSC or hepatocytes, may result 
in reduced peri-tumoural and intra-tumoural extracellular matrix formation, and reduced 
hepatic carcinogenesis.  
The role of HSC in acute liver injury is less well characterised. It was anticipated that 
integrin signalling on HSC and hepatocytes might also be relevant in the acute setting.  
The emerging technique of intravital microscopy (IVM) allows detailed, real-time 
investigation of the cellular processes involved in hepatocyte injury, cell death and repair. 
It was hypothesised that this could be coupled with mouse models of HCC and acute 
liver injury, to perform sequential imaging under anaesthesia.  
Aims: (i) To determine the effect of targeted inhibition of αv integrins on HSC and 
hepatocytes, during hepatocarcinogenesis, in a mouse model of HCC. (ii) To investigate 
the effect of targeted inhibition of αv and other integrins on HSC, hepatocytes, and liver 
sinusoidal endothelial cells (LSEC), during acute liver injury, in the mouse model of 
paracetamol-induced liver injury. (iii) To develop IVM of the liver, via an abdominal 
imaging window, with optimisation of surgical and imaging techniques, to allow 
sequential imaging of the same animal.  
Methods: The diethylnitrosamine (DEN)-induced mouse model of hepatocarcinogenesis 
was used, and PDGFRβ-Cre;αvfl/fl and Alb-Cre;αvfl/fl mice were employed to deplete αv 
integrins on HSC and hepatocytes respectively. Tumours were harvested at 40 weeks 
post-DEN. Tumour size and number was evaluated in all animals.  
PDGFRβ-Cre;αvfl/fl and Alb-Cre;αvfl/fl mice were used in the paracetamol model, to 
investigate the role of αv integrins in acute liver injury. PDGFRβ-Cre;β8fl/fl and Alb-Cre;β
8fl/fl animals were also tested in this model. The role of integrins in liver sinusoidal 
endothelial cells (LSEC) during paracetamol-induced liver injury was evaluated using 
Cdh5-Cre mice.  
IVM of the liver was performed by surgical implantation of an abdominal imaging window, 
consisting of a titanium ring and coverslip, secured in place with a purse string suture. 
Fluorescent reporter mice were used to identify hepatic and vascular architecture, and 
other label-free microscope technologies were utilised to image collagen, lipid 
distribution, necrotic areas and blood flow within tissues. 
Results: In large cohorts of PDGFRβ-Cre;αvfl/fl, Alb-Cre;αvfl/fl, and control animals, there 
was no difference in mean tumour size or number, at 40 weeks. Targeted inhibition of α
v integrins and β 8 integrin on hepatocytes, HSC or LSEC was not protective in 
paracetamol-induced liver injury. 
IVM of the liver can be performed on animals with HCC and throughout paracetamol-
induced liver injury, to obtain high quality, real-time images of multiple cell lineages and 
the hepatic microenvironment. 
Conclusions: The role of TGF-β in HCC pathogenesis is complex and context-
dependent. Targeted loss of αv integrin did not result in reduction in tumour burden in 
this non-cirrhotic model of HCC. IVM of the liver is a powerful tool to quantify 
inflammatory infiltrates and assessment of vascular remodelling throughout the course 
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of acute liver injury and regeneration, providing insights into the biological processes 
determining recovery. 
Lay summary  
Cancer of the liver (hepatocellular carcinoma) is the commonest cause of death in 
patients with chronic scarring of the liver (cirrhosis). Over 90% of liver tumours arise in a 
scarred or ‘fibrotic’ liver, and to date there are no effective anti-fibrotic treatments to halt 
the development of cirrhosis. Furthermore, chemotherapy options for hepatocellular 
carcinoma (HCC) are limited. Only one, sorafenib, is currently licensed for advanced 
HCC, and this provides at best a modest survival benefit. Many new chemotherapy 
agents have been tested in patients with HCC, but have not been proven to improve 
outcome. This may partly be due to the fact that the liver tissue surrounding the tumour 
is abnormal and scarred; signals from this cirrhotic environment may act to support the 
growth of cancer cells.  
The hepatic stellate cell is the major source of scarring proteins during liver injury and 
fibrosis. The integrin family of receptors are present on these cells, and form an important 
link between cells and their surrounding environment, as well as playing a role in 
signalling during scar formation. Using a mouse model of liver cancer, I have investigated 
the effect of removing an integrin protein (αv integrin) on stellate cells, and hepatocytes, 
to see if this protects against cancer formation.  
Acute liver failure is another life-threatening condition, and paracetamol poisoning is the 
main cause in the UK and US. Although there is an antidote available, this is not sufficient 
to cure all cases, and deaths still occur. Although liver transplant is effective for severe 
liver failure, this is a limited resource; furthermore around half of patients meeting 
transplant criteria will have psychiatric or medical contraindications to this treatment. As 
such, there is a pressing need for alternative treatments for paracetamol-induced acute 
liver failure.  
I have therefore investigated the effect of loss of different integrin proteins in a mouse 
model of paracetamol-induced acute liver failure. I have also developed a new way to 
study liver injury and repair, in this model. Other groups have previously shown that the 
liver can be imaged in live mice, by surgically placing a titanium window in the abdomen, 
with a glass coverslip, and secured in place with a suture. Using a microscope with 
powerful lasers, the animal can then be imaged under general anaesthetic. I have 
developed this technique in our laboratory, and modified and optimised surgical 
protocols. I have been able to image the same mouse over several days, allowing 
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assessment of biological processes occurring throughout the course of liver injury and 
regeneration.  
To our knowledge, this technique has not been performed before in mice with liver cancer 
or paracetamol-induced liver failure. The use of genetically modified mice, which express 
different fluorescent proteins to colour specific cell types (such as stellate cells and 
hepatocytes) has been coupled with microscope techniques to image liver scarring and 
blood flow, to obtain a large amount of information from one animal, in real-time. It is 
hoped that this will allow further experiments to investigate the biological processes 
governing recovery from acute liver injury, and potentially identify new targets for 
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Chapter 1: Introduction 
1.1 Clinical consequences of hepatic fibrosis: chronic liver disease  
Cirrhosis of the liver develops as a consequence of progressive tissue fibrosis. This is a 
wound-healing response, arising from chronic inflammation due to sustained or repeated 
liver injury. Histologically, cirrhosis is defined as advanced liver fibrosis with diffuse 
nodular regeneration, causing marked distortion of hepatic vascular architecture.1 Dense 
fibrotic septae link central veins and portal tracts. This creates a direct anastomosis 
between portal vessels and central veins, allowing shunting of blood. The resistance to 
portal blood flow leads to portal hypertension and hepatic synthetic dysfunction.2 This 
can manifest clinically with decompensating events such as abdominal ascites, hepatic 
encephalopathy, variceal haemorrhage, and hepatorenal syndrome. Furthermore, 
chronic liver disease is the major risk factor for development of hepatocellular carcinoma 
(HCC). These complications account for much of the morbidity and mortality attributable 
to cirrhosis, with HCC representing the commonest cause of death in these patients.  
Cirrhosis is an increasing problem, particularly in developed countries. It is the 14th 
commonest cause of death in adults worldwide but the fourth commonest in central 
Europe.2 It is responsible for 1.03 million deaths per year worldwide,3 and is the indication 
for 5500 orthotopic liver transplants each year in Europe.4 The aetiology of cirrhosis 
varies geographically. In sub-Saharan Africa and most parts of Asia chronic hepatitis B 
virus (HBV) infection is the commonest cause, whereas in more developed countries, 
hepatitis C virus (HCV) infection, alcohol misuse and, increasingly, non-alcoholic liver 
disease predominate.  
In the UK, deaths from liver disease have increased fourfold between 1980 and 2013. 
This has been largely attributed to increasing alcohol consumption. In contrast to 
improvements in health and life expectancy observed over the past 30 years for other 
chronic disorders such as stroke, heart disease, and many cancers, there is a highly 
conspicuous lack of progress in liver disease. Whilst alcohol misuse is a critical factor, 
there is growing concern for the long-term consequences of obesity. At present, 25% of 
the UK population are categorized as  ‘obese’. Most of these will have non-alcoholic fatty 
liver disease, and up to one in 20 of the UK population will have persistent inflammation 
and scarring, ultimately leading to cirrhosis. Whilst effective treatments for viral hepatitis 
have been developed, there are still substantial pools of people infected with HBV or 
HCV that remain unrecognized, and dissemination of treatment is a challenge. It is 
projected that the prevalence of end-stage liver disease from HCV infection will continue 




The hepatic myofibroblast in liver fibrosis  
The perisinusoidal hepatic stellate cell (HSC) is a key effector of fibrogenesis.6 HSC are 
mesenchymal cells, located in the space of Disse between specialized hepatic sinusoidal 
endothelium and hepatocytes. These cells are characterized by their cytoplasmic 
storage of vitamin A (retinoid) droplets. In acute and chronic tissue injury, HSC shed their 
retinoid and lipid droplets, transforming to an activated, myofibroblast-like phenotype. 
This state is typified by expression of collagen I and alpha smooth muscle actin (α-SMA). 
The extracellular matrix-secreting phenotype also results in production of fibrillar 
collagen, elastin and fibrotic matrix deposition.7-10 The specific origin of these cells has 
previously been a source of controversy. Portal myofibroblasts, circulating fibrocytes and 
mesenchymal stem cells, as well as peritoneal mesoepithelial cells can all give rise to a 
myofibroblast population.6,11-16 However, the relative contribution of each lineage is not 
entirely clear. It is likely that the cellular origin is related to the site and duration of injury; 
Iwaisako et al performed fate-mapping experiments to show that chronic hepatotoxic 
(CCL4-induced) injury preferentially activated HSC to myofibroblasts, whereas bile duct 
ligation (BDL) injury activated portal fibrobasts to this phenotype.17 However, evidence 
suggests that HSC remain the predominant source of hepatic myofibroblasts; in 
Iwaisako’s study, HSC contributed significantly to the myofibroblast population at later 
stages in the BDL model.17 
Critical stimuli to HSC activation include transforming growth factor β1 (TGF-β1) which 
promotes a fibrogenic collagen-secreting phenotype, and PDGF stimulation, which 
promotes a proliferative phenotype.18,19 HSC are also extremely sensitive to the 
extracellular components they are in direct physical contact with, which allows matrix 
elements to profoundly affect their behavior.20 HSC activation is accompanied by 
upregulation in expression of tissue inhibitors of metalloproteinases (TIMPs), 
chemotactic and vasoactive factors. 21-23 The accumulation of the fibrotic scar requires 
both increased matrix deposition and a simultaneous reduction in matrix degradation. 
The major secreted TIMP, TIMP-1 inhibits the matrix degrading activities of a wide variety 




Reversibility of fibrosis 
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It is increasingly recognized that hepatic fibrosis is a reversible process, after removal of 
the causative agent. This has been observed in both clinical practice and experimental 
fibrosis models induced by alcohol, CCL4 and BDL.24-27 Resolution of fibrosis is 
accompanied by senescence and apoptosis of myofibroblasts.25,28 Myofibroblast 
apoptosis simultaneously removes a critical source of extracellular matrix deposition, as 
well as TIMP production, thereby reverting the balance to favour matrix degradation.   
Loss of signalling from fibrogenic cytokines can lead to HSC senescence and death 
receptor mediated cell death.27 Reduction in fibrogenic signals or antiviral drug therapy 
can result in caspase 8/caspase3-dependent apoptosis of HSC, via increased HSC 
expression of Fas receptor, tumour necrosis factor (TNF) receptor 1 and their ligands. 
Caspase-9-mediated programmed cell death is also possible, via overexpression of pro-
apoptotic proteins including p53, Bax and Bcl-2.24 Furthermore, natural killer cells and 
liver specific T cells are involved in resolution of fibrosis. These cells are activated by 
interferon-γ (IFN-γ) to induce rapid killing of HSC.27 Additionally, myofibroblasts can 
regress to an inactive phenotype during resolution.29,30  
Despite extensive human and animal examples of regression of fibrosis, it is clear that 
there are some irreversible components of progressive chronic injury. The development 
of septal fibrosis, for example, is thought to be a factor in defining the extent to which 
fibrosis is reversible.31 Whilst significant remodelling (and therefore functional 
improvement) can occur in the context of cirrhosis if the injuring agent is removed, 
complete regression of all the anatomic features (such as pathological vascular shunts 
in portal-central septae) is unlikely to occur.31 In clinical practice, this has implications for 
long-term management of the potential complications of cirrhosis, in particular ongoing 
HCC risk.  
1.2 Clinical consequences of fibrosis: hepatocellular carcinoma 
HCC is the second leading cause of cancer-mortality, and was responsible for more 
nearly 746 000 deaths in 2012.32 Again, chronic hepatitis B virus infection remains the 
major risk factor globally, with 80% of cases occurring in eastern Asia and sub-Saharan 
Africa. In most countries, the mortality rate of HCC approximates the incidence, which is 
increasing.33-35 This partly due to the rising prevalence of advanced fatty liver disease 
and chronic hepatitis C, alongside other risk factors such as hepatitis B infection and 
alcohol-related cirrhosis. Some progress has been made with prevention, for example 
emerging antiviral agents and vaccination for hepatitis B. However, the vast majority of 
HCC cases are associated with fibrosis, and 90% of tumours develop in cirrhotic 
livers.33,34,36-39 Furthermore, liver disease severity markers correlate with tumour 
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formation. Currently there are no effective anti-fibrotic therapies available to halt the 
fibrosis-cirrhosis-HCC continuum. In the last twenty years, diabetes and obesity have 
emerged as significant risk factors for non-alcoholic fatty liver disease/non-alcoholic 
steatohepatitis. These conditions also confer increased risk of HCC, which typically is 
not universally associated with cirrhosis.40 This has implications for the future; whilst the 
advent of directly-acting antiviral treatments for hepatitis C is expected to significantly 
reduce HCC incidence in HCV-infected patients,41 conversely, metabolic risk factors are 
projected to increase, likely with an accompanying propensity to HCC.  
Patients who present with early disease may benefit from resection, transplantation or 
loco-regional therapy (radiofrequency ablation or transcatheter arterial 
chemoembolization). At present, the Barcelona Clinic Liver Cancer (BCLC) staging 
system is the most widely used prognostic scoring system for HCC, having been 
externally validated and updated.42,43 It is hoped that this system could be refined in 
future, by the incorporation of tumour marker and genetic expression profile information. 
At presentation, one third of patients are eligible for potentially curative therapies, and 
these can extend median survival times beyond 60 months.44 However, many are 
unsuitable for curative treatment due to advanced malignancy, or the severity of co-
existing liver disease. The multi-tyrosine kinase inhibitor sorafenib is the only available 
systemic chemotherapy agent with proven survival benefit for advanced stage HCC. 
However, it confers at best a modest overall survival benefit (from a median of eight 
months to eleven months) and its use is limited to those with well-preserved liver 
function.33 Whilst there is scope to optimize our use of existing treatments, for example 
by targeting tumours earlier and combining local and systemic approaches, efforts to 
broaden our chemotherapy armamentarium have been disappointing. Numerous 
molecular therapies with robust preclinical evidence for efficacy have failed to show 
benefit in clinical trials. This may in part reflect the abnormal tumour microenvironment, 
which acts to support the persistence and growth of cancer cells, and has resulted in the 
peri-tumoural stroma and its cellular inhabitants becoming an intense area of study in 




Advances in targeted therapies for HCC 
Over the past decade, genomics-based analyses of patients with HCC have identified 
subclasses of the disease, with respect to shared molecular features. This has allowed 
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an initial classification of tumours based on proliferative and non-proliferative 
genotypes.45-48 Each of these groups represents approximately 50% of patients.44 The 
proliferative subclass is characterized by activation of classic RAS, mTOR and/or insulin-
like growth factor (IGF) signalling. It is associated with poor outcome in comparison to 
the non-proliferative phenotypes.44,46-49 The proliferative subclass is subdivided into two 
more phenotypic groups, namely the Wnt/TGF-β group, which demonstrates activation 
of these pathways, and the progenitor-cell group. The progenitor cell group is in general 
more heterogeneous, but is characterized by expression of progenitor cell, epithelial cell 
adhesion molecule and keratin, and type I cytoskeletal 19 markers. These tumours tend 
to overexpress α-fetoprotein at early stages.44 However, at present, there is no definitive 
consensus as to whether a specific molecular subclass clearly determines patient 
outcome. It is also difficult to design adequately powered clinical trials to study a single 
molecular subclass. It is currently unclear, for example, whether patients with HCC 
exhibiting features of the Wnt/TGF-β subclass would respond to treatment with TGF-β 
inhibitors.44 Due to the challenges of investigating a single molecular subclass, interest 
has focused on whether gene prognostic signatures could be a better predictor of patient 
outcomes. These gene-expression signatures are defined by combinations of genes, 
that together, when dysregulated, correlate with prognosis.50 Although up to 30 
signatures from either the tumour or adjacent nontumour tissues could be prognostic 
indicators of HCC outcomes, the validation process needed before these can be 
incorporated into HCC treatment guidelines is extremely rigorous. Therefore, to date, 
only several have been identified for possible translation into clinical practice.44   
In general terms, survival benefits from molecular targeted therapies might be derived 
from two distinct approaches. One strategy might be to treat all patients with very 
effective and multi-targeted therapies with acceptable toxicity (such as sorafenib) or a 
broad mechanism of action (e.g. immune therapies). Another approach might be to target 
a specific sub-group of patients, who have tumours that depend on a specific molecular 
pathway to survive and grow. However, treatment with highly selective agents might be 
limited by factors such as tumour heterogeneity, cell plasticity and potential escape 
pathways.44  
Deep-genome sequencing of HCC samples has provided insights into the mutational 
profile of this tumour, identifying on average 30-40 mutations per tumour, of which 5-8 
might be driver mutations.44 Subsequent functional classification of mutated genes has 
allowed the identification of key carcinogenic signalling pathways, including the Wnt/β-
catenin pathway, chromatin remodelling, oxidative stress, and signalling involving 
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epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth 
factor (FGF), vascular endothelial growth factor (VEGF), and IGF, and intracellular 
mediators like RAS/RAF/MAPK and PI3K/AKT.51,52 Pharmacologic agents are currently 
in development to try to target these processes. Over the last ten years, clinical trials 
testing chemotherapeutic drugs for HCC have yielded little more than a survival benefit 
for sorafenib. These trials have been reviewed in depth by Llovet et al, and the authors 
have commented on some lessons from the results.44 For example, it is acknowledged 
that severity of liver disease is a potentially confounding factor, and that stratification for 
specific HCC progression end points, such as portal vein invasion and metastases must 
be considered. Furthermore, identification of accurate biomarkers of tumour response is 
highly desirable for use in future trials, so as not to miss potential benefit in subgroups 
of patients.44  
Targeted therapies for HCC have historically been focused on antiangiogenic pathways. 
However, no drug has yet been proven to demonstrate superior efficacy or non-inferiority 
to sorafenib. Advances in our knowledge of the molecular heterogeneity of this tumour 
are now being applied to the development of newer agents, which are less restricted to 
antiangiogenic effects.  
The TGF-β signalling pathway is one such example. This will be discussed in more detail 
in subsequent chapters, but part of the rationale for the development of TGF-β inhibitors 
for HCC is that such treatments may be expected to have positive effects on the cirrhotic 
liver, as well as the tumour itself. Galunisertib is a selective TGF-β tyrosine kinase 
inhibitor, and is currently being evaluated in patients with HCC and glioblastoma 
multiforme.44 It was previously shown to block tumour migration, invasion and 
angiogenesis in cell culture HCC models.53 In a randomized phase II study assessing 
two doses of galunisertib, a trend towards longer time to progression was observed in 
patients that had a greater reduction in serum α-fetoprotein and TGF-β1. Median overall 
survival was greater in those with a detectable α-fetoprotein response, compared to 
those without (21.4 months versus 6.8 months)54 highlighting the potential for activity in 
selected patient groups. Neutropenia, leukopenia and fatigue were the commonest 
adverse events. Although α-fetoprotein and TGF-β1 may be useful markers associated 
with therapeutic effects, a definite predictive marker for choosing patients that are most 
likely to benefit from galunisertib is still required, and will be pivotal to the ongoing 
development and use of this agent.44  
Other pathways of interest include FGF19/FGFR4 signalling, RAS signalling, immune 
checkpoint pathways and MET signalling.44 Going forward, HCC drug development will 
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need to encompass testing nonspecific agents (anticipated to benefit all patients) as well 
as targeted treatments (evaluated by trials designed with biomarker-based enrichment) 
expected to benefit certain subpopulations of patients. Ultimately, it is hoped that a 
personalized oncology approach might be feasible, in which molecular alterations driving 
tumour progression could be selectively targeted in a specific individual.  
1.3 Acute liver failure: clinical perspective 
Acute liver failure (ALF) is a rare, but life-threatening condition. It was originally defined 
as the development of hepatic encephalopathy and coagulopathy in the setting of an 
acute liver injury, in the absence of chronic liver disease.55 More modern definitions tend 
to quantify the interval between onset of symptoms and development of encephalopathy. 
This can help distinguish the aetiology of the liver injury, and estimate prognosis with 
supportive medical care alone.56 Hyperacute cases are usually caused by paracetamol 
toxicity or viral infection, and encephalopathy develops within a week. Subacute cases 
evolve more slowly, and may result from idiosyncratic drug-induced liver injury, 
autoimmune or indeterminate causes. These subacute cases have a worse outcome 
with medical care alone, despite typically demonstrating less dramatic coagulopathy and 
encephalopathy.56   
Current definitions of ALF are heterogeneous, and at present there is no clear 
consensus. However most studies consider an international normalized ratio >1.5 to 
represent coagulopathy and any grade of encephalopathy to represent ALF.57  
 
Aetiology of ALF 
Worldwide, ALF is more common in developing countries, where viral causes (hepatitis 
A, B and E) are the major precipitants. Conversely, drug-induced liver injury, such as 
paracetamol overdose, is the predominant cause of ALF in the developed world.56 Whilst 
emergency orthotopic liver transplantation is the mainstay of treatment for ALF with poor 
prognostic features, there are some nontransplant therapies specific to aetiology, which 
will be briefly summarized below.  
Hepatitis A and E are the main viral causes of ALF, although HBV infection is also a 
recognized cause, particularly in some Asian and Mediterranean areas. Reactivation of 
hepatitis B during immunosuppressive treatment for other conditions such as cancer or 
tuberculosis can also result in ALF. Nucleos(t)ide analogues are considered part of 
management in ALF secondary to hepatitis B infection, however evidence of efficacy is 
equivocal.57,58 According to recent data, ribavirin can be effective in acute hepatitis E 
infection.59 Rarer, viral causes of ALF include herpes simplex virus, cytomegalovirus, 
 
25
Epstein-Barr viruses and parvoviruses. IV acyclovir is indicated in cases of herpes 
simplex.60 
Drug-induced liver injury (DILI) resulting in ALF is either dose-dependent and 
predictable, such as paracetamol-induced, or idiosyncratic, probably dose-independent 
and unpredictable.56 Paracetamol-induced hepatotoxicity is treated with the antidote N-
acetylcisteine, and will be discussed in more detail in subsequent chapters. Whilst 
idiosyncratic DILI is a relatively rare cause of ALF, it carries significant morbidity and 
mortality.61 Data from the US Drug Induced Liver Injury Network indicates that 
antimicrobials and herbal or dietary supplements are the major causes of DILI.62 In a 
recent prospective study from this consortium, 899 out of a total of 1257 patients enrolled 
were considered to have probable, highly likely or definite DILI, and 10% of these died 
or underwent liver transplantation.61 In cases where drug hypersensitivity forms part of 
the clinical picture, or an autoimmune reaction to the drug is suspected, steroids may be 
employed.63  
Corticosteroids are also considered in the treatment of severe acute liver injury 
secondary to autoimmune hepatitis (AIH). There is a significant risk of septic 
complications in patients with advanced encephalopathy.57,64 However, a subset of 
patients with AIH-ALF has been shown to benefit from steroids (initial MELD score <27 
and low grade hepatic encephalopathy).65 
ALF can occur during pregnancy, due to progression of acute fatty liver of pregnancy, or 
development of the HELLP syndrome (haemolysis, elevated liver enzymes, low 
platelets). Good outcomes from ALF in this context can be achieved with early delivery 
of the fetus.66,67  
Ischaemic hepatitis is a condition observed in critically ill patients, secondary to cardiac, 
circulatory or respiratory failure. Management centres on cardiovascular support and 
resuscitation. There is some evidence that statin therapy prior to critical care admission 
may be protective, in critically ill patients with ischaemic hepatitis.68  
Wilson’s disease is a rare metabolic cause of ALF. Whilst initial treatment with 
penicillamine or trientine can be of benefit, the development of hepatic encephalopathy 
heralds extremely poor prognosis. Emergency liver transplantation is the only proven 
therapeutic option for ALF as a consequence of Wilson’s, which is otherwise universally 
fatal. 57,69 
Acute Budd-Chiari syndrome can present with ALF, and may respond to venous 
decompression via transjugular intra-hepatic portosystemic shunt or hepatic vein 
stenting.70 Other causes of ALF include neoplastic infiltration, heat-stroke and mushroom 
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ingestion. In 14-20% of patients with ALF, the cause is unidentified despite extensive 
investigations.71 These cases are often subacute in nature, and prognosis is poor without 
transplantation.56  
 
Pathophysiology of ALF and the systemic inflammatory response 
In ALF, hepatocyte cell death is associated with a systemic inflammatory response 
syndrome, triggering multiorgan failure. It is now recognized that immune dysregulation 
is likely to be a key factor in the pathogenesis of ALF, and that an individual patients’ 
outcome is probably determined by their innate immune response to liver injury, rather 
than the liver injury and hepatocyte necrosis itself.72  
The systemic inflammatory response syndrome (SIRS) in ALF comprises fever, 
tachycardia, leukocytosis and increased respiratory rate. It occurs due to both systemic 
pro-inflammatory cytokines (including TNF-α, IL-1 and IL-6) and anti-inflammatory 
cytokine release (such as IL-10). It may arise from sterile inflammation or the 
development of sepsis. Those with initial sterile inflammation are also likely to 
subsequently develop sepsis. The increased risk of infection probably relates to 
defective functioning of immune cells, particularly of the innate immune system.  
Pro-inflammatory cytokines recruit circulating neutrophils, B and T lymphocytes, and 
increase vascular permeability secondary to activation of vasoactive mediators, 
platelets, and the coagulation cascade.73 A compensatory anti-inflammatory response 
syndrome is also observed, which represents a counteractive homeostatic phenomenon, 
to try to prevent overwhelming inflammation. This is characterized by persistently 
elevated levels of IL-4, IL-10 and TGF-β, as well as defective cellular immune function.73 
Changes induced in monocyte phenotype, for example, result in deactivation of these 
cells. Not only is there an accompanying decrease in pro-inflammatory cytokine 
secretion, but IL-10 production is also increased. Eventually, the homeostatic 
compensatory inflammatory response changes into a pathological state, where there is 
excessive immunosuppression, leading to increased susceptibility to infection.73 This is 
likely to account for the late mortality in refractory septic shock.74 Other causes of innate 
immune dysfunction include changes in gut permeability, endotoxinaemia, lipoprotein 
and albumin dysfunction, and toll-like receptor (TLR) expression.72 TLR are innate 
pattern recognition receptors, present on multiple cell-types including neutrophils and 
hepatocytes. Once pathogen-associated molecular patterns bind to TLR on immune 
cells, an inflammatory response is initiated. Neutrophil TLR activation results in 
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phagocytic activity and cytokine release, but it is unclear whether this is a positive or 
detrimental event in patients with ALF.75 
Whilst acute liver injury begins with hepatocyte necrosis, the molecular mechanisms 
causing further necrosis in the absence of ongoing injury are not fully understood.72 
Activation of c-Jun N-terminal kinase (JNK) occurs after a cascade of events initiated by 
oxidative stress and production of reactive oxygen species. JNK activation results in 
mitochondrial dysfunction causing further hepatic necrosis and release of damage-
associated molecular patterns (DAMPs). These in turn activate hepatic macrophages, 
and can lead to the assembly of a cytosolic protein complex known as the 
‘inflammasome’.76 Inflammasomes sense intracellular danger signals via NOD-like 
receptors. They initiate the release of the pro-inflammatory cytokines IL-1β and IL-18 via 
caspase-1 activation. They are able to fine-tune the inflammatory response, by 
responding to low-threshold signals.76 
Specifically, the inflammasome in paracetamol-induced ALF is thought to be a critical 
part of the drug-mediated inflammation within the liver.76 Jaeschke et al described 
paracetamol-induced liver injury in terms of three key stages: initiation, amplification and 
inflammation.77 In the initiation phase, injury is triggered by production of the reactive 
metabolite N-acetyl-p-benzoquinone imine (NAPQI). Mitochondrial damage occurs 
during the amplification phase, and hepatocyte necrosis worsens. In the third 
inflammation phase, DAMPs released by dying hepatocytes activate the inflammasome. 
However the effect of this final event on the degree of hepatocyte death and overall 
outcome is controversial. It is also unclear whether paracetamol itself can directly cause 
formation of the immune cell inflammasome, or whether necrotic hepatocyte-derived 
DAMPs (such as DNA fragments, nuclear HMGB1 and heat shock proteins) are entirely 
responsible. It has been proposed that DAMPs and the inflammasome are important 
determinants of hepatic inflammation in response to paracetamol overdose, but their role 
in hepatocyte death (an early response triggered by toxic paracetamol metabolites) is 
likely to be limited.76 It remains unclear as to whether the inflammasome significantly 
affects liver regeneration in the recovery phase of paracetamol-induced acute liver injury. 
This is a key question for further research.  
 
Prediction of outcome in ALF 
In clinical practice, it is important to identify patients who will benefit most from 
emergency orthotopic liver transplantation. Candidates for transplantation should be 
selected early on in the course of liver injury, because progression of multiorgan failure 
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leads to significant deterioration. A number of different prognostic evaluation scoring 
systems have been developed to aid decision-making. The presence of encephalopathy, 
along with patient age, coagulopathy and jaundice are key indicators of poor prognosis 
without transplantation.56 The King’s College Criteria represent the most well 
characterized scoring system.78 In patients who fulfilled these criteria, a systematic 
review found that survival was found to be 24% in nontransplanted patients with 
paracetamol-induced ALF.79 This highlights the urgent unmet need for novel medical 
therapies to improve outcome. 
 
Experimental alternatives to orthotopic liver transplantation 
Orthotopic liver transplant is a limited resource, and the development of alternative 
strategies to support the failing liver has been a longstanding research aim. 
Extracorporeal liver assist devices (ECLAD) have been anticipated for many years as a 
potential bridge to temporarily replace liver function, whilst awaiting transplantation or 
liver regeneration. These remain at an experimental stage, however, with no single 
system having been proven to definitively benefit patients with ALF.56 They can be 
divided into biological or non-biological devices. Biological ECLAD utilize living liver cells, 
aiming to harness their hepatic synthetic functions and detoxification properties, for use 
on the blood or plasma of patients with ALF. Different sources of hepatocytes have been 
employed. The HepatAssist system, for example, uses porcine hepatocytes within a 
dialysis cartridge, before a moratorium in the use of porcine hepatocytes was put in 
place. The Extracorporeal Liver Assist Device uses cells derived from a human 
hepatoblastoma cell line.57  
Non-biological systems in contrast, simply aim to replace the detoxification functions of 
the liver, without providing any synthetic function (as no living cells are involved). The 
Molecular Adsorbent Recirculating System (MARS) device is one of the most commonly 
studied non-biological machines. Here, toxic molecules are removed by plasma dialysis 
across an albumin-porous exchange membrane, with absorption into a number of 
binding columns. Whilst the use of MARS in patients with ALF has been shown to 
correlate with biochemical improvements, these may not be sustained. 80,81 A 
randomized controlled trial of MARS therapy or standard of care alone, performed in 
patients fulfilling poor prognosis criteria, did not demonstrate a significant survival 
benefit.82 Attempts to quantify the overall potential for biological and non-biological 
ECLAD to improve outcome in ALF and acute on chronic liver failure have revealed 
conflicting results.57 One systematic review found that non-biological support systems 
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reduced mortality in acute on chronic liver failure, however neither biological nor non-
biological systems affected mortality in ALF.83 However, a separate systematic review 
and meta-analysis investigating survival following both biological and non-biological 
extracorporeal liver support found that these systems did improve survival in ALF (with 
number needed to treat of eight) but not acute on chronic liver disease.84  
To date, development of biological devices have been fraught with technical and 
logistical challenges. This may be changing, with technologic advances leading to a new 
generation of such devices.81 Recently, another novel therapeutic approach has been 
found to confer a survival benefit; Larsen et al hypothesized that high-volume plasma 
exchange (HVP) might prevent the development of multiorgan failure and thereby reduce 
mortality in ALF, by removing deleterious plasma cytokines and adhesion molecules, 
replacing plasma factors and immunomodulation.85 Whilst this does not fit the exact 
definition of an ECLAD, HVP does simulate some of the detoxifying purposes of hepatic 
support. In a prospective, randomized controlled multicenter trial, 182 patients with ALF 
received either HVP for three days, or standard medical therapy alone. It was found that 
treatment improved outcome by increasing liver transplant-free survival.85 Patients 
undergoing HVP had significantly reduced circulating levels of DAMPs, TNF-α and IL-6, 
and reduced markers of monocyte and neutrophil activation. The immunological findings 
were consistent with the hypothesis that HVP suppresses SIRS associated with ALF and 
this was also in agreement with the observed improvement in clinically relevant critical 
illness scores. This study included a relatively large proportion of patients whose 
aetiology of ALF was paracetamol.85 Whilst HVP represents a potentially promising 
adjunct to the management of ALF, further work is required to clarify which patients are 




Transplantation of cells, rather than a whole organ, is in principle, an attractive idea for 
restoring hepatic function.86 Repopulation of the liver with functional donor hepatocytes 
can be attempted by direct injection of cells into the liver, or into the spleen (from which 
they can subsequently migrate to the liver). In animal models of ALF, hepatocyte 
transplantation can improve survival.86,87 Translating this into a clinically applicable 
human therapy is not straightforward however. Difficulties include limited availability of 




Problems with access to hepatocytes could potentially be circumvented, for example by 
using stem cells, or stem cell-derived hepatocytes. In animal studies, rats transplanted 
with stem cell-derived hepatocyte-like cells had better survival outcomes in ALF (induced 
by D-galactosamine).87 However, in humans, stem cell survival post-transplant is a 
challenge. At present, there is much interest in identifying a source of infinitely 
expandable hepatocyte-like cells, with good function, phenotypic stability and minimal 
risk of tumourgenicity.86 Similarly, the development of protocols to ensure optimal cell 





Chapter 2: Hepatocellular carcinoma and hepatic stellate cells  
2.1.1 The role of the microenvironment in HCC 
The stroma is a central component of both hepatic fibrosis and carcinogenesis, and is 
likely a key player in the cellular and molecular mechanisms linking these processes. It 
remains unclear, however, whether liver fibrosis specifically promotes HCC, or if it is 
merely a wound-healing by-product of chronic hepatic injury and inflammation, with no 
direct impact on liver cancer formation.34-39,88 Evidence would suggest the former; the 
identification of gene signatures from non-tumoural tissue correlating with late 
recurrence of HCC, supports the concept of a ‘field effect’ in cancer development.33-38,88-
101 The role of the microenvironment in hepatocarcinogenesis has recently been 
reviewed, highlighting the complex interaction between immune, angiogenic, and 
cancer-associated fibroblastic cells.33-39,88,90,93,94,96,102 Hepatic stellate cells (HSC, also 
known as liver-specific pericytes) are the major source of extracellular matrix proteins 
during liver injury and fibrogenesis.24,35,37 As master regulators of the fibrotic matrix 
stellate cells may therefore directly support tumourigenesis. Following liver injury, 
quiescent stellate cells become activated to matrix-secreting myofibroblasts; it is well 
established in other systems that complex intercellular signalling networks exist between 
tumours and tumour-associated fibroblasts, contributing to cancer initiation, growth and 
progression.24,35,37,89,91,92,95,97-101 Tumour secretion of cytokines such as transforming 
growth factor-beta (TGF-β) stimulates myofibroblast activation, leading to profound 
changes in extracellular matrix (ECM) composition and organization. Therefore, HSC or 
HSC-secreted products may be either permissive or necessary for oncogenesis and 
HCC persistence. In other cancers, the identification of pathways that the tumour 
depends upon for growth and proliferation, so-called ‘oncogenic addiction loops’ has led 
to revolutionary therapeutic approaches. The landmark discovery of the protein kinase 
oncogene BCR-ABL and subsequent development of imatinib, allowed curative 
treatment of chronic myeloid leukaemia, and paved the way for targeted therapies in 
other malignancies.103,104 Other protein kinase inhibitors have translated to clinical 
practice, including trastuzumab for HER2 positive breast cancer,105,106 and several drugs 
for non-small-cell lung cancer: erlotinib and gefitinib in EGFR positive disease, and 
crizotinib in patients with ALK-rearrangements.107-112 Targeting other non-kinase 
oncogenes such as RAS and MYC has proven more challenging; despite extensive 
genomic profiling of HCC and the identification of promising candidate pathways, 
targeted inhibition of a driving molecular alteration, applicable to a significant proportion 
of patients, remains an alluring but elusive goal.113 Furthermore, the microenvironment 
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may modulate susceptibility to inhibition of specific oncogenic pathways. Straussman et 
al developed a co-culture system to test the ability of 23 stromal cell types to influence 
the susceptibility of 45 different cancer cell lines to 35 therapeutic agents.90 They 
demonstrated that stroma-mediated resistance to anti-cancer drugs (especially targeted 
agents) is common. In particular, although melanomas expressing mutant BRAF 
respond to vemurafenib, hepatocyte growth factor (HGF) secretion by peri-tumoural 
stromal cells correlated with resistance to vemurafenib-induced cell death.90,114,115 This 
illustrates the importance of stroma-derived resistance to chemotherapy, in many 
different organs and disease settings. Therefore, in the search for key driver mutations 
in HCC, the effect of the microenvironment cannot be underestimated. In clinical 
practice, this may mean that combinations of chemotherapeutic agents are required, to 
neutralize specific stromal interactions, resulting in greater overall efficacy.  
2.1.2 HSC, the extracellular matrix and myofibroblast phenotype in fibrosis 
It is well known that activated HSC infiltrate HCC stroma and peri-tumoural tissue, and 
are localized around tumour sinusoids, fibrous septae and the tumour capsule.116-118 
Activated HSC have also been identified around the periphery of dysplastic nodules 
within the liver.119 Following activation to the myofibroblast phenotype, HSC secrete 
substantial amounts of ECM proteins into the stroma. Fibrotic matrix deposition and 
degradation by HSC is tightly regulated in the liver. For example, TIMP-1 secretion 
favours scar deposition by inhibiting the endogenous matrix-degrading activities of 
various MMPs. However, the balance between and TIMPs and MMPs is complex; 
activated HSC are also a major source of MMP-2 in vitro, elevation of which has been 
correlated with increased tumoural collagen I, extracellular remodelling, and HCC 
progression.102,120,121 
The biomechanics of the ECM are also relevant. Differentiation of primary hepatocytes 
is inhibited by culture on a stiff collagen gel, with accompanying promotion of 
proliferation.122,123 Increasing matrix stiffness in vitro has also been shown to directly 
stimulate growth of the HCC cell lines, HuH-7 and HepG2, and reduce chemotherapy-
induced apoptosis.124 Integrin β1 signalling was an integral driver of this response, via 
Fak, Erk, Pkb/Akt and Stat3 pathways.124 Furthermore, stromal stiffness is self-
perpetuating, causing stellate cell activation, and therefore further fibrosis.39,125,126 Data 
in humans support these experimental findings. Ultrasound elastography has 
demonstrated that measurements of liver stiffness predict HCC development.127-129 
Similarly, established HCC exhibits further increases in matrix stiffness, more so than 
the peri-tumoural hepatic parenchyma.130 The mechanical tension provided by an altered 
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ECM is likely to act on HCC development and progression via outside-in signalling, for 
example by integrins (discussed below) to support tumour growth and progression. This 
has also been observed in other malignancies, such as a mouse model of breast 
cancer.131 Hepatocarcinogenesis in the context of cirrhosis, however, is a unique model 
of diseases ECM, and an ideal setting to further characterise and potentially target 
stromal drivers.   
2.1.3 The role of HSC in HCC 
The interplay between HSC biology and hepatocarcinogenesis is complex. The 
mechanisms by which HSC may facilitate HCC development and progression are likely 
to involve diverse biological processes including regulation of ECM turnover, growth 
factor and cytokine signalling, promotion of tumour angiogenesis and 
immunomodulation. These will be summarized below.  
 
Integrins as mediators of HSC/HCC crosstalk 
The integrin family of transmembrane receptors allow transduction of signals between 
the intracellular and extracellular environments.132 Integrins consist of an α and β subunit, 
and they regulate cell adhesion, spreading, migration, proliferation and differentiation, as 
well as ECM deposition and remodelling. Integrins will be discussed in more detail in the 
following chapter, however evidence for their role in crosstalk between HSC and HCC 
will be considered below.  
Activated HSC promote ECM deposition, via the focal adhesion kinase (FAK)-
phosphatidylinositol 3-kinase (PI3K)-Akt pathway, which is a downstream effector of 
integrin signalling.133 In vitro, a stiff ECM enhances integrin expression and activity, and 
formation of focal adhesions.131 Activation of downstream integrin signalling within the 
hepatocyte may support the growth and survival of precancerous cells. Matrix stiffness 
has been demonstrated to correlate with differentiation and chemotherapeutic resistance 
of human HCC cell lines. Softer matrices abrogate hepatoma proliferation, whereas 
stiffer matrices promote proliferation.124,134 An elegant in vivo study by Dong et al involved 
orthotopic implantation of cells from the HCC cell line McA-RH7777 into rats with different 
degrees of liver stiffness (achieved by treating with CCL4 for variable lengths of time). 
Subsequent microarray analysis of the tumours showed a positive correlation between 
matrix rigidity and tumour angiogenesis.134 Associations between collagen deposition, 
integrin expression and tumourigenicity have been reported in human HCC and murine 
HCC models.135,136 Integrin expression in HCC cell lines is highly heterogenous.137 This 
was also apparent in two mouse models of HCC; Lai et al characterized and compared 
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ECM protein changes occurring during tumour development in the PDGF-C 
overexpressing mouse (a model of HCC associated with fibrosis and angiogenesis) and 
in the PTEN null mouse (a model of liver tumours of mixed cholangio- and hepatocytic 
features).136 They demonstrated that each model had a specific pattern of integrin 
expression, and commented that specific integrin-laminin interactions could be promising 
targets for inhibiting microenvironmental factors promoting HCC growth, in tumours with 
dysregulated PTEN function.136  
The β1 integrin subfamily has been extensively studied with respect to HCC, and 
hepatocarcinogenesis is associated with the enhanced expression of integrins α1β1, 
α2β1 and α3β1, and the acquisition of a migratory phenotype by hepatocytes.138-140 
Moreover, integrin β1 expression in human HCC tissues correlated positively with ECM 
stiffness, pathological grade and metastasis.141 Integrin β1 blockade in vitro significantly 
abrogated migration and invasion of HCC cell lines, induced by TGF-β and EGF.140,142 
This finding was supported by the work of Mizuno et al, who reported that integrin β1 
overexpression enhanced HepG2 cell migration.143 Dong et al more recently suggested 
that integrin β1 was involved in transduction of ECM signalling into HCC cells, 
culminating in downstream activation of angiogenic signalling.134 Using a high-stiffness 
gel to culture HCC cell lines, Dong et al found that VEGF expression is suppressed by 
treatment with an integrin β1-specific antibody.134 SERPINA5 (Protein C inhibitor), a 
member of the serine protease inhibitor superfamily known to have anti-metastatic and 
anti-angiogenic effects,144 is down-regulated in human HCC tissues. Further assessment 
of its anti-tumourigenic activity demonstrated that this was mediated by effects on the 
fibrogenic-integrin β1 signalling pathway.145 The relationship between integrin β1 and 
ECM stiffness in HCC is further highlighted in a study where resistance of the HCC cell 
line, Hep3B, to sorafenib, was found to be mediated by integrin β1 and its downstream 
effector JNK.146  
Integrin subunits other than β1 have been found to have important roles in HCC 
progression. Fan et al showed that integrin α6 expression correlated strongly with HCC 
metastasis in humans.147 They used a viral short hairpin RNA-mediated strategy to 
overexpress integrin α6 in HCC cell lines. It was found that integrin α6 could form a 
complex with CD151, a tetraspanin protein also associated with HCC invasion.147 Further 
investigation of this in vivo indicated that the CD151/α6 complex stimulated the PI3K-Akt 
signalling pathway, leading to enhanced epithelial-mesenchymal transition (EMT) of 
HCC cell lines.147  
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Crosstalk between integrins and TGF-β signalling has also been investigated in 
hepatocarcinogenesis. TGF-β receptor 1 (TGF-β R1) activation has been shown to 
promote HCC cell invasiveness by phosphorylation of the intracellular portion of the β1 
subunit of the α5β1 integrin, via Smad-2 and Smad-3. This led to an inside-out 
conformational change and stimulation of vascular invasion.148 TGF-β1 has been shown 
to upregulate other integrins, including α3β1 and α6β1, resulting in increased tumour 
invasiveness.149 Specific crosstalk between fibronectin-binding integrins and TGF-β1 
can promote cell cycle progression in HCC cells, by activation of c-Src.150 Crosstalk 
between integrins, growth factor receptors and ECM proteins, including collagen, have 
also been shown to modify downstream signal transduction pathways, such as Smad, 
acting in favour of hepatocyte proliferation, and ongoing HSC activation.151,152 TGF-β1 
has also been shown to affect α5β1 expression and synergistically enhance integrin-
mediated FAK phosphorylation and cell adhesion in the HCC cell line SMMC-7721.153 
Integrins may therefore (via modulation of TGF-β signalling) render hepatocytes less 
sensitive to pro-apoptotic signals in early HCC stages, and more sensitive to 
tumourigenic differentiation and metastasis signals, in advanced HCC.  
 
HSC growth factor signalling 
HSC have been shown to favour HCC tumourigenicity, potentially as a result of a change 
in their secretory phenotype upon activation. In vitro studies, using conditioned media 
from activated HSC, have consistently reported increased proliferation, migration and 
invasion of tumour cells.154-156 Isolation and subsequent co-culture of human 
intratumoural HSC with hepatoma cell lines enhanced their viability and migratory 
capacity.154 Furthermore, co-transplantation with HCC cells into nude mice promoted 
tumour formation and growth.157 Utilising both co-culture and conditioned media from 
primary human HSC, Giannelli et al found laminin-5 was a mediator of HSC-induced 
HCC migration via its activation of the MEK/ERK pathway.158 This was supported by in 
vivo experiments, in which co-transplantation of murine activated HSC with murine HCC 
cells (H22 line) into immunocompetent mice resulted in significantly larger tumour 
volumes.155 Moreover, implantation of human HCC cell lines (PLC and Hep3B) into nude 
mice did not form tumours unless activated HSC were concurrently implanted.154 HepG2 
cells did form tumours when implanted alone, however tumour growth was more rapid 
when co-transplanted with activated HSC.154 Activated HSC secrete a broad range of 
growth factors including HGF, TGF-β, FGF, EGF, VEGF and IGF. The following sections 




Hepatocyte growth factor 
HGF is expressed by HSC and myofibroblasts,159,160 and is a highly potent hepatocyte 
growth factor, regulating cell proliferation, migration, survival and angiogenesis.161-164 As 
such, it is widely regarded as a key factor for tumour cell invasion and metastasis.165 
HGF binding to its receptor, c-MET, induces receptor homodimerization, and a 
subsequent phosphorylation cascade. A transmembrane receptor tyrosine kinase, c-
MET is found in 20-48% of HCCs,166-168 and has been shown to be expressed by multiple 
HCC lines.154 Correlations between increased c-MET and HCC tumour size or 
invasiveness of HCC have been reported in some studies.169,170 c-MET overexpression 
is also associated with a reduced five-year HCC survival, and a c-MET-regulated 
expression signature has been reported to define a subset of patients with poor 
prognosis and an aggressive phenotype.170,171 Within HCC tumours, activated HSC have 
been found to initiate signalling pathways downstream of c-MET, including NF-κB and 
ERK leading to tumour proliferation and migration.154,172 
The pro-tumourigenic activity of fibroblast-secreted HGF has also been reported in vitro. 
Conditioned media from isolated and activated HSC, pre-incubated with anti-HGF 
antibodies, was found to abrogate the proliferative and migration-inducing effects on 
HCC cell lines, seen in non-treated conditioned media.154 This has also been 
demonstrated in cancer-associated fibroblasts (CAF) isolated from HCC, where 
treatment of CAF-conditioned media with an anti-HGF antibody significantly reduced 
HCC proliferation in Hep3B and MHCC97L cell lines.156 Moreover, a HGF/c-MET specific 
antagonist, NK4, has been found to inhibit markedly the fibroblast-induced invasion of 
cancer cells, both in vitro and in vivo,173-175 although this has yet to be translated into the 
clinical setting. Recently, PDGF-C transgenic mice were developed as a murine model 
of HCC, with similarities to the human disease. In this model, progressive fibrosis and 
cirrhosis, initiated by ectopic expression of PDGF-C, precedes hepatocyte dysplasia and 
eventual HCC development.176 Analysis of livers from these animals demonstrated that 
expression of hepatic HGF and its receptor were elevated at the time point at which 
dysplastic foci are present, further suggesting a pro-tumourigenic role for HGF. 
Activation of HGF/c-MET signalling has also been shown to enhance HCC 
chemoresistance. Conditioned media from the activated HSC cell line LX-2 enhanced 
resistance of the HCC cell line Hep3B to the chemotherapeutic agent cisplatin, an effect 
mediated by HGF.177 Tumour cells may also potentiate pro-metastatic c-MET signalling 
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via an autocrine mechanism involving TIMP-1, leading to downstream expression of 
metastasis-promoting genes.178,179 
However, HGF signalling is not unidirectional. A high level of bi-directional crosstalk 
between tumour cells and stromal cells, has been reported. Nakamura et al showed that 
inducers of HGF are expressed in several carcinoma cell lines, including squamous cell 
carcinoma, human epidermoid carcinoma, human non-small cell lung cancer cells, 
human cholangiocarcinoma cells, and SBC-3 human small cell lung carcinoma cells.180 
These HGF inducers include interleukin (IL)-1β, FGF, PDGF and TGF-α and were 
reported to up-regulate HGF expression by stromal fibroblasts.180,181 Taken together, 
these studies highlight that HGF and aberrant c-MET signalling have a critical role in 




The large latent TGF-β complex is secreted by most cell types, including human HSC 
and hepatocytes.182,183 It is fixed in the ECM by tranglutaminase-dependent linkage of 
latent TGF-β binding protein to fibronectin and other ECM proteins, forming a reservoir 
of latent TGF-β. Evidence would suggest that the role of TGF-β in HCC pathogenesis 
may be highly context-dependent.184 It has been postulated that defective TGF-β 
signalling may promote tumourigenesis secondary to reduced responsiveness to the 
anti-proliferative effects of TGF-β signalling.185,186 However, whilst tumour-suppressor 
functions are observed in the early stages of liver damage and regeneration, TGF-β may 
also exacerbate tumour invasiveness and metastatic behaviour.187 Furthermore, TGF-β 
and PDGF signalling crosstalk has been shown to support EMT and promote tumour 
growth, and the acquisition of an invasive phenotype.188  
Autocrine TGF-β signalling has been shown to be necessary for the survival and 
malignancy of HCC cell lines, including Huh7 and HepG2, with exogenous TGF-β 
leading to growth inhibition of HCC cells.189 Using HCC cell lines, Meindl-Beinker et al 
revealed a heterogeneic response to TGF-β, reflective of different stages and 
mechanisms of disease. Variation between cell lines in their endogenous TGF-β and 
Smad7 levels, and their transcriptional activity of Smad3, was related to the maintenance 
of TGF-β cytostatic activity. Specifically, the Hep3B, HepG2 and PLC hepatoma cell lines 
were found to have low TGF-β and Smad7 levels, and strong Smad3 transcriptional 
activity and were therefore sensitive to TGF-β cytostatic activity, representative of the 
early stages of chronic liver disease.190  
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Importantly, an analysis of TGF-β expression in HCC patients revealed that tumours 
displaying an invasive phenotype and increased recurrence were characterized by a late 
TGF-β signalling signature, with transcriptional activation of genes associated with matrix 
remodelling and cell adhesion.191 A significant body of evidence supports the hypothesis 
that TGF-β-driven epithelial plasticity of neoplastic hepatocytes is a critical event in cell 
dissemination and intrahepatic metastasis.192 Furthermore, a correlation between 
circulating levels of TGF-β1 and increased aggressiveness of HCC phenotype, has been 
observed in patients with HCC.193 Hoshida et al stratified patients with HCC according to 
molecular pathway activation and clinical outcome. Interestingly, TGF-β activation was 
associated with the worst survival. Upon activation, HSC secrete, and are receptive to 
TGF-β signalling; I would hypothesise that TGF-β signalling could therefore be an 
important stromal factor in hepatocarcinogenesis.    
 
Toll-like receptors and epiregulin 
The gut microbiome is increasingly recognized as a powerful modulator of fibrosis, 
cirrhosis, and infectious complications in chronic liver disease. Much interest is currently 
focused on the translocation of bacterial pathogen-associated molecular patterns, which 
activate inflammatory responses through TLRs. Recently Dapito et al demonstrated that 
Tlr4mut mice (harbouring non-functional TLR4) that received diethylnitrosamine (DEN) 
and carbon tetrachloride (CCL4) show 80-90% reduction in HCC tumour size and 
number, compared with mice expressing wild-type TLR4.194 Gut sterilization significantly 
reduced this effect whereas lipopolysaccharide (LPS) treatment enhanced it, suggesting 
a role for the LPS-TLR4 pathway in promotion of hepatocarcinogenesis. Interestingly, 
alongside hepatocytes, HSC were identified as candidates for TLR4-dependent tumour 
promotion in the chronically injured liver. LPS and the gut microbiome were found to 
induce HSC activation, resulting in production of the mitogens HGF and epiregulin, which 
likely act on malignant hepatocytes. Epiregulin is a member of the EGF family, and 
results in EGF receptor and human epidermal growth factor receptor 2 activation during 
early stages of DEN/CCL4 carcinogenesis, whereas it reduces hepatocyte apoptosis by 
NF-κB nuclear translocation during later stages.194,195 This suggests that there may be 
merit in evaluating whether long-term antibiotic treatment confers any protection against 
HCC development. This could initially be investigated by following up patients with 
cirrhosis on long-term prophylaxis for spontaneous bacterial peritonitis or 




HSC and angiogenesis 
Angiogenesis has a critical role in HCC initiation, progression and metastasis, as 
reflected by the efficacy of sorafenib, which targets this process. The rapid growth pattern 
of malignant hepatocytes requires new vessel formation, stimulated by multiple pro-
angiogenic factors. This pro-angiogenic environment in turn supports tumour 
progression and metastasis. The relevance of tumour vascularity is reinforced by the 
observation that VEGF expression progressively increases from low-grade dysplasia to 
early-stage HCC.196 VEGF overexpression is also associated with high tumour grade, 
and vascular and portal vein invasion.197-201 Furthermore, raised plasma VEGF and 
angiopoietin 2 (Ang-2) are independent predictors of poor prognosis in advanced 
HCC.202 
HSC are known to secrete VEGF as well as other angiogenic factors including PDGF, 
MMPs, FGF, TGF-β1, EGF, angiopoietin (Ang)-1 and Ang-2.203-205 Upon activation, HSC 
express multiple smooth muscle cell markers, suggesting they may act like pericytes 
during angiogenesis.206,207 They also express angiogenic growth factor receptors, such 
as VEGF receptor, PDGF receptor and Tie-2.208-210 In liver injury and HCC, this facilitates 
reciprocal signalling between HSC and endothelial cells or malignant hepatocytes and 
contributes towards a pro-angiogenic microenvironment. VEGF secretion by HSC can 
be hormonally induced by leptin, or by physical stress such as hypoxia, and is 
upregulated in HCC.204,208,211 VEGF receptor upregulation also occurs during HSC 
activation, resulting in increased mitogenesis in response to VEGF.37  
Conditioned media from HCC cells can activate HSC and stimulate VEGF production. 
Coulouarn et al co-cultured LX2 cells with HepRG HCC cells, and analysis of differential 
gene expression identified a gene network linked to VEGFA and MMP9.212 This was 
shown to promote angiogenesis, as conditioned medium from LX2-HepaRG co-culture 
(but not LX2 or HepaRG medium alone) induced tubule complex formation by primary 
human umbilical vein endothelial cells. A gene signature of this cross-talk correlated with 
poor prognosis and metastasis in humans.212 
Lin et al have also shown increased angiogenesis by activated HSC in vitro using a 
murine HCC cell line (H22) and rat colon microvascular endothelial cells.213 They went 
on to demonstrate, in vivo, using an orthotopic HCC model, that activated HSC promote 
tumour vascularization via increased VEGF and possibly PDGF secretion. 
Of particular interest in HCC is the interaction between malignant hepatocytes, 
endothelial cells and activated HSC. Torimura et al characterized expression of Ang-1, 
Ang-2 and Tie2 receptors in HCC cell lines (HLE and HuH-7) and human HCC cases.214 
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They concluded angiopoietin-Tie2 signalling in the vascular wall may act in favour of 
vessel remodelling in HCC. Ang-2 production by hepatoma cells, HSC and smooth 
muscle cells binds Tie2 (on HSC, smooth muscle and endothelial cells) and destabilizes 
connections between endothelial cells, perivascular support cells and ECM. This allows 
exposure to VEGF, which in these relatively hypoxic conditions, is upregulated. 
Proliferation of endothelial cells ensues, allowing neovascularization and further tumour 
growth.  
Recently, it has been shown that metformin inhibits angiogenesis in vitro, in an HCC 
(HepG2 line) and HSC (LX2) co-culture system.215 This was associated with reduced 
VEGF production. It was postulated that metformin was acting via AMPK activation, and 
specifically targeting HSC in this model. Indeed, inhibition of AMPK on LX2 cells (but not 
on HepG2 cells) using siRNA did restore VEGF levels and abrogate metformin’s anti-
angiogenic effect. Metformin would seem a promising candidate for human HCC 
treatment, but unfortunately retrospective data would suggest a lack of survival 
benefit.216 However, considering the well-established tolerability of metformin, its 
potential HSC-mediated effect on angiogenesis merits further investigation.  
Some of the factors mediating crosstalk between HSC and HCC are summarized in 








Figure 2.1 Crosstalk between HSC and HCC  
Reproduced from Thompson et al 2015.184 
HSC-secreted factors such as HGF may promote hepatocarcinogenesis. Similarly, HCC 
signalling results in further HGF production from activated HSC. TGF-β demonstrates 
both tumour-suppressive and tumour-promoting functions, depending on context. HSC 
produce angiogenic cytokines, supporting new vessel growth. HCC cells contribute to 
angiogenic signalling, and HSC also possess receptors for some of these factors. LPS 
induces HSC activation, resulting in epiregulin and HGF production, with mitogenic 





HSC and immunomodulation 
Tumour immune evasion is a hallmark of cancer progression, and this process has been 
shown to occur in human HCC.184 Increased levels of immunosuppressive cells (such as 
regulatory T-cells (Tregs)) within peripheral blood and tumours have been reported in 
human HCC cases.217-219 Intratumoural Treg accumulation has also been shown to 
correlate with disease progression and poor prognosis in HCC.220  
HSC themselves have immunosuppressive properties. Activated HSC have been shown 
in vitro and in vivo to strongly suppress T-cell responses. Furthermore, in an orthotopic 
rat model of HCC, intratumoural HSC number correlated with T-cell apoptosis and 
metastatic lung nodules.221 Zhao et al showed that co-transplantation of HCC cells and 
HSC into immunocompetent mice promoted HCC proliferation and enhanced tumour 
angiogenesis. This was associated with inhibition of lymphocyte infiltration and apoptosis 
of infiltrating monocytes.155 In another orthotopic model of HCC, activated HCC in 
tumour-bearing mice significantly increased Treg and myeloid-derived suppressor cell 
(MDSC) populations in the spleen and tumour stroma.222 Tumours co-transplanted with 
HSC also had increased vascular and lymphatic vessel density.  
The immunomodulatory effects of HSC in HCC may be mediated by upregulation of 
human B7 homolog 1 (B7-H1; programmed death ligand 1 (PDL-1)) on tumoural HSC.223-
225 B7-H1 can act as both receptor and ligand, and its immunosuppressive functions 
include promotion of activated T-cell apoptosis and inhibition of T-cell-mediated tumour 
cell apoptosis.226-228 Its counter-receptor, PD-1, is expressed on activated (but not 
quiescent) T-cells, B-cells and monocytes.229 B7-H1/PD-1 signalling has been reported 
to promote Treg cell induction and immunosuppressive function through down-regulation 
of mTor and AKT phosphorylation.230,231 Incubation of T-cells with anti-B7-H1 monoclonal 
antibody in vitro resulted in a significant reduction in HSC immunomodulatory activity 
and HCC migration and invasion.224  
Following on from these mechanistic studies, three monoclonal anti-PD-1 antibodies 
have been developed, and one against B7-H1.232,233 Phase 1 data was promising in a 
range of different tumours. A Phase-1 dose escalation study in HCC, investigating the 
effects of anti-PD-1 therapy in patients with advanced HCC is underway 





Therapeutic approaches to targeting HSC and HSC signalling 
HSC represent a small percentage of cells within the liver, and specific therapeutic 
targeting of HSC remain challenging. Recently, transgenic mice have been developed 
that allow reliable fluorescent labelling genetic manipulation in HSC and 
myofibroblasts.234,235 These transgenic mice will hopefully prove useful not only in 
elucidating the molecular mechanisms in HSC that regulate the stroma-HCC interface, 
but also in facilitating the identification of rational, new therapeutic targets in 
hepatocarcinogenesis.  
If a targetable, HSC-dependent pathway driving hepatocarcinogenesis is identified, cell-
specific therapy is conceivable, albeit not entirely straightforward. ECM homeostasis is 
a key physiological process and modifying HSC functions may impair this, with potential 
for severe adverse effects. Practically, delivering drugs to HSC is hindered by a lack of 
multiple transport receptors and endocytic capacity. Furthermore, candidate compounds 
may include siRNA and cytokines, which have a short half-life in plasma following 
systemic administration hindering therapeutic efficacy.236 
To overcome these problems, a number of groups have explored active targeting of HSC 
to deliver therapeutic compounds. This involves coupling the selected compound to a 
carrier possessing a specific receptor-binding ligand, or an antibody. 
Carriers recently employed have included an antibody to the synaptophysin receptor on 
HSC, and a liposome specific to the vitamin A receptor on HSC.237,238 Furthermore, 
Poelstra et al have used proteins substituted with a sugar moiety that binds the mannose-
6-phosphate-IGFII receptor.239 They have also utilized a peptide that binds the PDGF 
receptor-β,240 to deliver a protein or an adenovirus to HSC.241,242 An RGD-peptide which 
binds to RGD-binding integrins has also been used to create a carrier that accumulates 
in HSC.243,244 Of note, the carrier molecules used must fit strict criteria such as low 
immunogenicity, and high stability, biocompatibility and selectivity, if they are to translate 
into clinical practice. Moreover, the target receptors on HSC should be selectively 
expressed and ideally upregulated during disease activity. A further challenge is the 
requirement for endocytosis of the construct following target receptor binding. This can 
be particularly problematic in the case of biological therapeutics, which usually fail to 
withstand the endosomal degradation process.  
With these challenges in mind, Bansal et al subsequently developed a recombinant 
protein construct to deliver IFN-γ to HSC. This elegant system transported the signalling 
moiety of IFN-γ to the PDGF-receptor with a carrier molecule that was simplified and 
miniaturized. They found that IFN-γ could be effectively delivered to human HSC in vitro, 
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and to mouse HSC in vivo. Furthermore, the targeted fusion proteins were shown to 
ameliorate hepatic fibrosis in CCL4-treated mice.245-247 This suggests that directing a 
cytokine to HSC is a feasible and potentially tractable therapeutic approach, both in the 
context of developing new treatments for patients with liver fibrosis, as well as HCC. 





Figure 2.2 Therapeutic approaches to targeting HSC 
Reproduced from Thompson et al 2015184 
HSC have been targeted by coupling a compound to a carrier possessing either a HSC-
specific receptor-binding ligand or an antibody. Carriers utilized include: a monoclonal 
human single chain antibody (scAb) fragment to synaptophysin; a sugar moiety that 
binds the mannose-6-phosphate (M6P) insulin-like growth factor receptor; a liposome 
specific to the vitamin A (retinol-binding protein) receptor; PDGFβ receptor recognizing 
peptide (PPB); an RGD peptide bound to a liposome or coupled to a human serum 
albumin (HSA). scAb Fv, single chain antibody variable fragment; PEG, polyethylene 
glycol; pCVI, 10 cyclic peptide moieties that recognize collagen type VI receptors.  
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2.2 Modelling HCC 
The laboratory mouse is widely accepted as one of the best model systems for cancer 
due to ease of gene targeting methods, animal size and breeding capacity, and 
comparability to human biology. Models range from simple xenografts of cancer cells to 
immunodeficient mice, to complex genetically modified mice, and chemical 
carcinogenesis. 
DEN is a genotoxic DNA alkylating agent. It forms mutagenic DNA adducts, and 
bioactivation by cytochrome P450 can produce reactive oxygen species which damage 
DNA, proteins and lipids, and cause hepatocyte death. It has been used since 1966 to 
induce HCC in rodents, and is the commonest chemical used for hepatocarcinogenesis 
in mice.248,249 If injected when hepatocytes are actively proliferating (i.e. less than two 
weeks of age) it acts as a complete carcinogen in male, but not female mice (30% of 
females develop HCC).249 If administered later, another form of tumour promotion is 
needed, such as phenobarbital, CCL4, partial hepatectomy or high fat diet.250 Consistent 
with human HCC, tumour development is a multi-step process, with repeated cycles of 
necrosis and regeneration resulting in neoplastic transformation. As dysplastic lesions 
progress to malignant tumours, genomic alterations accumulate. 251,252 Lesions induced 
by a single DEN injection often have activating H-ras mutations,253 whereas those 
induced with both DEN and phenobarbital tend to demonstrate activating β-catenin 
mutations and genomic instability.254,255 A limitation of this model is the lack of hepatic 
fibrosis in livers challenged by a solitary early postnatal DEN injection; in contrast, human 
HCC typically arises in the context of cirrhosis. Nonetheless, activating mutations do 
appear to be comparable, and gene expression profiling of the DEN model suggests 
there is a good overlap between the resulting mouse tumours and their human 
counterparts.256 
2.3 Hypothesis and aims 




 To characterise HSC infiltration of human HCC, using immunohistochemistry, 




2.4 Characterisation of HSC infiltration and collagen deposition in HCC 
2.4.1 Materials and methods 
Human HCC tissue was obtained from archived tissue held by the South East Scotland 
SAHSC (Scottish Academic Health Sciences Collaboration) BioResource, following 
appropriate ethical approval.  
2.4.2 General immunohistochemistry protocol with formalin-fixed, paraffin-
embedded sections 
Immunohistochemistry was carried out at room temperature unless otherwise stated. 
Paraffin-embedded sections were de-paraffinised twice in xylene (for five minutes each 
time) and rehydrated in ethanol (50-100%) and distilled water. Antigen retrieval was 
performed at this stage (table 1) and the sections were then washed 2 x 5 minutes in 
phosphate buffered saline (PBS). Endogenous peroxidase activity was blocked by 
incubation with hydrogen peroxide (3%) solution in PBS for 10 minutes. Slides were then 
washed 3 x 5 minutes in PBS. Slides were then mounted into Shandon Sequenza slide 
racks. An endogenous avidin-biotin block (Vector Laboratories, Peterborough, UK) was 
performed by applying 3 drops of avidin solution to each slide for 15 minutes. Slides were 
then washed 3 x 5 minutes in PBS, then 3 drops of biotin reagent were applied for a 
further 15 minutes. Washing was repeated, 3 x 5 minutes in PBS. Non-specific protein-
binding was inhibited by incubation with blocking buffer containing species-specific 
serum diluted (1:5) in PBS for 30 minutes. Species-specific serum was chosen to match 
the species in which the relevant secondary antibody was raised. Without washing, 
samples were then incubated with a primary antibody solution (appropriately diluted in 
blocking buffer) for 2 hours at room temperature   
Slides were then washed 3 x 5 minutes in PBS. A secondary antibody solution 
appropriate to each primary antibody was made by dilution (table 1) of secondary 
antibody in blocking solution. Samples were incubated with secondary antibody solution 
for 30 minutes and then washed 3 x 5 minutes in PBS. Slides were then treated with 3 
drops of Vector RTU ABC reagent for 30 minutes, and washed 3 x 5 minutes in PBS. A 
chromogen solution containing 3, 3’diaminobezidine (DAB) was applied to each slide for 
between 1-5 minutes, until a colour change was observed. This was followed by washing 
3 x 5 minutes in PBS. Counterstaining was performed in Harry’s haematoxylin solution 
(10 seconds), rinsed in running tap water and immersed in Scott’s tap water (10 
seconds). Sections were then rinsed in running tap water and dehydrated in graded 
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ethanol solutions (50-100%) 20 seconds each, and xylene for 2 x 5 minutes. Slides were 
mounted on glass cover slips with mounting media. 
Immunohistochemistry on human and mouse HCC specimens 
Immunohistochemistry was performed on formalin-fixed paraffin-embedded 5μm 
sections mounted on glass slides. Primary and secondary antibodies were used at 
different concentrations (table 1). The primary antibodies used were α-SMA and 
PDGFRβ. For all targets, an antigen retrieval step was performed, to unmask epitopes 
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Table 1: Summary of antibodies used with their concentrations, antigen retrieval 
and secondary antibodies 
 
Picosirius red (PSR) staining 
PSR staining was performed on 5μm liver sections. Sections were de-paraffinsied in 
xylene and rehydrated in ethanol (50-100%) and distilled water. Sections were then 
incubated for 90 minutes in saturated picric acid solution containing 0.1% Sirius red, and 
then 0.1% Fast green. Sections were then rinsed in distilled water to remove excess dye, 
and dehydrated in ethanol (50-100%) and xylene. Slides were mounted on glass cover 
slips with aqueous mounting media.   
2.4.3 Microscopy and digital image analysis 
Microscopic examination of tissue specimens was performed using an inverted Zeiss 





Digital image analysis of immunostained sections 
Quantification of α-SMA, PDGFRβ and PSR immunostaining in liver specimens was 
performed by digital image analysis using ImageJ (National Institute of Health, USA). For 
each HCC sample, tumour area was identified by a pathologist, from a haematoxylin and 
eosin (H and E)-stained section.  Whole sections were scanned in digitally, and a Wacom 
pad used to draw round tumours, to accurately quantify staining within HCC. Values are 
expressed as the total percentage area of positive staining per tumour sample. Detection 
thresholds were set for the brown colour of DAB or the red colour of PSR staining, from 




2.5 HSC infiltration and collagen deposition in human HCC 
 
 
Figure 2.3 HSC infiltration and collagen deposition in human HCC 
A Representative scanned images of slides of human HCC tissue stained with (i) α-SMA 
(ii) PDGFRβ (iii) PSR B High magnification (x20) images of intratumoural staining for 
markers of HSC, myofibroblasts and collagen (PSR). (i) α-SMA; corresponding graph 
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shows percentage positive immunostaining within 17 human HCC, grouped by tumour 
grade: well differentiated (WD) n=4, moderately differentiated (MD) n=6 and poorly 
differentiated (PD) n=7. (ii) PDGFRβ IHC of human HCC tissue (n=4 WD, n=5 MD, n=7 





HSC presence within human HCC shows a trend towards deteriorating tumour 
differentiation grade 
Figure 2.3 shows IHC performed on human HCC cases, obtained from archived tissue 
as described above. Slides were stained for markers of activated HSC, namely α-SMA 
and PDGFRβ, and for the collagen marker, PSR. Sections were also stained with H  and 
E, to establish where the areas of HCC were. Results of immunostaining are presented 
as percentage positive staining within the whole tumour area (mean and standard error 
of the mean). I found that activated HSC were distributed throughout each tumour, and 
not simply around the fibrous tumour capsule. In a sample of 17 HCC cases, percentage 
α-SMA staining was 23.50 (+ 6.39) in n=4 well-differentiated (WD) tumours; 21.70 (+ 
5.06) in n=6 moderately differentiated (MD) tumours; 33.44 (+4.92) in n=7 poorly 
differentiated (PD) tumours. There was no significant difference in staining positivity 
between any of the tumour grades (p=0.83 WD vs MD, p=0.13 MD vs PD, p=0.25 WD 
vs PD).  
In a sample of 16 HCC cases, percentage PDGFRβ staining was 24.95 (+2.85) in n=4 
WD tumours; 27.13 (+14.07) in n=5 MD tumours; 37.8 (+4.89) in n=7 tumours. Difference 
in staining positivity did not reach significance between any of the tumour grades (p=0.90 
WD vs MD, p=0.43 MD vs PD, p=0.10 WD vs PD). However, there did appear to be a 
trend towards increasing staining positivity (for both α-SMA and PDGFRβ) within 
tumours from low to high differentiation grade.  
In a larger sample of 38 HCC cases, percentage PSR staining was 5.17 (+ 1.59) in n=7 
WD tumours, 9.28 (+1.76) in n=18 MD tumours, and 6.19 (+1.07) in n=13 PD tumours. 
These groups were not significantly different from one another (p=0.19 WD vs MD, 
p=0.18 MD vs PD and p=0.59 WD vs PD). 
2.6 Discussion 
In these experiments I stained archived human HCC sections with antibodies to markers 
of HSC, myofibroblasts and collagen. These tumours had all arisen in cirrhotic livers, 
from a variety of different aetiologies (including non-alcoholic fatty liver disease (NAFLD), 
alcoholic liver disease (ALD), HCV and primary biliary cirrhosis (PBC)). My sample size 
was slightly limited by quality of tissue; in some cases the tissue was torn or had holes. 
These were excluded from analysis. As the numbers were therefore relatively small, I 
did not look for any differences in staining between different aetiologies of liver disease, 
however it would be interesting to explore this in more depth in future studies.  
Whilst the sample size was small, I was confident that the image analysis process was 
robust. For each case a pathologist independently identified the area of HCC. Each 
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malignant nodule was outlined on the haematoxylin and eosin-stained section; I then 
scanned in the antibody-stained slides and used a graphics pad to draw round the 
nodules, correlating these with the annotated H and E slides. This meant that for each 
case I could analyse percentage staining throughout the whole tumour, maximizing the 
intratumoural area studied.  
There did appear to be a trend towards increased staining of HSC and myofibroblasts 
with decreasing tumour differentiation, suggesting a possible correlation between high 
numbers of intratumoural mesenchymal cells, and high tumour grade. However this did 
not reach significance, and would require analysis of larger sample sizes to fully explore 
this. Interestingly, this trend was not apparent when comparing collagen staining across 
the three tumour grade groups. Inability to tease out statistical differences may have 
been secondary to a range of confounding factors. For example, unfortunately I had no 
record of what treatments the patients had received. It is conceivable that specific tumour 
ablation treatments, such as trans-arterial chemoembolization, may have affected 
mesenchymal cell and collagen content.  
The variance in staining positivity for mesenchymal cells and collagen was relatively 
high. Since carrying out this work, a study of 300 patients with HCC who underwent liver 
resection or transplantation has been performed, investigating the effect of ‘stroma-rich’ 
tumours on prognosis.257 Patients were divided into a stroma-rich group (stroma >50% 
on assessment of H and E sections) and stroma-poor (stroma <50%). It was concluded 
that tumour-stroma ratio is an independent prognostic factor for overall survival in 
patients undergoing liver resection for HCC, and both overall survival and recurrence-
free survival in patients who underwent liver transplantation. The authors acknowledged 
some limitations of this retrospective study, however felt that tumour-stroma ratio would 
allow improved risk stratification of patients following curative treatments.257  
Tumour-stroma ratio has previously been shown to be an independent prognostic factor, 
in node-negative, premenopausal breast cancer,258 early cervical cancer,259 and 
oesophageal squamous cell carcinoma.92 It is not entirely clear what the underlying 
mechanism conferring poor prognosis in a stroma-rich tumour is. Tumour-associated 
mesenchymal cell types (i.e. cancer-associated fibroblasts (CAF) and pericytes) have 
attracted much attention in recent years, in terms of their pro-tumourigenic effects and 
contributions to the ‘hallmarks of cancer’ that are required for a cell to become 
malignant.260 The CAF is the dominant cell type within the tumour stroma of numerous 
cancers, especially breast and pancreatic.261 CAF are heterogeneous due to their 
various origins, and in HCC may originate from fibroblasts and activated HSC. CAF have 
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also been reported to arise from bone marrow-derived progenitor cells, or 
transdifferentiating epithelial cells.260 Stromal fibroblasts within tumours are 
characterized by (only partly) overlapping marker expression, including α-SMA, PDGF 
receptors, and fibroblast specific protein (FSP)-1. 262,263 This is likely to reflect distinct 
origins of subpopulations of CAF.260 Tumour pericytes (contractile cells in close contact 
with vascular endothelial cells) also express PDGFRβ and α-SMA, and contribute to 
angiogenesis.260 A CAF gene signature has been identified as predictive for response to 
neoadjuvant chemotherapy in breast cancer,264 and pre-clinical studies show that CAF 
can mediate resistance to anti-angiogenic therapy, and targeted tyrosine kinase 
inhibitors.92,260,265 They can also influence transport of drugs within tumours, by PDGF 
receptor-mediated regulation of interstitial fluid pressure in tumours.266 CAF may induce 
EMT through paracrine TGF-β signalling, 267,268 and TGF-β is likely to be a key player in 
the interaction between HCC and the stroma.269  
A large prospective study of human HCC cases would be informative, perhaps looking 
at markers of activated HSC and CAF, and correlating this with aetiology of liver disease 
and treatments. I investigated ethical approval for this, which was straightforward, 
however the time scale for patient recruitment would have been outwith the constraints 
of this project. I felt there was a considerable body of evidence implicating stromal TGF-
β signalling in HCC growth and progression, and therefore decided to proceed with in 





Chapter 3: The role of αv integrins during hepatocarcinogenesis 
3.1 The integrin family and TGF-β signalling 
The integrin family of cell adhesion molecules, of which there are 24 known members in 
humans (noncovalent α/β heterodimers composed from 18 different α subunits and 8 β 
subunits) mediate many key cell-cell and cell matrix interactions implicated in fibrosis. In 
particular, the αv integrin subunit forms heterodimers with the β1, β3, β5, β6 or β8 
subunits (Figure 3.1). Integrins are transmembrane receptors, allowing communication 
between the intra- and extracellular environments. They bind the ECM and cytoskeleton, 
thereby facilitating transduction of signals to regulate cell adhesion, migration, 
proliferation and differentiation, as well as ECM deposition and remodelling.270  
When integrins bind to growth factors or ECM ligands such as collagen, laminin and 
fibronectin, they form membranous plaque products, known as focal adhesions. Focal 
adhesions activate specific intracellular effector pathways, including protein kinase C, 
talin, paxillin and the phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein 
kinases (MAPK) pathways. Downstream, integrins coordinate the fibrogenic response, 
and help regulate cell survival, differentiation and proliferation, control of which is often 
lost in cancer cells.271,272 
Integrins are important in TGF-β signalling and secreted TGF-β is a critical regulator of 
fibrosis in multiple organs.270,273-275 The three mammalian isoforms of TGF-β are 
synthesized as precursor proteins. These are subsequently processed by proteolytic 
cleavage within the endoplasmic reticulum. They are assembled as a non-covalent ‘small 
latent complex’. This consists of a disulfide-linked homodimer of the mature cytokine (a 
short C-terminal fragment), which is encased within a disulfide-linked  
homodimer of a larger amino terminal fragment known as the latency-associated peptide 
(LAP) forming the ‘small latent complex’. The distinct conformation of the associated LAP 
homodimer (in contrast with free dimer) prevents the mature C-terminal fragment from 
binding to its receptors. This ‘small latent complex’ is modified further in the endoplasmic 
reticulum by disulfide linkage to latent TGF-β binding proteins. These are cross-linked to 
the ECM, and therefore store and tether TGF-β extracellularly, in this latent form. The 
latency cage can be disrupted by cellular contraction, resulting in release of mature 
dimer, and allowing activation of TGF-β (figure 3.1.2). The biological effects of TGF-β 
are mostly regulated by extracellular activation of this stored latent complex.276-278 All 
three of the mammalian TGF-β isoforms mediate their effects at least partly through the 




Figure 3.1 The integrin family of cell adhesion molecules 
Reproduced from Hynes, Cell 2002.  
 
 
Figure 3.2 TGF-β activation by αv integrins 
LAP: Latency-associated peptide 
RGD: linear arginine-glycine-aspartic acid motif 
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They have overlapping functions, although TGF-β1 appears to be most extensively 
implicated in fibrogenesis. Two of the three isoforms (TGF-β1 and TGF-β3) can be 
activated by members of the integrin family that interact with a linear arginine-glycine-
asparatic acid (RGD) motif present in an N-terminal of the LAP.279-283 Importantly, all αv 
integrin heterodimers can activate TGF-β in this way. This is not the only pathway by 
which integrins contribute to TGF-β activation; integrin-mediated generation of 
mechanical force by the actin cytoskeleton can also activate latent TGF-β1.284 Similarly, 
myofibroblast αv integrins can free TGF-β1 from the ECM via mechanical force. 
Furthermore, a stiff ECM results in more force-stimulated TGF-β1 release in comparison 
with a relaxed ECM, i.e. latent ECM-bound TGF-β1 can effectively be primed by the 
surrounding fibrotic matrix.278,285  
 
αv integrins 
Manipulation of specific members of the αv integrin family has been shown to have 
significant effects in experimental hepatic fibrosis (Table 2, adapted from Conroy et al 
2016278). Reed et al developed a small molecule inhibitor of αvβ1, and demonstrated that 
this is the predominant fibrogenic αv integrin on fibroblasts, mediating adhesion to the 
TGF-β1 LAP.286 The inhibitor compound c8 could reduce fibrosis in CCL4–treated mice, 
to a similar degree as seen with conditional deletion of all αv integrins on 
myofibroblasts.234 The reduction of phosphorylation of Smad3 (the intracellular 
downstream signalling effector of TGF-β) in these models provided further evidence that 
the antifibrotic effect is due to the inhibition of αvβ1-mediated TGF-β activation.234,286  
Similarly, αvβ6 has been implicated in the progression of biliary fibrosis.287 This was 
perhaps unsurprising, considering that hepatic expression of this integrin is low at 
baseline, but increased with inflammation and fibrosis.278,287 Moreover, patients with 
fibrotic liver disease secondary to a wide range of aetiologies (including primary biliary 
cirrhosis, alcohol, viral hepatitis) have elevated αvβ6 integrin mRNA expression,278 and 
in hepatitis C, the level has been shown to correlate with fibrosis stage.288  
This is consistent with the findings from a growing body of in vivo evidence using the 
BDL and genetic models of acute biliary fibrosis. In the BDL model, bile duct obstruction 
was found to increase cholangiocyte expression of αvβ6.287 Genetic knockout of β6 
integrin resulted in a 50% reduction of biliary fibrosis in BDL-treated mice, compared with 
wild-type controls. Additionally, administration of an αvβ6-blocking antibody significantly 
reduced acute biliary fibrosis after BDL.287 Patsenker et al then went on to show that 
pharmacological treatment with a small molecule inhibitor of αvβ6 (EMD527040) could 
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inhibit biliary fibrosis in BDL rats and Mdr2 (abcb4)-/- mice (another genetic model of 
biliary obstruction) in the context of established fibrosis.289 More recently, Peng et al 
showed that αvβ6 is expressed on hepatic progenitor cells, and genetic disruption or 
selective targeting of αvβ6 with 3G9 antibody could inhibit progenitor cell responses in 
two models of chronic biliary injury (Mdr2-/- mice and DDC diet-treated mice) resulting in 
less fibrosis and, importantly, cirrhosis-associated tumourigenesis.290  
The effect of modulation of αv integrin subunits is not universally antifibrotic however. 
For example, whilst αvβ6 has a convincing role in biliary fibrosis, ablation of this integrin 
was not protective in CCL4-induced hepatic fibrosis.287 This lack of effect may relate to 
the expression pattern of αvβ6, which is restricted to a subset of epithelial cells.287,291,292 
Therefore, αvβ6-mediated ββ activation is only very localized; any activated TGF-β 
generated could only be detected by cells in direct contact with the integrin-expressing 
cell.279 Specifically, these αvβ6-expressing epithelial cells may be located at a substantial 
distance from collagen-producing myofibroblasts, responsible for tissue fibrosis.234  
There is also evidence to suggest that some αv integrins may have a protective role in 
hepatic fibrosis. Pharmacological blockade of αvβ3/αvβ5 actually worsened hepatic 
inflammation and collagen deposition in the thioacetamide (TAA) and BDL rat models of 
fibrosis.293 Inhibition of αvβ3 and αvβ5 in different organs have shown relatively 
inconsistent results, suggesting that there may be compensatory effects of other 
integrins.278  
The effect of αvβ8 inhibition in adulthood has been less well characterized. Embryonic 
inhibition and blockade of both αvβ6 and αvβ8 result in perinatally lethal phenotypes 
similar to all of the developmental effects of loss of TGF-β1 and TGF-β3, suggesting 
these two integrins are critical for most or all important roles of these TGF-β isoforms in 
development.294 Assessing the effect of these integrins in older animals has required the 
development of conditional genetic models, or specific pharmacological inhibitors. Whilst 
αvβ6 blocking antibodies are available, with relatively well-established 
pharmacokinetics, inhibitors of αvβ8 have not, to date, been easily available. There is 
some evidence, however, that pathological TGF-β activation in the setting of biliary 
atresia may be partly mediated through increased αvβ8 expression and altered MMP14 
expression.278 Liver biopsies from patients with biliary atresia have increased αvβ8 
integrin expression compared with controls,295 and both human and animal models of 
the disease have dysregulated MMP14 expression.296 It has been postulated that αvβ8 
can activate TGF-β1 by presenting LAP complexes to cell-surface MMPs that degrade 
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the LAP, allowing release of free TGF-β1.278,297 Further investigation of this pathway in 
the context of liver fibrosis is required.  
αv integrins are key players in the molecular pathways regulating TGF-β, and therefore 
fibrosis, in multiple organs including the liver. They represent attractive targets for 
antifibrotic therapies, although rigorous investigation of the effects of blocking individual 
subunits is warranted. Pan-TGF-β inhibition risks potential side effects related to loss of 
TGF-β activity in normal tissue homeostasis. In particular, inhibition of TGF-β1 could be 
pro-carcinogenic, or result in pathological autoimmunity and inflammation, due to its 
anti-proliferative effect on epithelial cell types, and role in immunosuppression 
respectively.278,298-300 Therefore, further characterisation of the effects of individual αv 
integrin subunit inhibition, on specific cell-types within the liver, may allow development 
of targeted therapies to ameliorate fibrosis. Similarly, in view of the strong association 
between advanced liver fibrosis and development of HCC, it is possible that 
manipulation of αv integrins could also be a useful strategy in the development of new 







Model Method of inhibition Summary Reference 
β1 CCL4 Small molecule inhibitor, c8 Inhibition of αvβ1significantly 
reduced hepatic fibrosis 
 
Reed et al 2015286 
β3     
β5     
β3/β5 BDL/TAA Small molecule inhibitor, Cilengitide Increased hepatic collagen 
deposition and pro-fibrogenic 
gene expression 
 
Patsenker et al 2009293 
β6 BDL Antibody, 3G9 Reduced acute biliary fibrosis 
 
Wang et al 2007287 
β6 BDL Small molecule inhibitor, EMD527040 Inhibition reduced bile duct 
proliferation and peribiliary 
collagen deposition and 
increased fibrolytic gene 
expression 
 
Patsenker et al 2008289 
β6 DDC β6 function-blocking monoclonal 
antibody, 3G9 and β6 knockout mice 
Biliary fibrosis rescued by anti-
αvβ6 antibody treatment through 
inhibition of progenitor cell 
expansion 
 
Peng et al 2016290 
β6 CCL4    
Abbreviations: BDL, bile duct ligation; TAA, thioacetamide; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
 
Table 2: Effects of αv integrin inhibition in pre-clinical models of fibrosis.  




Anti-integrin therapies in clinical practice 
There are several anti-integrin pharmaceutical agents that are used in clinical practice, 
or are currently being evaluated in trials. At the time of writing, there are various clinical 
trials in progress involving potential use of integrins as biomarkers, for example in 
Paget’s disease (αvβ3 integrin), myocardial infarction and aortic stenosis (αvβ3 and αvβ5 
integrin).    
The largest area of experience with anti-integrin drugs, however, relates to therapies 
for inflammatory bowel disease.301 Natalizumab is a recombinant humanized 
monoclonal IgG4 antibody against integrin α4, that blocks both α4β7 and α4β1.302 It 
was the first anti-adhesion treatment developed in IBD, although was initially approved 
for relapsing multiple sclerosis.303-306 In the gut, natalizumab disrupts the interaction 
between α4β7 (on leukocytes) and it’s ligand MAdCAM-1 (expressed on intestinal 
endothelial cells).307 This reduces the recruitment of effector T lymphocytes, which 
contribute to dysregulated immune responses and tissue inflammation. Natalizumab 
also interferes with the α4β1/VCAM-1 interaction, affecting lymphocyte migration to the 
CNS, providing the rationale for its efficacy in multiple sclerosis.308 However, this is 
also thought to result in susceptibility to an opportunistic brain infection. Although 
natalizumab was able to induce and maintain clinical remission in patients with Crohn’s 
disease,309-311 its use was complicated by three cases of progressive multifocal 
leukoencephalopathy (PML).312,313 Blocking α4β1/VCAM-1 with natalizumab prevents 
CNS migration of T cells, allowing reactivation of latent JC polyoma virus, and 
development of (typically fatal) PML.301 This highlights potential off-target adverse 
effects of targeting integrins in humans.  
Vedolizumab is a humanized IgG1 monoclonal antibody against α4β7 integrin, specific 
for the α4β7/MAdCAM-1 interaction.307 It is therefore anticipated that the drug will not 
affect lymphocyte trafficking anywhere other than the gut, abrogating the risk of PML. 
Vedolizumab is currently licensed for induction and maintenance of remission in 
moderately to severely active ulcerative colitis and moderately to severely active 
Crohn’s disease, that has failed to respond to standard immunosuppression.314,315 It 
has also been suggested that this treatment could be considered in primary sclerosing 
cholangitis, where it is hypothesized that aberrant hepatic expression of MAdCAM-1 
recruits effector cells originally activated in the inflamed gut.316 This is hoped to be the 
subject of a clinical trial.  
Following on from the discovery that partial inhibition of integrin αvβ6 could prevent 
pulmonary fibrosis in a murine (bleomycin) model, a monoclonal antibody (3G9) is now 
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being evaluated in humans with idiopathic pulmonary fibrosis.317 Horan et al 
demonstrated that αvβ6 monoclonal antibody treatment attenuated fibrosis in the 
mouse model, without causing inflammation in multiple organ systems relating to TGF-
β deficiency.317 Results from human studies are awaited with interest.  
Translating positive results from animal models into the development of clinically useful 
anti-integrin therapies is not entirely straightforward however. Integrins αvβ3 and αvβ5 
are expressed abundantly in tumour-associated endothelial cells;318,319 promising results 
from pre-clinical experiments in models of glioblastoma led to the development of the 
pentapetide integrin inhibitor cilengitide.320 Unfortunately, when investigated in two 
clinical trials (to separately analyse efficacy in patients with or without a certain O6 –
methylguanine DNA methyltansferase promoter methylation) neither the ‘CENTRIC’321 
nor the ‘CORE’322 trials met their primary endpoints. Subsequent immunohistochemical 
analysis of integrin expression patterns within the tumours included in the phase III 
CENTRIC trial found that αvβ3 and αvβ5 expression did not correlate with prognosis in 
these patients.320 There was a weak association with improved outcome with cilengitide 
in the phase II CORE trial, suggesting that patient enrichment based on αvβ3 expression 
within tumours might be useful in future studies. However it has been suggested that 
agents with higher potency than cilengitide might be needed to clarify whether integrins 
are a worthwhile target in glioblastoma, and that downstream markers of integrin 
pathway activation might be more useful biomarkers to guide patient enrichment rather 
than integrin expression patterns alone.320  
3.2 Targeted αv integrin depletion on HSC in HCC 
 
Targeting HSC 
Transgenic mouse technology has progressed from simple global gene knockout 
systems, to the development of Cre-lox technology in the 1980s.323 This has transformed 
our ability to manipulate specific genes and cell lineages, to better understand their roles 
in the pathophysiology of liver disease. The bacteriophage P1 cre (cyclization 
recombinase) gene catalyses DNA recombination between pairs of ‘locus of X-over in 
P1’ (loxP) sites. The desired location of Cre expression is achieved by using cell-specific 
cre promoters. Similarly, inducible systems can temporally restrict cre expression. Cre 
can initiate deletion, inversion or translocation of the ‘floxed’ (flanked by loxP) locus 
depending on the location and orientation of loxP sites. Usually, loxP sites are inserted 
on the same chromosome, a small distance apart, and in the same orientation. This 
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results in excision of the floxed segment, therefore precluding the assembly of a 
functional gene product (Figure 3.3).324  
Cre-lox can also be utilized to provide intrinsic cellular labelling, by cell-specific 
fluorescent protein expression. This is achieved by the insertion of a floxed STOP codon, 
meaning that transcription of the downstream sequence (in this case a fluorescent 
reporter construct) only occurs following Cre-mediated excision.324 Whilst the Cre-lox 
approach is a sophisticated method of influencing a gene of interest, interpretation of 
results must incorporate consideration of potential off-target effects, or ‘Cre toxicity’. 
Unintended Cre expression in nontargeted cell lineages can confound the conclusions 
drawn from gene-deletion or fate-tracing experiments.325 The recombination efficiency 
(sensitivity) and expression pattern (specificity) for each Cre strain should therefore be 
extensively characterized prior to use.324 
Up until recently, there was a relative lack of tools allowing consistent, specific 
inactivation of genes in nonparenchymal cells within the liver, such as HSC. Currently, a 
number of Cre drivers are available to target HSC/myofibroblasts (Table 3). 
Pdgfrb-Cre mice target both quiescent HSC and activated myofibroblasts;234 Cre is 
expressed under the control of a Pdgfrb gene fragment, driving efficient recombination 
in both HSC phenotypes, with high specificity. Henderson et al characterized this Cre 
driver extensively in both uninjured and fibrotic liver.234 The Pdgfrb-Cre strategy was then 
used to demonstrate that targeted depletion of αv-containing integrin subunits on HSC 
protects against CCL4-induced hepatic fibrosis. Furthermore, αv-null HSC had reduced 
ability to activate TGF-β. This was confirmed with use of a small-molecule inhibitor to 






Figure 3.3 Schematic diagram of cell-specific Cre recombinase-induced gene 
inactivation and fluorescent reporter expression systems.  
Reproduced from Greenhalgh et al 2015.324 
A Cell-specific expression of Cre recombinase results in excision of loxP-flanked 
sequences leading to gene inactivation or fluorescent reporter expression. 
B Spatiotemporal regulation of Cre activity: tamoxifen (TAM) administration permits entry 
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HSC, VSMC, portal fibroblast 
Michelotti et al 2013,326 Swiderska-
Syn 2014327 
Kisseleva et al 201229 
Kisseleva et al 201229 
Troeger et al 201230 
Abbreviations: c, constitutive; i, inducible; VSMC, vascular smooth muscle cells 
Table 3: Cre drivers that may be used to target HSC/myofibroblasts (adapted from Greenhalgh et al324)
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3.3 Hypothesis and aims 
HSC αv integrins are key regulators of TGF-β activation during the stromal reaction in 
hepatic carcinogenesis. Targeted inhibition of αv integrin-mediated TGF-β activation by 




 To investigate the role of HSC αv integrins during hepatocarcinogenesis in a 
mouse model of HCC, by targeted αv integrin depletion on HSC 
 To also assess the role of hepatocyte αv integrins during hepatocarcinogenesis 
in a mouse model of HCC, by targeted αv integrin depletion on hepatocytes 
3.4 DEN model of murine hepatocarcinogenesis 
Animals 
Animals were housed in standard sterile conditions with free access to chow and water. 
All procedures were undertaken in accordance with the local ethical committee.  
Pdgfrb-Cre mice were a kind gift from Ralf Adams.328 Pdgfrb-Cre and Alb-Cre329 mice 
(obtained from the Jackson Laboratory) were crossed with Itgavflox/flox mice330 (C57/BL6 
background). Genotyping of all animals was performed by polymerase chain reaction.  
 
Hepatocarcinogenesis 
Male mice aged 12-14 days received a single intraperitoneal (IP) injection of DEN (25 
mg/kg body weight; Sigma Chemical Co, St. Louis, MO, USA) and were sacrificed at ten 
months post-injection. Livers were rapidly excised and weighed. The presence and 
dimensions of surface nodules were evaluated and recorded. The median lobe was fixed 
in 10% formalin then paraffin embedded, from which 5μm slides were cut and stained 
with H and E. HCCs were confirmed histologically from either grossly or histologically 
evident nodules. A proportion of liver tissue was snap-frozen in liquid nitrogen for later 
analysis. A further sample was fixed in methacarn and paraffin-embedded. A last liver 
sample from each mouse was fixed in 4% paraformaldehyde, taken through sucrose 




Figure 3.4 Induction of hepatocarcinogenesis: DEN injection 
Male transgenic mice and cre negative controls were injected at 12-14 days of age with 
a once-off IP dose of 25mg/kg DEN. Animals were sacrificed and livers harvested at 10 





Figure 3.5 Confirmation of ɑv integrin loss  
A Western blot for ɑv integrin: primary mouse HSC, PDGFRβCre+/-;ɑvfl/fl 
versus cre negative control. B Western blot for ɑv integrin:  




3.5 Targeted αv integrin depletion on HSC in a mouse model of HCC  
 
Loss of HSC αv integrins does not affect tumourigenesis in the DEN model of 
HCC 
Confirmation of αv integrin loss on HSC in PDGFRβ-Cre+/-;αvfl/fl positive animals was 
previously established by Neil Henderson by western blot (Figure 3.5). At ten months 
post DEN injection, virtually all animals had tumours within the harvested liver. One 
animal in each group had a macroscopically normal liver with no visible lesions; these 
were excluded from analysis. Mean lesion size in the PDGFRβ-Cre+/-;αvfl/fl  cohort was 
7.94mm ± 1.44 (standard error of the mean, (SEM)). This cohort consisted of 18 
animals. Mean lesion size in the cre negative control group was 10.34mm ± 1.33 
(n=17). There was no significant difference between the two groups (p=0.23). Lesion 
number was also similar between the two groups: mean 12.50 ± 2.06 in 
PDGFRβCre;αvfl/fl animals, and 14.82 ± 2.45 in controls, p=0.47. Lesion number was 
also analysed by size, to ensure large tumours were not overrepresented in either 
group (Figure 3.6). Numbers of small, medium and large tumours were comparable, 
with no clear effect of αv integrin loss on HSC. There was no difference in liver-to-body 




Figure 3.6 Targeted αv integrin depletion on HSC during hepatocarcinogenesis 
A (i) Comparison of lesion size (measured using digital calipers) and number (ii); (iii) 
liver:body-weight ratio; (iv) lesion numbers grouped by size  




3.6 Targeted αv integrin depletion on hepatocytes in HCC 
 
Loss of αv integrins on hepatocytes does not affect tumourigenesis in the DEN 
model of HCC 
Loss of αv integrin on hepatocytes in AlbCre+/-;αvfl/fl animals was previously 
demonstrated by Neil Henderson (Figure 3.5).  
In this experiment, two animals in the control group and one AlbCre+/-;αvfl/fl animal had 
no visible liver lesions at ten months, and were therefore excluded from the analysis. 
This left 10 animals in the AlbCre+/-;αvfl/fl group, and 17 controls. AlbCre+/-;αvfl/fl mice 
showed similar lesion characteristics to control animals (mean size 11.68mm ± 1.93 
compared with 9.39mm ± 3.85, p=0.52). Again, there was no difference in lesion 
number, mean 8.60 ± 2.14 vs 12.00 ± 1.97, p=0.28. Similarly, liver-to-body weight 






Figure 3.7 Targeted αv integrin depletion on hepatocytes during 
hepatocarcinogenesis 
A (i) Comparison of lesion size (measured using digital calipers) and number (ii);  
(iii) liver:body-weight ratio; (iv) lesion numbers grouped by size 




The results presented demonstrate that loss of αv integrin on HSC or hepatocytes does 
not protect against hepatocarcinogenesis in the murine model of DEN-induced HCC. 
Lesion size and number were similar in large cohorts of mice with cell-specific, targeted 
αv loss compared with controls. This was unexpected, as I had anticipated that loss of 
αv integrin on HSC or hepatocytes might have reduced hepatocarcinogenesis in this 
model. I hypothesized this might have occurred via a TGF-β-mediated mechanism, 
particularly in light of evidence linking TGF-β to hepatocellular EMT and intrahepatic 
metastasis.192 However, further consideration of the strengths and weaknesses of this 
murine model of HCC is required before drawing firm conclusions about the role of HSC 
and hepatocyte αv integrins and TGF-β in human HCC. The DEN model was chosen 
primarily because the tumours generated display similar gene expression patterns to 
human HCC.256 It is a well-established model for testing the effect of specific genes using 
transgenic mice, or the efficacy of experimental drug treatments. However, it is a model 
with a long latency period, requiring ten months before reliable development of HCC. 
This was a limitation in terms of the time constraints of my PhD project; the lack of a 
robust, rapidly growing, in vivo HCC model is also a significant limitation in this field of 
research. Currently, implantation models of HCC are widely used, due to their much 
shorter latency period and lower cost.331 Most commonly, the subcutaneous xenograft 
model is used, in which human HCC cells, or tumour tissue fragments, are implanted 
into immunodeficient mice (such as nude mice, severe combined immune deficient mice, 
or nonobese diabetic-severe combined immunodeficiency disease mice).331 Cells or 
tissue fragments are typically implanted subcutaneously into the flank. Whilst these 
systems are relatively easy to set up and monitor tumour size (estimated tumour volume 
can be calculated every few days from caliper measurements, or by using an in vivo 
fluorescence imaging approach332) any interaction with the native hepatic parenchyma 
is lost. Additionally, all contributions of the hepatic microenvironment to tumour growth 
are eliminated, which I hypothesized might be critical in any αv integrin-mediated effects. 
It is recognized, for example, that spontaneous metastasis is extremely rare when HCC 
cells are subcutaneously implanted. Conversely, in orthotopic implantation models 
(where the tumour cells are injected into the liver, or tissue fragments are implanted 
directly into the liver of immunodeficient mice) spontaneous metastasis is reported.331,333 
Orthotopic xenograft models therefore have some advantages in terms of reproducing 
the microenvironment. However tumour volume can only be measured upon sacrificing 
the animal. There are some further technical issues; during injecting tumour cells, it is 
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possible that seeding along the needle track or into blood can occur, and implanting 
tumour tissue into the liver is more practically challenging in comparison with ectopic 
xenografts. Moreover, the requirement for using immunodeficient mice in all xenograft 
models also eliminates contributions from the host immune system, which may be highly 
relevant in terms of tumour progression and metastasis.  
Allograft models involve injecting murine tumour cells via the portal vein or splenic vein, 
or orthotopic implantation of murine HCC cell lines.331 These have the advantage of not 
requiring immunodeficient host mice, although it is not entirely clear how well tumour 
biology in these systems replicates the human disease. Kornek et al implanted murine 
HCC cells into fibrotic mice livers, to investigate HCC angiogenesis in animals with pre-
existing fibrosis.334 This approach mimics human HCC arising in cirrhotic liver. However, 
overall I felt that whilst the xenograft models were useful in terms of testing changes in 
tumour progression and metastasis, they were less helpful in cases where a gene might 
affect the early stages of tumour initiation. For these reasons, I used the chemically-
induced method of hepatocarcinogenesis using the well-characterised genotoxic agent 
DEN. I felt this was a more faithful method to tease out any potential protective effect of 
loss of HSC or hepatocyte αv integrins, in transgenic, immunocompetent mice. Whilst 
there are a number of genetically engineered mouse models of HCC, very few 
constitutive or conditional expression systems have a shorter latency period than the 
DEN model, and not all have 100% incidence of HCCs.331 Although one inducible 
expression system (a tetracycline-controlled system) resulted in liver tumours after 
approximately 12 weeks,335 combining this with targeted deletion of αv integrins would 
require a prolonged, cumbersome breeding strategy.  
Although I had reservations about engineering a second genetic manipulation in αv 
integrinfl/fl mice to try to reduce the DEN latency period, I was interested in whether 
combining a genetic modification with this chemical carcinogen could achieve earlier 
HCC formation, as this would represent a useful contribution to the field of liver cancer 
research. To this end, I collaborated with Dr Rachel Guest to try to generate a novel 
model of HCC with reduced tumour latency. Here, IP DEN administration at day 15 was 
combined with genetic loss of the tumour suppressor p53 in hepatocytes. The Ahcre 
transgenic line was used, in which cre expression is inducible from a cytochrome P450 
promotor element, that is transcriptionally up-regulated in response to the lipophilic 
xenobiotic beta-napthoflavone. The transgene was induced by IP beta-napthoflavone at 
six weeks of age (i.e. p53 lost at this stage) and animals monitored for clinical signs and 
weight loss for 52 weeks prior to harvest (n=6 and n=6 controls). There was no significant 
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difference in tumour size or number at harvest, and no animals required early harvest 
due to clinical deterioration suggestive of advanced malignancy. Other attempts to 
accelerate carcinogenesis in the DEN model include phenobarbital injection,336 
expression of foxm1b,337 HGF,338 interleukin-22,339 macrophage inflammatory protein-1 
and its receptor (CCR1/CCL3).331,340 To date, these additions to DEN alone have had 
relatively weak effects on tumour latency.  
One limitation of the DEN model was that tumour growth could not be easily monitored 
prior to culling the animal. I considered magnetic resonance imaging at various time 
points but concluded this would not be cost-effective. I also considered sacrificing 
animals at different time points, such as six months, eight months and ten months. This 
would perhaps have demonstrated any early effect of αv integrin loss on tumour initiation, 
which might have been lost by ten months. However this would have required larger total 
animal numbers, and my experience (having culled a few animals early in a small pilot 
experiment) was that very few lesions were visible at six months. I felt that any small 
effect on tumour initiation that could have been missed by harvesting all animals at one 
time point would be unlikely to have significant therapeutic implications, if this effect was 
lost by the time the tumours had fully matured.  
Another disadvantage of the DEN model was the fact that hepatocarcinogenesis occurs 
in a non-cirrhotic liver. Since the start of this project, Uehara et al published a protocol 
for co-treatment of mice with a once-off low dose DEN injection at day 14, and 
subsequent regular low-dose injections of CCL4 as a pro-fibrogenic agent.341 This 
resulted in hepatic fibrosis and development of adenomas at 5 months, at which point 
50% of animals also had HCC lesions. The reported acceleration of tumourigenesis was 
relatively modest, however it perhaps recapitulates human HCC more faithfully, with 
lesions arising on a fibrotic background.341,342 The time constraints of my project 
precluded the use of this new protocol in αvfl/fl mice, but this would be very interesting to 
compare with DEN alone in future studies.   
In my DEN HCC models, animals developed multiple visible lesions at ten months. It is 
acknowledged that, like human HCC, DEN-induced HCC occurs in a stepwise process, 
starting with preneoplastic foci of abnormal hepatocytes, progressing to adenoma 
formation and then carcinoma. I did not proceed with independent examination of the 
harvested livers by a histopathologist, as there was no macroscopic difference in tumour 
size or number, making an overall difference in propensity to HCC highly unlikely. It is 
therefore possible that some of the lesions counted could have been benign adenomas 
rather than HCC, but in the absence of a clear macroscopic phenotype, I felt that detailed 
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histopathological analysis was not indicated. Similarly, analysis of downstream changes 
in TGF-β signalling between the two groups was not performed as we had not observed 
a clear phenotype between the groups.  
Finally, it should be considered, that the observed standard deviation for lesion number 
in all cohorts, was relatively large. Using my exploratory study data from the PDGFRβ-
Cre+/-;αvfl/fl experiment, to inform a sample size calculation, a total of 204 mice would be 
required to enter this two-treatment parallel-design animal study. The probability is 80% 
that this study would detect a treatment difference, at a two-sided 0.05 significance level, 
if the true difference between treatments were 3.7 lesions (25% change from the mean 
of the baseline population). This is based on the assumption that the common standard 
deviation of the response variable is 9.36. Similarly, for the AlbCre+/-;αvfl/fl group, using 
my study data to inform a sample size calculation, a total of 208 mice would be required 
to enter this two-treatment, parallel-design animal study. The probability is 80% that the 
study would detect a treatment difference at a two-sided 0.05 significance level, if the 
true difference between treatments were 3 lesions (25% change from the mean of the 
baseline population). This is based on the assumption that the common standard 
deviation of the response variable is 7.7. The experiments were therefore underpowered, 
although this was something I could not have fully anticipated; I used sample sizes that 
were larger than many examples in the literature, and the time constraints of my project, 
combined with the long latency period of tumour formation, meant that a pilot study for a 
power calculation was not feasible.  
In summary, the role of TGF-β in HCC pathogenesis is complex and context dependent. 
It may have tumour-suppressive actions in the early stages of liver injury and 
regeneration, but could exacerbate tumour invasiveness and metastasis during HCC 
progression. Targeted loss of αv integrin on HSC or hepatocytes did not result in any 
reduction in tumour burden in this non-cirrhotic model of hepatocarcinogenesis. However 
this could inform future investigation in larger cohorts. Furthermore, evaluation in a 
cirrhotic model of HCC may provide further insight into the role of local αv integrin-




Chapter 4: HSC and acute liver injury 
4.1 Introduction 
Paracetamol poisoning is the major cause of ALF in the UK and US.56 Despite the 
availability of an effective antidote (N-acetylcysteine) and public health measures such 
as restricting sales, deaths from paracetamol-related acute liver failure still occur. ALF is 
more common with late presentation to medical attention due to unintentional overdose 
as opposed to deliberate self-poisoning.56 Although orthotopic liver transplantation is 
effective, around 50% of patients will have psychiatric or medical contraindications 
precluding this treatment.343 Eligible patients who meet criteria for transplantation are at 
risk of perioperative complications related to coagulopathy, organ failure, sepsis, and 
encephalopathy. As such, there is a pressing need for alternative treatments for 
paracetamol-induced acute liver failure.  
Nontransplant therapies available for non-paracetamol ALF are scarce.57 Use of N-
acetylcysteine has been explored for other aetiologies, as it can improve liver 
oxygenation, and has antioxidant, anti-inflammatory and immunologic properties.344 It 
may also improve haemodynamic parameters and cerebral perfusion pressure.57,345,346 
However, whilst N-acetylcysteine may have a role in mushroom poisoning and drug-
induced liver injury resulting in ALF,57 a meta-analysis of the safety and efficacy of the 
drug in adult non-paracetamol ALF found no significant overall survival benefit.347 Other 
nontransplant therapies for specific aetiologies include steroids for drug-induced liver 
injury, and ribavirin for acute hepatitis E infection.57 However there is currently no 
available medical therapy of proven benefit to all cases of ALF, regardless of aetiology. 
Patient outcome is highly dependent on the extent of liver regeneration post-injury. This 
has prompted investigation into potential drug targets which could be manipulated to 
boost the regenerative response. This could be particularly relevant in paracetamol-
induced ALF, where an attractive management strategy might include the co-
administration of N-acetylcysteine with a novel hepatic regenerative agent, alongside 
established multi-organ supportive measures.  
There has been some progress in efforts to augment the regenerative response, at least 
in experimental models of ALF; for example stimulation of regeneration by administration 
of growth factors such as VEGF has been shown to improve survival following 
paracetamol overdose in mice.348 Additionally, macrophage colony-stimulating factor 1 
(CSF1) could represent a promising therapeutic target.57 Stutchfield et al showed that 
low serum levels of CSF1 in patients with paracetamol-induced ALF was associated with 
increased mortality.349 Furthermore, CSF1-Fc (fragment, crystallizable) administration 
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increased innate immunity in mice after paracetamol overdose, promoting hepatic 
macrophage accumulation via proliferation of resident macrophages, and monocyte 
recruitment.349  
 
HSC and acute liver injury  
Innate immune dysregulation in ALF is a critical part of this pathophysiological 
process.73 Much attention has therefore focused on the role of neutrophils, monocytes 
and macrophages, in particular the plasticity of hepatic macrophages, which can range 
from pro-inflammatory to pro-resolution in their functional phenotype. The contribution 
of non-immune, non-parenchymal cells is less well characterized. Although it has long 
been acknowledged that HSC play a key role in the fibrotic response to injury,37 their 
function in acute liver injury is less clear.  
As discussed previously, tools to reliably deplete activated HSC have only relatively 
recently become available. There is some evidence that these cells may be protective in 
acute liver injury, but a number of different cell-targeting methods and models of injury 
are used in these studies, and each set of results must therefore be interpreted carefully.  
Shen et al hypothesized that during acute liver injury depletion of activated HSC may 
lead to more significant liver damage and abnormal liver regeneration.350 They used the 
fungal metabolite gliotoxin to induce apoptosis of activated HSC. Gliotoxin was 
administered two hours after paracetamol overdose in mice. Elevated ALT levels, more 
severe necrosis, and reduced survival were observed in the gliotoxin group. This was 
accompanied by reduced hepatocyte replication in this group, which was demonstrated 
by a reduction in hepatocyte bromodeoxyuridine (BrdU)-positivity. The authors 
hypothesized that HSC-derived growth factors and cytokines might be protective to 
hepatocytes during acute injury. However, an unconventional paracetamol dosing 
scheme was used in these experiments (three doses of 300mg/kg with three days in 
between each dose) which might have induced some chronicity of injury, perhaps 
modelling acute liver injury less faithfully. Furthermore, relatively small numbers (n=4 in 
each group) of animals were used for an experiment to check gliotoxin itself was not 
hepatotoxic, which may not have been adequately powered.350  
The same group went on to investigate the roles of HSC at different activation stages, 
during acute liver injury.351 Mouse HSC were cultured in vitro, to either an early stage of 
activation (‘initiation HSC’), or a more established activation state (‘perpetuation HSC’). 
Paracetamol-injured mice were then treated (in vivo) with conditioned medium (CM) from 
these two HSC groups. It was found that conditioned medium from the initiation HSC 
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was protective in terms of survival and histological grading of necrosis. This may relate 
to a reduction in hepatoprotective HSC-derived factors (such as IL-10 and HGF) with 
later stages of activation.351  
Conversely, Stewart et al proposed that HSC contribute to hepatocellular damage during 
acute liver injury, using ischaemia/reperfusion and endotoxin-induced injury models.352 
Here, mice expressing HSV-thymidine kinase under the glial fibrillary acidic protein 
(GFAP) promoter were treated with CCL4 to activate HSC, and render them susceptible 
to phosphorylated ganciclovir-induced death. Animals subsequently received 10 days 
ganciclovir treatment prior to undergoing acute liver injury. Injury was more pronounced 
in the CCL4/ganciclovir-treated groups compared with controls.352 However, the authors 
acknowledge that 10-15% of HSC do not express GFAP,353 and this genetic marker is 
no longer widely accepted as a robust method of targeting HSC. 235,354 Evidence also 
implicates HSC in the recovery phase of acute liver injury, via generation of induced 
regulatory T cells (iTregs), which act to terminate inflammation and promote healing.355 
Lu et al postulated that HSC may contribute to iTreg formation by two parallel pathways. 
Active TGF-β, together with all-trans retinoic acid (RA), can induce peripheral naïve 
CD4+ cells into functional iTregs (CD4+CD25+Foxp3+). Therefore HSC may help 
generate iTregs via both MMP-mediated TGF-β activation and the retinol/RA pathway.355 
Lu et al demonstrated that TGF-β activation and iTreg induction were impaired in MMP9 
and MMP13 knockout mice, and in mice with conditionally defective TGF-β signalling in 
CD4 T cells.355 The same group also showed that adoptive transfer of HSC in the context 
of hepatic ischaemia/reperfusion injury was protective, although the underlying 
mechanism was not confirmed.356 Subsequently, Feng et al went on to demonstrate that 
tail vein injection of HSC followed by acute thioacetamide-induced liver injury resulted in 
improved ALT and liver histology compared with controls.357 Depletion of Tregs 24 hours 
after HSC treatment abrogated this improvement, suggesting that they are involved in 
the protective effects of HSC. Furthermore, in culture, HSC medium was able to induce 
Tregs from naïve T cells.357 However, definitive evidence that this occurs in vivo is 
currently lacking.    
Although these studies suggest that TGF-β may favour resolution of injury by immune 
mechanisms, others have suggested that TGF-β1/Smad3 signalling may have 
deleterious effects in drug-induced acute liver injury. Niu et al showed that TGF-
β1/Smad3 signalling was increased in acute CCL4 injury.358 Overexpression of Smad3 
(by tail vein injection of Smad3-expressing plasmids) during CCL4 treatment resulted in 
worse liver injury, with increased infiltration of inflammatory cells, cytokine release and 
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hepatocyte apoptosis.358 TGF-β therefore, may have distinct local and temporal effects 
in acute liver injury, and warrants further investigation.  
Whilst Henderson et al demonstrated a clear protective role for targeted αv integrin 
inhibition on HSC in CCL4-induced chronic liver injury,234 the role of HSC and integrin-
mediated TGF-β activation in acute liver injury is much less clear; in view of intriguing 
research suggesting that HSC may attenuate acute liver injury, I was therefore interested 
in investigating the effect of selectively targeting αv integrin on HSC (i.e. without blocking 
all HSC-mediated effects) in vivo, in this setting. I hypothesized that this might result in 
reduced TGF-β activation and possibly reduced injury. Similarly, I was interested in 
specifically targeting the β8 integrin subunit on HSC, as this specific αv integrin subfamily 
member (αvβ8) has been shown to have an important role in TGF-β activation in vivo in 
other systems.359 Global loss of β8 integrin in mice is embryonically lethal, therefore 
Henderson et al conditionally depleted this on HSC, to investigate its role in chronic liver 
fibrosis.234 Depletion of this integrin subunit was not found to protect against CCL4-
induced hepatic fibrosis. However, multiple αv-containing integrins might be involved in 
hepatic fibrogenesis and TGF-β activation by HSC. In human studies, others have found 
that integrin αvβ8 expression was increased in the livers of children with biliary atresia,295 
leading the authors to suggest that increased TGF-β activation via αvβ8 interactions with 
MMPs might contribute to the pathogenesis of this condition. Again, little is known about 
the effects of this integrin in acute liver injury, and therefore I investigated the role of 
HSC αvβ8 in acute liver injury, using a genetic approach (PDGFRβCre+/-;β8fl/fl mice).  
 
Liver sinusoidal endothelial cells and acute liver injury 
Liver sinusoidal endothelial cells (LSEC) are highly specialized endothelial cells that form 
the wall of the liver sinusoids. They are selectively permeable, allowing passage of 
certain molecules and cells between blood cells on one side, and hepatocytes and HSC 
on the other.360 They are key drivers of liver regeneration in the context of liver injury361,362 
and have a close relationship with HSC in the space of Disse; activated HSC are 
wrapped round the exterior of LSEC and are thought to induce sinusoidal 
constriction.363,364 Similarly, it has been suggested that LSEC could regulate blood flow 
by swelling, and thereby creating an inlet and an outlet sphincter.363 They have also been 
shown to maintain HSC quiescence, counteracting their vasoconstrictive actions.360,365 
Following acute liver injury, they are thought to regulate the balance between hepatocyte 
and vascular proliferation.360 In paracetamol-induced injury, LSEC have been identified 
as an early and direct target for drug toxicity. LSEC swelling, gap formation and 
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coalescence of fenestrae are observed as early as two hours post-paracetamol, i.e. prior 
to hepatocellular injury.366 It is hypothesized that centrilobular microvascular congestion, 
resulting from sinusoidal wall collapse due to endothelial damage, may represent an 
early, significant event in the pathophysiology and progression of paracetamol-induced 
liver injury.367  
The role of LSEC integrins in acute liver injury has not been studied extensively. 
However, interestingly, Lalor et al demonstrated that αv integrins mediate platelet 
adhesion to LSEC, leading to platelet and endothelial activation and leukocyte 
recruitment.369 It is therefore conceivable that this could be relevant in acute liver injury, 
with integrin-dependent platelet adhesion resulting in sinusoidal injury, via immune cell 
recruitment to the activated endothelium.  
4.2.1 Modelling acute liver injury 
There are numerous methods to induce acute liver injury in different animal models, 
including ischaemia/reperfusion injury, partial hepatectomy and drug overdose. The 
paracetamol model of liver injury is unique in that it is directly comparable to the 
pathogenesis of a major cause of acute liver injury in humans, paracetamol overdose 
being the commonest cause of acute liver failure in the Western world. Large animal 
models of paracetamol overdose such as dogs or pigs allow measurement of 
physiological parameters including intracranial pressure and cardiac output. However 
the murine model facilitates understanding of the pathological mechanisms of liver injury 
and the immune response, as multiple immune markers and antibodies are available for 
this species, as well as numerous knockout mice.370 The pathological mechanisms of 
liver damage in this model, and practical considerations for the experimental protocols 
are discussed in more detail below. 
Whilst I have predominantly used the paracetamol model for the following experiments, 
other pharmacological agents used to induce acute liver injury in the mouse include anti-
Jo-2 antibody (which rapidly leads to hepatocyte apoptosis) and CCL4, and I have utilised 
these models in subsequent intravital imaging experiments.  
4.2.2 Paracetamol model of acute liver injury 
At therapeutic doses, paracetamol is conjugated safely with glucuronic acid or sulphate 
and excreted. In overdose, the drug causes massive hepatocyte necrosis, due to 
excessive metabolism to the reactive metabolite N-acetyl-p-benzoquinone-imine 
(NAPQI), via cytochrome P450 enzymes. Progress in characterizing the mechanisms of 
injury has been made using animal models. NAPQI can be scavenged through 
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conjugation with glutathione, and can react with protein sulhydryl groups to form adducts. 
These protein adducts are thought to precipitate mitochondrial dysfunction and early 
oxidant stress, thereby activating a number of MAP kinases. Finally, c-jun-N-terminal 
kinase is phosphorylated by the actions of different kinases, and subsequently 
translocates to the mitochondria, amplifying oxidant stress and peroxynitrite 
production.344 This results in opening of the membrane permeability transition pore 
(MPT), with loss of membrane potential, and failure of adenosine triphosphate (ATP) 
synthesis. The MPT also causes mitochondrial matrix swelling, with outer membrane 
rupture, and liberation of intermembrane proteins, including endonuclease G and 
apoptosis-inducing factor. Upon translocation to the nucleus, these induce DNA 
fragmentation. The end result is cell necrosis.371 The mode of paracetamol-induced cell 
death was traditionally thought to be via oncosis or oncotic necrosis,371,372 although this 
was contested by a number of authors suggesting a major role for apoptosis. This was 
based on observation of DNA fragmentation and laddering,373 cleavage of poly(ADP-
ribose)polymerase,374 DNA strand breaks detected by TUNEL assay,375 and 
morphological assessment of individual hepatocytes.376,377 These events may not be 
specific to apoptosis, however it is likely that both necrosis and apoptosis are important 
in paracetamol-induced hepatocyte death. More recently, Gujral et al found extensive, 
confluent, centrilobular, oncotic necrosis of up to 60% of hepatocytes in the first 24 hours 
following overdose.378  
 
Paracetamol overdose in the mouse is a well-characterised model of acute liver injury, 
and is widely used for research purposes. Typically, mice are fasted for 12 hours prior 
to administration of IP paracetamol,370 because maintaining normal oral intake results in 
only mild liver injury, poorly representative of acute liver failure. IP doses range from 
300mg/kg to 750mg/kg. At 300mg/kg, spontaneous recovery and 100% survival is 
expected.379 At higher doses (eg 600mg/kg) liver regeneration is significantly impaired. 
From 350mg/kg upwards a degree of mortality can be expected. Hepatocyte necrosis 
starts about one hour after paracetamol administration. Selection of an appropriate 
endpoint depends on the research objective. In the first five hours after injection, 
paracetamol metabolism and initial hepatocyte necrosis are the predominant features. 
From six hours onwards, immune processes are stimulated by hepatocyte necrosis.370 
Hepatocyte injury peaks at 12 hours post-paracetamol.379 Typical endpoints are two 
hours (for metabolism), four hours (for intrinsic cell death pathways) and 6, 12 and 24 
hours (for inflammation and immune-related responses). Liver injury can be assessed 
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by ALT measurement and quantification of the degree of hepatic necrosis observed 
histologically. The course of liver injury and resolution is relatively rapid, but dose-
dependent; at 300mg/kg, in certain strains of mice, regression of injury is seen at 48 
hours, and complete histological recovery and normalization of ALT is observed at 72 
hours. At 600mg/kg there is approximately 25% mortality between 48-96 hours, and 
injury is sustained at 96 hours.379  
4.2.3 FAS model 
Programmed cell death by apoptosis is important in liver development, injury, fibrosis 
and carcinogenesis. Cells dying by apoptosis shrink and condense, with disassembly of 
the nuclear envelope, condensation and fragmentation of the nuclear chromatin, and 
cytoskeleton collapse. If the cell is large, the surface often breaks up into membrane-
enclosed fragments, ‘apoptotic bodies’. Chemical alteration of the cell surface/apoptotic 
bodies means neighbouring cells or macrophages can rapidly engulf them before 
spillage of their contents. This allows neat cell death and rapid clearance without causing 
a damaging inflammatory response.  
Apoptosis can occur by two distinct pathways, the death receptor or extrinsic pathway, 
and the mitochondrial or intrinsic pathway. The DR pathway comprises ligation and/or 
oligomerisation of cell surface receptors to trigger the apoptotic pathway. The 
mitochondrial pathway is triggered by a number of intracellular stress responses 
including intracellular calcium changes and endoplasmic stress responses.380 
Death receptors (DR) are cell surface receptors belonging to the tumour necrosis/nerve 
growth factor (TNF/NGF) receptor superfamily. DRs include Fas and TNF receptors 1 
and 2, death receptor 3 and TNF-related apoptosis-inducing ligand (TRAIL) receptors 1, 
2, 3, and 4. Apoptosis-inducing death receptors are often characterized by a 60-80 amino 
acid death domain in the cytoplasmic tail of the receptor, known as the death domain. 
This allows recruitment of adaptor molecules important for initiating the death signal.380 
The Fas-Receptor (APO-1/CD95) has a single membrane-spanning domain, and is 
expressed in hepatocytes, cholangiocytes, activated stellate cells and Kupffer cells.380 
An alternatively spliced soluble form of the Fas-R without the transmembrane-spanning 
domain can also be expressed by hepatocytes. The soluble form of Fas-R may serve to 
bind Fas ligand on cytotoxic T cells, to minimize liver injury.381 The Fas-R plays critical 
roles in hepatic homeostasis and pathophysiology; the Fas-null mouse develops liver 
hyperplasia likely due to growth unchecked by apoptosis.382 Fas-R expression correlates 
with activity of viral hepatitis.383-385 Inflammatory cytokines can induce and upregulate 
Fas-R expression, suggesting a role for Fas-R dependent liver injury.380,386 This is 
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supported by the discovery that injecting mice with Fas-R agonistic antibodies causes 
rapid fulminant hepatic failure and death.387 
4.2.4 Acute carbon tetrachloride 
CCL4 injection induces an oxidant-mediated hepatocyte injury. Its hepatotoxic properties 
have been recognized for many years,388,389 and it has been extensively studied, mainly 
using chronic injection to induce liver fibrosis. Its toxicity is thought to involve the P450 
cytochrome enzyme 2E1, with the production of an active metabolite.388,390 Cell death 
occurs by apoptosis and necrosis, with the majority of cell damage occurring in the 
centrilobular region.391 In the past, it was widely used in animal models of acute hepatic 
failure. However, it was found to be poorly reproducible and the clinical syndrome of 
acute hepatic failure was not well represented by CCL4 intoxication (little encephalopathy 
and late stage hepatic coma).390 It is therefore more commonly used for chronic fibrotic 
models rather than acute liver injury.  
4.3 Hypothesis 
HSC and LSEC αv integrins are key regulators of TGF-β activation during acute liver 
injury. Targeted inhibition of αv integrins on these cell types may be protective in 
paracetamol-induced acute liver injury. 
4.4 Aims 
 To investigate the specific role of hepatocyte, HSC and LSEC αv integrins in the 
mouse model of paracetamol-induced acute liver injury, using genetic 
approaches 
 To investigate the effects of specific β8 integrin subunit depletion on HSC and 
hepatocytes, in paracetamol-induced acute liver injury. 
 To gain experience with murine models of acute liver injury, in order to develop 
a novel, IVM approach to investigating the cellular and molecular mechanisms of 
hepatic injury and repair.  
4.5 Materials and methods 
Animals 
Animals were housed in standard sterile conditions with free access to chow and water. 
All procedures were undertaken in accordance with the local ethical committee. Animals 
were between eight and 22 weeks old. Within each experiment, the maximum age 
difference between animals was four weeks.  
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Pdgfrb-Cre328 and Alb-Cre329 mice (obtained from the Jackson Laboratory) were crossed 
with Itgavflox/flox mice.330 Pdgfrb-Cre and Alb-Cre animals were also crossed with 
Itgb8flox/flox mice.392 All were maintained on a C57/BL6 background. Cdh5-cre-ERT2 mice 
(Tg(Cdh5-cre/ERT2)1Rha)393 were a kind gift from Ralf Adams. These were crossed with 
Itgavflox/flox animals. Cre recombinase was induced by tamoxifen injection. Tamoxifen was 
prepared in corn oil (20mg/ml) and given IP 100mg/kg daily for three days, followed by 
three days of rest, then daily for three days.  
 
Induction of liver injury 
Paracetamol model 
After an overnight fast, mice were injected IP with 300 or 350mg/kg of paracetamol, 
dissolved in sterile PBS, warmed to 42°C and allowed to cool prior to administration 
(Figure 4.2). After IP injection groups of mice were scored as follows for signs of systemic 
illness: clinically well (0 points), presence of piloerection (1 point), with additional 
hunched posture (2 points) and lack of spontaneous movement (3 points) 24 hours after 
paracetamol. They were harvested at 24 hours; one lobe from each liver was fixed in 
10% formalin, and one in 4% paraformaldehyde. Remaining liver tissue was flash-frozen 
and stored at -80°C for downstream analysis. Serum was also stored at -80°C.    
 
Serum analysis 
All murine serum analyses were kindly performed by Forbes Howie (Centre for 
Inflammation Research, University of Edinburgh) as detailed below.   
 
Total bilirubin 
Total bilirubin was determined by the acid diazo method described by Pearlman and 
Lee394 using a commercial kit (Alpha Laboratories Ltd., Eastleigh, UK) adapted for use 
on a Cobas Fara centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK).  
In this method a surfactant is used as a solubiliser.  Conjugated and solubilised 
unconjugated bilirubin react with diazotised sulphanilic acid to produce an acid 
azobilirubin, the absorbance of which is proportional to the concentration of bilirubin in 
the sample and can be measured at 550nm. Within run precision was CV < 4% while 
intra-batch precision was CV < 5%. 
 
Alanine aminotransferase (ALT)  
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ALT was measured using the method described by Bergmeyer et al,395 utilising a 
commercial kit (Alpha Laboratories Ltd., Eastleigh, UK) adapted for use on a Cobas Fara 
centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK).  Within run 
precision was CV < 4% while intra-batch precision was CV < 8%. 
 
Aspartate aminotransferase (AST)   
AST was determined by a commercial kit (Randox Laboratories, UK) adapted for use on 
a Cobas Fara centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK). 
-oxogluterate reacts with L-aspartate in the presence of AST to form L-glutamate plus 
oxaloacetate. The indicator reaction utilises the oxaloacetate for a kinetic determination 
of nicotinamide adenine dinucleotide (NADH) consumption. Within run precision was CV 
< 4% while intra-batch precision was CV < 5%. 
 
Alkaline phosphatase (ALP)  
ALP was determined by a commercial kit (Randox Laboratories, UK) adapted for use on 
a Cobas Fara centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK). 
The substrate p-nitriphenyl phosphate is hydrolysed by ALP from the sample, in the 
presence of Magnesium ions, to form p-nitophenol which is yellow in colour and it’s 
production can be monitored at 405 nm. Within run precision was CV < 4% while intra-
batch precision was CV < 5%. 
 
Serum albumin 
Mouse serum albumin measurements were determined using a commercial serum 
albumin kit (Alpha Laboratories Ltd., Eastleigh, UK) adapted for use on a Cobas Fara 
centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK). The 
measurement of serum albumin is based on its quantitative binding to bromocresol 
green. The albumin-bromocresol green-complex absorbs maximally at 578nm, the 
absorbance being directly proportional to the concentration in the sample. Within run 
precision was CV < 2.5% while intra-batch precision was CV < 4%. 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded sections were stained with H and E, for analysis of 
tissue injury. 
  
Microscopy and digital image analysis 
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Microscopic examination of tissue specimens was performed using an inverted Zeiss 
Axiovert-200 microscope and Axiovision image acquisition software (Zeiss, Heidenheim, 
Germany).  
Initially, histological grading of hepatic necrosis was performed by a blinded observer 
using H and E-stained sections, using a scoring system from 1-5 (ranging from minimal 
injury to severe haemorrhagic necrosis). More detailed quantification of liver injury was 
then performed using ImageJ (National Institute of Health, USA) and a Wacom tablet. 
For each H and E-stained section (in all cases the left hepatic lobe was used for 
sections), six consecutive fields of x5 magnification were acquired using the Axiovert-
200 microscope. The Wacom tablet was used to draw round patches of necrosis, 
allowing quantification of the necrotic area. The non-cellular area in each field was also 
quantified in this way, as some of the specimens contained a substantial vascular 
component. The final ‘percentage necrotic area’ for each field was therefore calculated 
by subtracting the ‘total necrotic area’ from the ‘total cellular area’ (total field area minus 
non-cellular area). The average of the six fields quantified for each liver sample was then 
taken.  
 
Inhibition of αv integrins by the novel small molecule CWHM 12 
The protocol for inhibition of αv integrins by the small molecule inhibitor CWHM12 was 
devised in collaboration with David Griggs (Saint Louis University, St. Louis, USA). 
CWHM 12 was solubilized in PBS, for IP injection. The dosing regimen for the inhibitor 
was based on simulated pharmacokinetic profiles of CWHM 12 plasma levels following 
single dose and repeated dose IP administration. Following 100mg/kg IP CWHM 12 
injection, drug concentration was expected to fall below the 3 uM threshold concentration 
after three hours, according to the simulated graph (Figures 4.3 and 4.4). Therefore in 
order to sustain constant integrin inhibition throughout paracetamol-induced liver injury, 
three-hourly dosing intervals were chosen. From simulated calculations, increasing the 
dose to 200mg/kg was not expected to significantly lengthen the dosing interval required. 
Animals were fasted prior to induction of liver injury as described above. The first IP 
injection of CWHM 12 (100mg/kg) was given 1 hour prior to paracetamol injection 
(350mg/kg). CWHM 12 was then administered 3 hourly (100mg/kg each time) for a total 




Figure 4.1 Paracetamol metabolism 
Adapted from Mossanen et al 2015.370 
N-acetyl-p-aminophenol (paracetamol) is metabolized by different isoforms of 
cytochrome P450 (mainly CYP2E1) leading to formation of the toxic metabolite NAPQI 
in hepatocytes. Glutathione binding can convert low levels of NAPQI into the inactive 
reduced form. In paracetamol overdose, glutathione stores are depleted, and NAPQI 
starts to bind mitochondrial proteins. The NAPQI protein adducts lead to hepatocyte 
necrosis. N-acetyl-cysteine, a glutathione precursor, is an effective treatment option 












Figure 4.3 CWHM 12 Simulated plasma concentrations (uM)  
Graph showing simulated plasma concentrations of CWHM 12 after single or repeated  
IP injections. Calculated from rat IV data. From 100mg/kg mini-pump studies, steady  
state mean plasma concentrations ranged from 3.58 to 9.03 uM. Simulations were  
based on 3uM troughs. With 100mg/kg dose every 3 hours, plasma concentration 
would drop below 3 uM after 9 hours. With 50mg/kg dose every 2.5 hours, plasma 
concentration would drop below 3 uM after 7.5 hours. With 25mg/kg dose every 2 














Figure 4.4 CWHM 12 Simulated plasma concentrations (uM)  
Graph showing simulated plasma concentrations of CWHM12 after repeated doses. 
From 100 mg/kg mini-pump studies, steady state mean plasma concentrations ranged  
from 3.58 to 9.03 uM. Simulations were based on 3 uM troughs.100 mg/kg dose every 
3 hours was projected to result in plasma levels below 3 uM after 10hr. 200 mg/kg 





4.6 Targeted αv integrin depletion on HSC in a mouse model of paracetamol-
induced acute liver injury 
All experiments presented in Chapter 4 will be summarised in Confirmation of αv integrin 
loss on HSC in PDGFRβCre+/-;αvfl/fl animals was previously established by Neil 
Henderson by western blot (Figure 3.5). The first acute liver injury experiment was 
performed using 14 week-old male mice, n=6 PDGFRβCre+/-;αvfl/fl and n=6 cre negative 
control animals (Figure 4.5). The length of overnight fast was 16 hours. Three animals 
died before the intended harvest point at 24 hours. Post-mortem examination revealed 
macroscopically haemorrhagic liver, consistent with death from acute liver failure. From 
the H&E liver sections harvested at 24 hours, an initial injury score for each animal was 
calculated by a blinded observer. Mean injury score was 3.33 for the PDGFRβCre+/-;αvfl/fl 
group, and 4.67 for the control group. There was a striking mortality difference: 50% 
mortality observed in the control group, compared with no deaths in the PDGFRβCre+/-
;αvfl/fl group. ALT data was unfortunately not obtained for the animals that died. Of the 
animals for which serum was successfully analysed, all had evidence of acute liver injury, 
with ALT >2000 at 24 hours. Mean ALT in the PDGFRβCre+/-;αvfl/fl cohort was 6287 + 
2360 (SEM) and 7747 + 3660 in the controls (p=0.74). Percentage necrosis was 
calculated from H&E sections for each harvested liver, including the animals that died. 
The mean percentage area of necrosis for each group was 34.00 + 10.00 for 
PDGFRβCre+/-;αvfl/fl animals and 64.99 + 10.02 for controls, which did not quite reach 
significance (p=0.0534).  
In the next experiment (Figure 4.6) I used female mice, hypothesizing that they might 
tolerate liver injury better than males. I therefore anticipated that all animals might survive 
the experiment, allowing ALT measurement in all cases. Here, n=6 (in each group) 11 
week-old female mice received 350mg/kg paracetamol after a 16 hour fast. As expected, 
all animals survived the experiment, allowing a full set of ALT measurements to be 
obtained. Mean ALT was 2902 + 721 in the PDGFRβCre+/-;αvfl/fl  compared with 4790 + 
1550 in the control group (p=0.30). There was an outlier in the PDGFRβCre+/-;αvfl/fl group, 
in whom ALT was only 560 at 24 hours, suggesting less severe liver injury. This was 
consistent with a smaller percentage necrotic area of 44.86 in this animal. Mean 
percentage necrotic area was 58.07 + 2.81 in the PDGFRβCre+/-;αvfl/fl group, and 58.42 
+ 3.79 in controls (p=0.94). On re-analysis of the data without this outlier, there was still 






Figure 4.5 Targeted αv integrin depletion on HSC during paracetamol-induced 
acute liver injury  
In this experiment, n=6 male animals in each group. 
A H and E-stained sections (x5 magnification) of liver 24 hours post-paracetamol from 
(i) control animal showing centrilobular necrosis and (ii) control animal that succumbed 
to ALF; (iii) PDGFRβCre+/-;αvfl/fl animals showing centrilobular necrosis and (iv) H and E 
from a PDGFRβCre+/-;αvfl/fl animal with haemorrhagic necrosis. B Percentage mortality 
in each group C (i) Serum ALT at 24 hours post-paracetamol and (ii) Percentage 





Figure 4.6 Targeted αv integrin depletion on HSC during paracetamol-induced 
acute liver injury 
In this experiment, n=6 female animals in each group.  
A H and E-stained sections of liver 24 hours post-paracetamol (x5 magnification) from 
(i) and (ii) control animal showing centrilobular necrosis. (iii) and (iv)  
PDGFRβCre+/-;αvfl/fl animals showing centrilobular necrosis. B (i) Serum ALT at 24 hours 
post-paracetamol and (ii) Percentage necrosis quantified digitally from H and E sections.  
Next, I repeated the experiment using 9 week-old male animals, but shortened the 
duration of the overnight fast to 12 hours, and harvested at 18 hours post-paracetamol 
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injection (Figure 4.7). Here, I anticipated that the younger age, shorter fast, and earlier 
time point for culling might result in all animals surviving to the end of the experiment, 
allowing ALT measurement. Group sizes were again n=6 PDGFRβCre+/-;αvfl/fl and n=6 
control animals. One animal in each group did, however, succumb to acute liver failure 
prior to the end point. This left n=5 in each cohort for ALT analysis. Mean ALT was 
11580 + 1333 in the PDGFRβCre+/-;αvfl/fl group and 7212 + 1901 in the control group 
(p=0.10). Mean percentage necrosis was 66.73 + 7.192 in PDGFRβ-Cre+/-;αvfl/fl 
animals, compared with 68.65% in controls (p=0.85).  
In all three of these experiments, there was no significant difference in ALT or percentage 





Figure 4.7 Targeted αv integrin depletion on HSC during paracetamol-induced 
acute liver injury 
In this experiment, n=6 male animals in each group.  
A H and E-stained sections of liver 18 hours post-paracetamol  (x5 magnification) from 
(i) control animal showing centrilobular necrosis and (ii) control animal that succumbed 
to ALF; (iii) PDGFRβCre+/-;αvfl/fl animal showing centrilobular necrosis and (iv) H and E 
from a PDGFRβCre+/-;αvfl/fl animal that succumbed to ALF. B Percentage mortality in 
each group C (i) Serum ALT at 18 hours post-paracetamol and (ii) Percentage necrosis 
quantified digitally from H and E sections. 
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4.7 Pharmacological αv integrin blockade in a mouse model of paracetamol-
induced acute liver injury 
Finally, a small-molecule inhibitor of αv integrins (CWHM 12) was administered at 3-
hourly intervals, to male C57/Bl6 mice (n=6 in each group), beginning one hour before 
paracetamol injection. The control group received PBS rather than CWHM 12. Animals 
were harvested at 24 hours post-paracetamol. In this experiment, there was a high 
overall mortality (Figure 4.8). In the treatment group 4/6 animals (83.33%) died prior to 
the 24-hour endpoint. In the control group 2/6 animals (33.33%) died. One animal in 
the treatment group had evidence of acute bowel obstruction, and one in the control 
group had urinary retention; these were likely to be complications from multiple IP 
injections. Post-mortem examination of the other animals revealed haemorrhagic liver 







Figure 4.8 Small molecule inhibition of αv integrins during paracetamol-induced 
acute liver injury  
Graph showing percentage mortality in each group  
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4.8 Targeted αv integrin depletion on hepatocytes in a mouse model of 
paracetamol-induced acute liver injury 
Confirmation of αv integrin loss on hepatocytes in AlbCre+/-;αvfl/fl animals was previously 
established by Neil Henderson by western blot (Figure 3.5). 
In this experiment, n=6 female AlbCre+/-;αvfl/fl and n=6 cre negative control animals (all 
11 weeks old) received 350mg/kg paracetamol after a 16 hour fast (Figure 4.9). There 
was no premature mortality. Mean ALT was 6710 + 2016 in the AlbCre+/-;αvfl/fl compared 
with 4062 + 1172 in controls (p=0.28). Mean percentage necrosis was 62.35 + 3.97 in 





Figure 4.9 Targeted αv integrin depletion on hepatocytes during paracetamol-
induced acute liver injury 
In this experiment, n=6 female animals in each group. 
A H and E-stained sections of liver 24 hours post-paracetamol (x5 magnification) from 
(i) and (ii) control animal showing centrilobular necrosis; (iii) and (iv)  
PDGFRβCre+/-;αvfl/fl animals showing centrilobular necrosis  
B (i) Serum ALT at 24 hours post-paracetamol and (ii) Percentage necrosis quantified  
digitally from H and E sections.  
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4.9 Targeted β8 integrin depletion on HSC in a mouse model of paracetamol-
induced acute liver injury 
Confirmation of β8 integrin loss on HSC in PDGFRβCre+/-;β8fl/fl animals was previously 
established by Neil Henderson.234 Acute liver injury was induced with 350mg 
paracetamol after a 16 hour fast, in 11 week-old male mice, n=5  
PDGFRβCre+/-;β8fl/fl and n=6 control animals (Figure 4.10). In this experiment, two 
control animals died prior to the 24 hour end point (33.33% mortality in the control group 
compared with no mortality in the PDGFRβCre+/-;β8fl/fl group). Mean ALT was 2928 + 
833.1 in the PDGFRβCre+/-;β8fl/fl cohort, and 8060 + 3652 in controls (p=0.17). Mean 
percentage necrosis was 43.00 in PDGFRβCre+/-;β8fl/fl animals, and 65.14 + 9.80 in 
controls (p=0.08).  
This experiment was repeated, using a larger cohort of younger male animals, and using 
a reduced dose of paracetamol (Figure 4.11). It was anticipated that all animals would 
survive to 24 hours, in order to obtain a complete set of ALT measurements. Accordingly, 
n=10 PDGFRβCre+/-;β8fl/fl and n=10 control animals received 300mg/kg paracetamol 
after a 16 hour fast. Here, all animals survived.  
Mean ALT was 4696 + 700.9 in the PDGFRβCre+/-;β8fl/fl group, compared with 6096 + 
853.1 in the control group (p=0.22). Mean percentage necrosis was 49.83 + 3.848 in 
PDGFRβCre+/-;β8fl/fl animals, and 50.29 + 4.233 in controls (p=0.94).  
4.10 Targeted β8 integrin depletion on hepatocytes in a mouse model of 
paracetamol-induced acute liver injury 
Confirmation of β8 integrin loss on hepatocytes in AlbCre+/-;β8fl/fl animals was previously 
performed by Neil Henderson (Figure 4.12). Acute liver injury was induced with 
350mg/kg paracetamol after a 16 hour fast. Animals were 12 weeks old, with n=6 in each 
group (Figure 4.12). There was no early mortality in this experiment. Mean ALT was 
6545 + 929 in AlbCre+/-;β8fl/fl animals and 6560 + 628.7 in controls (p=0.10). Mean 
percentage necrosis was 54.01 + 5.94 and 61.69 + 3.75 in AlbCre+/-;β8fl/fl and control 






Figure 4.10 Targeted β8 integrin depletion on HSC during paracetamol-induced 
acute liver injury 
In this experiment, n=6 control and n=5 PDGFRβCre+/-;β8fl/fl male animals in each group.  
A H and E-stained sections of liver 24 hours post-paracetamol (x5 magnification) from 
(i) control animal showing centrilobular necrosis and (ii) control animal that succumbed 
to ALF showing haemorrhagic necrosis; (iii) and (iv) PDGFRβCre+/-;β8fl/fl animals 
showing centrilobular necrosis. B Percentage mortality in each group C (i) Serum ALT 
at 24 hours post-paracetamol and (ii) Percentage necrosis quantified digitally from H and 





Figure 4.11 Targeted β8 integrin depletion on HSC during paracetamol-induced 
acute liver injury 
In this experiment, n=10 male animals in each group received IP paracetamol 300mg/kg. 
A H and E-stained sections of liver 24 hours post-paracetamol (x5 magnification) from 
(i) and (ii) control animals showing centrilobular necrosis; (iii) and (iv)  
PDGFRβCre+/-;β8fl/fl animals showing centrilobular necrosis. B (i) Serum ALT at 24 hours 




Figure 4.12 Confirmation of β8 integrin loss on hepatocytes 
Graph showing β8 mRNA relative expression on hepatocytes from  
AlbCre+/-;β8fl/fl animals and controls (AlbCre-/-;β8fl/fl). Primary mouse hepatocytes were 







Figure 4.13 Targeted β8 integrin depletion on hepatocytes during paracetamol-
induced acute liver injury 
In this experiment, n=6 male animals in each group received IP paracetamol 
350mg/kg. 
A H and E-stained sections of liver 24 hours post-paracetamol (x5 magnification) from 
(i) and (ii) control animals showing centrilobular necrosis; (iii) and (iv) AlbCre+/-;β8fl/fl 
animals showing centrilobular necrosis. B (i) Serum ALT at 24 hours post-paracetamol 




4.11 Targeted αv integrin depletion on LSEC in a mouse model of paracetamol-
induced acute liver injury 
In this experiment, acute liver injury was induced with 300mg/kg paracetamol after a 16 
hour fast (Figure 4.14). Mice were 13 weeks old (n=7 control and n=6 Cdh5Cre+/-;αvfl/fl 
animals). Mean ALT was 3338 + 942 in the Cdh5Cre+/-;αvfl/fl group and 3839 + 658.6 in 
controls (p=0.66). Mean percentage necrosis was 44.66 + 6.53 in Cdh5Cre+/-;αvfl/fl 
animals and 51.46 + 4.46 in controls (p=0.4). All animals survived, and there was no 





Figure 4.14 Targeted αv integrin depletion on LSEC during paracetamol-induced 
acute liver injury 
In this experiment, n=7 control and n=6 Cdh5Cre+/-;αvfl/fl male animals in each group 
received IP paracetamol 300mg/kg. 
A H and E-stained sections of liver 24 hours post-paracetamol (x5 magnification) from 
(i) and (ii) control animals showing centrilobular necrosis; (iii) and (iv) Cdh5Cre+/-;αvfl/fl 
animals showing centrilobular necrosis. B (i) Serum ALT at 24 hours post-paracetamol 





4.12 Summary of Chapter 4 acute liver injury experiments 






















4.5 PDGFRβCre+/-;αvfl/fl 6 M 16 350 24 p=0.74 p=0.0534 50% controls 
4.6 PDGFRβCre+/-;αvfl/fl 6 F 16 350 24 p=0.30 p=0.94 0 
4.7 PDGFRβCre+/-;αvfl/fl 6 M 12 350 18 p=0.10 p=0.85 16.67% each group 
4.8 C57/Bl6 6 M 12 350 24 n/a n/a 83.33% vs 33.33% 
controls 
4.9 AlbCre+/-;αvfl/fl 6 F 16 350 24 p=0.28 p=0.35 0 
4.10 PDGFRβCre+/-;β8fl/fl 5 M 16 350 24 p=0.17 p=0.08 33% controls 
4.11 PDGFRβCre+/-;β8fl/fl 10 M 16 300 24 p=0.22 p=0.94 0 
4.13 AlbCre+/-;β8fl/fl 6 M 16 350 24 p=0.10 p=0.25 0 




Although the initial acute liver injury experiment (Figure 4.5) did not reach statistical 
significance, I still wondered whether targeted αv integrin inhibition on HSC might confer 
protection in this paracetamol model. Whilst the difference in necrotic area did not quite 
reach significance, there did seem to be a mortality benefit in the PDGFRβCre+/-;αvfl/fl 
group. I therefore decided to try to test the hypothesis in the context of slightly less severe 
injury. I was aware that a number of factors could affect the severity of liver injury in this 
mouse model. For example, it is well established that female mice tend to develop less 
hepatic necrosis than male mice, independent of their genetic background.396 In the next 
experiment, therefore, female mice were used, in order to achieve 100% survival at 24 
hours. This allowed ALT sampling in all animals. As expected, liver injury was slightly 
less severe compared with the first experiment. In the control group, mean ALT was 
4790 + 1550, and necrotic area 58.42% + 3.794; conversely in the initial experiment 
using males, mean ALT was 7747 + 3660, and necrotic area was 64.99% + 10.02 in the 
control group. 
In the female experiment, there appeared to be an outlier (Figure 4.6) in the 
PDGFRβCre+/-;αvfl/fl group, which did not demonstrate significant liver injury (ALT 560, 
percentage necrosis 44.86). Whilst this could have been an isolated injection failure, I 
did observe some variety in liver injury throughout these experiments. This is consistent 
with the findings of others, who have presented results from large cohorts of 
paracetamol-treated mice, in which not all animals achieved a rise in ALT.397 However, I 
did find that the variance in ALT and necrotic area improved as my experience with the 
model increased. Practical reasons for this might include a shortening of the injection 
and harvesting times with experience, meaning that animals were dosed and culled at 
very similar times. Additionally, the use of clean cages during the fasting period 
eliminated any chow deposits. Conversely, some factors were difficult to control for. For 
example, even if a strict fasting time is employed, animals might have different individual 
hepatic glutathione levels. Similarly, individual animals might have differing levels of 
hydration throughout induction of liver injury.  
On testing the role of depletion of αv integrin on HSC in female mice during paracetamol-
induced liver injury, I found no significant benefit compared with controls. I then decided 
to investigate this in one more experiment, using male animals, but harvesting at 18 
hours. Here, the aim was to induce significant liver injury, but to harvest animals at an 
earlier time-point, hopefully before any animals succumbed to multiorgan failure. This 
was expected to allow ALT measurement in all mice. However, one animal in each group 
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died before 18 hours. Again, there was no difference in severity of liver injury at 18 hours 
between the groups.  
I therefore concluded that a degree of mortality should be expected at 350mg/kg IP 
paracetamol. I also concluded that targeted inhibition of αv integrin on HSC during 
paracetamol-induced liver injury did not influence severity of liver injury, assessed by 
ALT and quantification of necrotic area.  
In calculating adequate sample sizes for these and subsequent experiments, I used data 
from Mossanen et al.370 They advised that 10 animals per group should be used for 
experiments using IP injection of paracetamol, in order to detect an ALT difference of 
30%. For example, to detect a 50% difference in ALT, only four animals in each group 
would be needed. I therefore chose to use 6-10 animals for these and subsequent 
experiments, as a compromise between achieving sufficient power, but taking into 
consideration the principles of reduction and refinement, in the performance of ethical 
animal research.  
On performing the same experiment in AlbCre+/-;αvfl/fl animals vs controls, I also found 
no difference in severity of liver injury. I therefore decided to use a different method of 
αv inhibition, this time using a global systemic small molecule inhibitor. This experiment 
resulted in significant mortality in both groups, although more in the treatment group. 
However, one animal in each group died from complications of multiple IP injections. 
Excluding these from analysis, mortality would have been 1/5 in the control group vs 3/5 
in the treatment group. It is possible that global αv integrin inhibition is detrimental during 
paracetamol-induced acute liver injury, however I think that the numbers are too small 
make meaningful conclusions from these data. A way to circumvent repeated IP 
injections would be to deliver CWHM 12 continuously via mini-pump. However, on the 
basis of my previous experiments, I did not think there was strong enough evidence for 
potential benefit from treatment, to warrant repeating CWHM 12 administration during 
acute liver injury, using this more invasive approach.  
In subsequent experiments, I used similar methodology to test whether targeted 
inhibition of β8 integrin on HSC or hepatocytes, and αv integrin on LSEC had any effect 
on severity of paracetamol-induced liver injury. Because an initial experiment suggested 
a potential survival benefit for PDGFRβCre+/-;β8fl/fl animals, I repeated this with a large 
sample size (10 in each group), using 300mg/kg rather than 350mg/kg paracetamol. This 




Overall, in this set of experiments, I found that targeted inhibition of αv integrin, or β8 
integrin, on HSC or hepatocytes, and αv integrin on LSEC, did not appear to confer 
protection in a paracetamol-induced mouse model of acute liver injury. Although I initially 
observed greater mortality in the control groups compared with PDGFRβCre+/-;αvfl/fl and 
PDGFRβCre+/-;β8fl/fl animals, this was not borne out upon repetition of the experiments. 
I think this was an artefact secondary to the severe liver injury model used, rather than 
a true survival benefit. To complete these set of experiments, it would have been 
interesting to analyse markers of hepatic regeneration, as well as those of injury. It is 
possible that targeted integrin inhibition on HSC, hepatocytes or LSEC could result in a 
phenotype in hepatic regeneration, in the context of paracetamol-induced acute liver 
injury, even if differences in severity of damage are not seen. It would therefore be useful 
to evaluate Ki67 and BrdU staining in hepatocytes at different time points post-injury in 
these models.  
 
I gained experience with the paracetamol model throughout these studies, which was 
important for planning IVM experiments. I found that using a dose of 300mg/kg IP 
paracetamol resulted in zero mortality at 24 hours (and was well-tolerated in both female 
and male animals) and gave acceptable liver injury. This was useful to identify a 
reasonable starting dose for experiments in which animals had to undergo both 
abdominal surgery and acute liver injury within a relatively short time period. 
Furthermore, I was able to use my expertise with the paracetamol model to contribute to 
the work of other researchers, resulting in co-author publications. I obtained serum from 
animals with acute liver injury for miRNA analysis. Paracetamol toxicity in mice resulted 
in increased miR-122-5p and miR-151a-3p and decreased miR-382-5p, which was 
consistent with the human data in this area.398 These are currently being evaluated as 
potential biomarkers for liver injury in humans. I also performed a series of experiments 
administering paracetamol to C57Bl6 mice at subclinical and toxic doses, to investigate 
the effect of the drug on cell-cell tight junctions. By immunohistochemistry on liver 
sections from paracetamol-treated mice, it was demonstrated that disruption of the tight 
junction-associated zona occludens-1 protein correlated with modulation of hepatic 
ultrastructure. This was dose-dependent, and may have implications for the development 
of therapeutic tight junction-stabilising proteins, relevant to the clinical syndrome of 





Chapter 5: Intravital imaging of the liver  
5.1.1 Intravital microscopy: excitation fluorescence and label-free techniques 
Intravital microscopy (IVM) is a rapidly developing technology, whereby live animals are 
imaged at microscopic resolution. It allows interrogation of cellular interactions in real-
time, and the opportunity to investigate biological processes under nearly natural 
conditions. Imaging is mostly centred on the detection of fluorescence, although label-
free techniques (such as the detection of second harmonic signals) complement this, 
and crucially, add context to cellular events.  
Multiphoton (MP) microscopy is preferentially used for IVM, which facilitates fluorescent 
imaging at greater depths of tissue penetration.399 The MP microscope allows selective 
excitation of fluorescence (Figure 5.1); a fluorophore is excited when it simultaneously 
absorbs two low-energy, near-infrared (NIR) photons, allowing excitation in a particular 
focal plane, where the two photons coincide (two-photon excitation fluorescence 
(TPEF)). Emission of fluorophores in wavelengths that fall in visible light or ultraviolet 
(UV) region can therefore be induced with low-energy NIR photons. Because the two-
photon absorption only occurs in the plane of focus, background scatter from regions 
outside focus is minimized; this results in less photobleaching, reduced phototoxicity, 
and less autofluorescent signal, as compared with confocal microscopy.400,401 TPEF can 
only be achieved at extremely high photon concentration in space and time, 
necessitating very high NIR laser intensities.401 Ultra-short pulsed lasers have now been 
developed, which produce extremely high laser powers transiently, with the pulse 
duration ranging in the femtoseconds, and at high pulse frequency of 80-90 MHz.402 
TPEF signals can therefore be successfully generated at average laser powers lower 
than 5mW incident on the sample.401,403  
 
A number of other microscope technologies can enhance the utility of MP imaging, 
including broad-band MP imaging404,405 and optical frequency domain imaging,406 which 
allow greater imaging depth, and quantification of angiogenesis, lymphangiogenesis and 
tissue viability respectively.400 However, the label-free, nonlinear optical processes of 
second harmonic generation (SHG) and coherent anti-Stokes Raman scattering (CARS) 






Figure 5.1 Jablonski diagram  
Jablonski energy diagram demonstrating the principles of two photon excited  
fluorescence (TPEF) and second harmonic generation (SHG). TPEF requires the  
presence of an actual excited state, whilst SHG is energy-conserving, and does not. 






Figure 5.2 Principles of confocal and two-photon microscopy 
Adapted from: http://www.microscopyu.com/articles/fluorescence/multiphoton/multiphotonintro.html 
Confocal microscopy: excitation light (blue) is focused into the specimen, and the 
fluorescence (green) from that focal spot is captured by the objective lens, passes 
cleanly through the pinhole, and reaches the photomultiplier detector. However, some of 
the fluorescence light can be scattered as it passes back through the specimen (A). This 
scattered fluorescence is lost and not detected. The losses reduce the detected 
fluorescence signal. As the excitation light passes through the specimen, it may be 
absorbed (B) or scattered before it reaches the focus (C). If it is absorbed, it can generate 
fluorescence, but because this does not arise from the focal spot, it is not efficiently 
detected. However, a small portion of out-of-focus fluorescence can be scattered into 
the pinhole, and detected. This creates a background fog, reducing image contrast. The 
scattered excitation can also generate fluorescence (C) which can also contribute to 
background fog (D). 
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Two-photon microscopy: excitation photons (red) can be scattered (E) like in the confocal 
system. However the probability of two photons being scattered simultaneously to the 
same specimen location is essentially zero, eliminating background fog. A greater 
proportion of excitation light reaches the focal plane (F) and (G). The fluorescence 
generated (green) is more likely to be detected by the photomultiplier tube because no 





Unlike other microscope systems, the MP microscope can be easily modified to detect 
second harmonic signals, allowing second harmonic imaging microscopy (SHIM). This 
is a powerful label-free technique that permits visualization of well-ordered protein 
structures, such as collagen, microtubules and muscle myosin.407 SHG is a nonlinear 
optical effect, also known as frequency doubling. It occurs when intense laser light is 
passed through a highly polarizable material (such as an inorganic crystal) with a 
noncentrosymmetric molecular organization. The second harmonic light that is emitted 
from the material is exactly half the wavelength of the light being absorbed. The SHG 
process within the nonlinear optical material replaces two near-infrared incident photons 
with a single visible photon at twice the energy and half the wavelength.401 Whilst TPEF 
(described above) involves an excited state, meaning some of the incoming energy is 
lost during relaxation, SHG does not. SHG is therefore relatively energy-conserving, and 
coherence of the laser light is preserved. Furthermore, the amplitude of SHG is 
proportional to the square of the incident light intensity, meaning SHIM has the same 
intrinsic optical sectioning properties as TPEF.407 It is therefore an important three-
dimensional contrast tool, allowing high-resolution imaging of protein structures such as 
collagen networks, without requiring excitation of fluorescent molecules.  
 
In addition to fluorescence and SHIM, use of vibrational microscopy techniques can 
provide information about the exact chemical composition of tissue structures. 
Fluorescence microscopy is limited in chemical selectivity; there are relatively few 
intrinsic fluorophores, and the introduction of extrinsic fluorophores can result in 
unwanted alterations.408 SHIM has inadequate sensitivity and specificity for tissue 
constituents other than certain protein structures. In contrast, the vibrational spectra of 
biological specimens provide molecular signatures, which can be utilized to identify 
specific biochemical tissue components.408 The CARS technique is an important 
application of Raman spectroscopy, involving inelastic or ‘Raman’ scattering of 
monochromatic laser light.409 The laser light is shined on a sample, and the emerging 
scattered light is detected. Most scattered light is of the same frequency as the excitation 
source (referred to as Rayleigh or elastic scattering). A small amount of the scattered 
light (approximately 10% of the incident light intensity) is shifted in energy from the laser 
frequency, because of the interaction between the incident electromagnetic waves and 
the vibrational energy levels of the molecules in the sample. Plotting the intensity of the 




The CARS process generates much stronger vibrational signals (Figure 5.3). CARS is a 
four-wave mixing process, where a pump, a Stokes, and a probe field, with frequencies 
ωpump, ωStokes and ωprobe, induce a polarization in the sample P(3).409 The oscillating-
induced polarization creates an anti-Stokes radiation, with a frequency ωanti-Stokes = ωpump 
+  ωprobe – ωStokes. In most experiments, the pump field and probe field come from the 
same laser beam. The CARS signal intensity is proportional to the square modulus of 
the induced polarization ICARS (P(3))2. The size of P(3) is determined by the field strength 
of the excitation fields, and the nonlinear optical susceptibility of the material χ(3). χ(3) is 
separated into a resonant and nonresonant part. Both CARS and spontaneous Raman 
scattering essentially provide the same information, however because of the interference 
between the Raman component and the nonresonant component, the CARS spectral 
shape differs from the Raman lineshape. Due to the complex nature of χ(3) and this 
interference between resonant and nonresonant background parts, CARS demonstrates 
a dispersive lineshape. Compared with the spontaneous Raman spectrum, the 
vibrational resonances show a shift of the peak to lower frequency, and the appearance 
of a dip at a higher frequency.408-410  
Like SHIM, CARS microscopy allows nondestructive molecular imaging without any 
labelling, meaning that small molecules such as lipids or drugs can be imaged without 
disturbance of their molecular properties by labelling. Because the CARS signal is larger 
than that generated from Raman microscopy alone, high-speed vibrational imaging can 
be achieved. Furthermore, the CARS signals appear at a wavelength shorter than 
excitation wavelengths, and are therefore spectrally separated from the one-photon 
fluorescence background. The main limitation of CARS is the presence of a 
nonresonance background, arising from the electronic contribution to χ(3). This 
background is coherently mixed with the vibrationally resonant signal, making it difficult 
to detect weak Raman bands. The detection of low-concentration molecules is also 
difficult, because the resonant CARS signal decreases quadratically with the molecular 
concentration. Some progress has been made in recent years however, to suppress the 






Figure 5.3 CARS energy diagram  
CARS is a nonlinear four-wave mixing process, used to enhance the weak 
(spontaneous) Raman signal. A pump laser beam (at frequency ωpump) and a Stokes 
laser beam (ωStokes) interact, resulting in an anti-Stokes signal at frequency ωCARS = 





5.1.2 Development of IVM of the liver 
Certain organ systems lend themselves particularly well to IVM via an imaging window, 
and there are well-established mouse models for relatively superficial tissues such as 
skin, (dorsal skin window chamber model411-414) breast, (mammary imaging window415-
417) and brain and bone marrow (via cranial imaging window418-420).421 Surgical 
procedures can be employed to render other organs more accessible, for example a skin 
incision to expose the popliteal lymph nodes,422 and more recently, the intestine.423,424 
The maximum depth of penetration for fluorescent IVM is 1mm, meaning imaging intra-
abdominal organs requires surgical exposure. The liver has traditionally been 
exteriorized and imaged by laser scanning or spinning disk confocal microscopy. The 
surgery comprises a midline laparotomy, removal of peritoneal skin and muscle, and 
externalization of a hepatic segment, usually the right lobe.425-432 The mouse is 
anaesthetized throughout, and the liver is superfused with physiological saline. Due to 
the invasive surgical approach, the animal is killed at the end of imaging. This provides 
a good model for investigating biological processes occurring in the short term, but 
successful imaging has only been achieved for a maximum of six hours433 (with the 
implementation of careful anaesthesia and intensive care monitoring) limiting the yield of 
such experiments.  
For longer experimental periods, Ritsma et al devised a protocol for surgical implantation 
of a static abdominal imaging window, using a titanium ring and coverslip, secured in 
place with a purse string suture. This was used to visualize liver metastasis formation 
over 14 days; windows were also left in situ until dislodgement, which occurred on 
average after five weeks (maximum of 63 days).421,424 
5.1.3 Application of IVM to the study of liver injury, carcinogenesis and repair 
 
Focal liver injury 
Necrotic cell death generates sterile inflammation, characterized by an influx of innate 
immune cells within the damaged tissue. In a landmark IVM paper, Kubes et al performed 
an elegant set of in vivo experiments to investigate the mechanisms governing neutrophil 
recruitment and migration to sites of sterile tissue injury and cell death.430 Focal hepatic 
necrosis was induced in anaesthetized mice by localized thermal injury, on the 
exteriorized liver surface. A 0.022+/- 0.001mm3 area of focal injury was achieved to a 
depth of approximately 80μm, using the tip of a heated 30-guage needle, mounted on 
an electro-cautery device. Necrotic cells were then labelled with propidium iodide. Using 
spinning disk confocal IVM with this model, the authors were able to record the kinetics 
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of enhanced GFP (eGFP)-labelled neutrophil migration towards the necrotic lesion. They 
observed that neutrophils remained intravascular during transit to sites of injury, 
potentially to protect healthy tissues from collateral damage en route. It was also 
demonstrated that neutrophils adhere and crawl inside liver sinusoids during hepatocyte 
death, an interaction mediated by the integrin αMβ2, and its endothelial ligand 
intercellular adhesion molecule-1 (ICAM-1). Furthermore, an intravascular gradient of 
chemokines directed neutrophils towards foci of damage, with specific chemotaxis to the 
necrotic area stimulated by DAMPs.430  
Dal-Secco et al subsequently used the same focal injury model to track both neutrophils 
and two subsets of monocytes (with either pro-inflammatory CCR2hiCX3CR1low or 
reparative CX3CR1hiCCR2low phenotype) to the necrotic lesion in vivo.434 They were able 
to show that CCR2hiCX3CR1low monocytes were recruited early to the site of damage, 
and formed a ring-like structure around the injury, persisting for 48hrs. Interestingly, 
these monocytes were converted to CX3CR1hiCCR2low cells in situ, showing local, 
cytokine-directed phenotypic switching. This conversion was required for successful 
repair, as evidenced by failure of clearance of necrotic debris, and inhibition of collagen 
redisposition within the injury, when the switch was prevented by anti-cytokine 
treatment.434 This demonstrates the vast potential for in vivo imaging using IVM to 
improve our understanding of immune cell plasticity during liver injury and regeneration.  
 
Hepatic ischaemia and reperfusion injury 
Hepatic ischaemia-reperfusion (I/R) injury is a defect of the hepatic microcirculation, 
induced by the reintroduction of oxygenated blood after a period of ischaemia. The 
oxygenated blood causes oxidative stress, characteristically resulting in increased 
microvascular permeability, intracellular ATP loss, inflammatory cell infiltration, and cell 
death.435 It is clinically relevant in liver transplantation (as a major cause of graft 
dysfunction) and hepatic resection.436 Modelling and imaging this acute process in vivo 
is relatively well-established; Khandoga et al initially demonstrated that I/R induces 
platelet-endothelial cell interactions in the hepatic microvasculature, by IVM of an 
exteriorized liver lobe during the early reperfusion phase.437 They also showed that P-
selectin expressed on endothelial cells mediates the first interaction of platelets with 
post-ischaemic endothelium.437 In subsequent experiments, they observed that platelet-
endothelial interactions contribute significantly to microvascular I/R damage, 
independently of leukocyte-endothelial cell interactions.438 Furthermore, it was shown 
that attenuation of platelet adhesion by administration of anti-fibrinogen antibody in vivo 
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(to prevent fibrinogen-mediated ICAM-1 dependent platelet-endothelial cell binding) 
resulted in improved sinusoidal perfusion. This was supported by a reduction in ALT and 
markers of apoptosis.438  
Ongoing work using this model has provided insights into precise regulation of the routes 
of cell death following I/R, and has identified the platelet receptor protease-activated 
receptor 4,439 and the augmenter of liver regeneration protein,440 as two potential 
therapeutic targets for post-ischaemic liver injury.  
Other groups have applied hepatic IVM to developing diagnostic modalities, for example 
to demonstrate tissue damage in vivo, in the setting of I/R injury. Thorling et al used 
fluorescent lifetime imaging microscopy (FLIM) in combination with MP IVM, in a rat I/R 
model.441 Here, the fluorescent properties of NADH were utilized; the free and protein-
bound forms of NADH have similar excitation and emission wavelengths, but can be 
separated by their fluorescent lifetimes (0.4-0.5 and 2.0-2.5ns respectively).441,442 The 
free form of NADH is involved in the anaerobic production of ATP whereas the bound 
form relates to aerobic production. Therefore, changes in the free/bound ratio of NADH 
provides information about cellular metabolism. In this model, decreased metabolic 
activity (demonstrated by increased ratio of free/bound NADH) was shown during I/R 
injury. Similarly, MP microscopy was able to detect structural damage, in a predominantly 
midzonal pattern, at one hour of reperfusion.441 In later work, they were also able to 
correlate I/R injury with specific fluorescent lifetime changes in NAD(P)H.443  
The same group also investigated the transport of the fluorescent probe fluorescein, in 
the rat I/R model, by MP imaging after intravenous (IV) sodium fluorescein 
administration.443 There was a delayed appearance and clearance of fluorescein within 
liver sinusoids undergoing I/R injury. This was mathematically modeled, establishing a 
role for in vivo MP microscopy in the study of drug distribution. It was felt that combining 
MP imaging with the kinetics of fluorescein uptake and clearance could potentially be 
employed to assess liver function intraoperatively or post-transplantation, providing a 
relatively non-invasive, early measure of I/R-induced damage.443 More recently, Wang 
et al performed MP microscopy with FLIM on a number of different mouse models 
mimicking human liver diseases (including primary sclerosing cholangitis, chronic 
fibrosis, HCC and I/R perfusion).444 This allowed simultaneous imaging and 
quantification of cellular morphology and microenvironment, and the authors anticipated 
that the technique could be refined to acquire real-time histology of liver disorders.444 
Other authors have proposed the development of autofluorescent molecular imaging as 
another bioanalytical tool to measure I/R injury. Lu et al used the endogenous 
 
121
autofluorescent properties of mitochondrial flavins to quantify cellular deoxygenation and 
reoxygenation. IVM of exteriorized rat liver in vivo following I/R injury showed a significant 
reduction in cellular autofluorescence intensity immediately after ischaemia, with a 
gradual return to baseline throughout reperfusion.445 Again, it was postulated that this 
approach could ultimately be applied to intraoperative and postoperative assessment of 
organ function.  
A variety of IVM studies of hepatic I/R injury have provided additional insights into cellular 
interactions throughout this process, and have led to experiments involving 
administration of biological compounds to reduce injury in these animal models.446-450 
 
Acute liver injury 
Drug-induced liver injury represents another attractive IVM model, allowing high-
resolution imaging of cell death. Paracetamol and concanavalin-A (Con A) are the most 
established pharmacological agents;432 paracetamol has the added benefit of clinical 
relevance to human disease, allowing comparison to the major problem of fulminant 
hepatic failure secondary to paracetamol overdose.   
Li et al used a metallic liver window device to image mice 24 hours after paracetamol 
overdose (500mg/kg) by MP microscopy.451 IV injection of fluorochromes was employed 
to delineate sinusoidal veins and bile canaliculi. Extent of injury was assessed by 
permeability of cells to dextrans or sytox green, and loss of labelling by R6G. They 
focused on sequential morphological changes during hepatocyte necrosis in vivo. 
Electron microscopy had previously demonstrated that the injured liver showed 
congestion, extravasation of erythrocytes into the space of Disse, dilatation of bile 
canaliculi and a spongy appearance of necrotic hepatocytes.452 The authors went on to 
demonstrate an unexpected canalicular membrane rupture during injury in vivo, with 
flooding of bile back into hepatocytes.451 Membrane rupture was accompanied by an 
abrupt drop in mitochondrial membrane potential, and it was hypothesized that this could 
indicate a point of no return in hepatocyte necrosis. Concomitant NAC administration 
reduced canalicular membrane rupture, potentially supporting this hypothesis. IVM was 
also able to demonstrate that release of hepatocellular contents from dying cells occurs 
in the form of dislodged blebs. These events were unable to be observed in cultured 
cells, because the in vivo pressure gradient between bile canaliculi and hepatocytes is 
not reproducible in cell culture systems. The ability to image paracetamol-induced 
hepatocyte death in vivo has therefore permitted the discovery of a mechanism in which 
elevation of bile duct pressure might contribute to induction of hepatocyte necrosis.  
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Whilst Li et al used IVM to further our understanding of hepatocyte biology during 
paracetamol overdose, other groups have harnessed the technique to demonstrate the 
effects of a specific pharmacological intervention on paracetamol-induced injury. Amaral 
et al hypothesized that ATP released from dying hepatocytes following paracetamol-
induced necrosis, could contribute to progression of liver injury by immune system 
stimulation and modulation of cytosolic calcium levels.453 Mice were given paracetamol 
by oral gavage (500mg/kg) after a 15 hour fast. Two hours later, an exogenous ATPase 
(apyrase) was administered to the treatment group. Liver injury was reduced in the 
apyrase-treated animals, with lower serum ALT and levels of pro-inflammatory cytokines. 
Confocal IVM of exteriorized liver also demonstrated a reduction in neutrophil 
recruitment to necrotic areas. Further in vitro experiments led the authors to propose that 
ATP may signal via purinergic receptors to increase intracellular calcium, causing direct 
hepatotoxicity and cell death.453  
In an earlier experiment, Ito et al characterized the role of nitric oxide (NO) in 
microvascular injury, in the context of paracetamol overdose.454 Here, IVM was 
employed to demonstrate liver microcirculatory dysfunction, such as impaired sinusoidal 
perfusion and swelling of liver sinusoidal endothelial cells (LSECs) erythrocyte infiltration 
to the extrasinusoidal space, and phagocytic activity of activated Kupffer cells. Using 
specific inhibitors of iNOS or cNOS, injury was then quantified in vivo (again via 
exteriorization of liver) and pre-treatment with a pharmacological inhibitor of iNOS was 
found to reduce paracetamol-induced liver injury, as well as hepatic microcirculatory 
dysfuction.454  
More recently, DNA-binding probes (such as Sytox green, propidium iodide, DAPI) have 
been used to visualize and measure hepatic necrosis in vivo, allowing real-time 
assessment of cell death.432,455 428,456 
In most cases, IVM following ALI has been restricted to short, once-off imaging sessions. 
Heymann et al completed longer imaging sessions to investigate lymphocyte migration 
during acute or chronic liver injury (induced by acute or chronic IP administration of CCL4) 
using CXCR6.gfp knock-in mice.433 Here, TPEF and MP microscopy was performed on 
exteriorized liver. Longer imaging duration was facilitated by using intensive care 
monitoring, including electrocardiogram electrodes, a carbon dioxide level sensor and 
external temperature sensor. These measures allowed more rigorous control of 
anaesthesia and respiration, as well as stabilization of the circulation. 
IVM has also proven valuable in discerning differential roles of immune cells in 
paracetamol-induced liver injury. Marques et al first demonstrated that liver injury causes 
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massive extracellular DNA deposition in the liver.429 They subsequently selectively 
depleted Kupffer cells (KC) by intravenous clodronate liposomes (CLL) injection, and 
imaged after paracetamol administration. This did not result in any reduction in 
hepatotoxicity. However, use of anti-Ly-6G antibody to deplete circulating neutrophils did 
significantly reduce liver injury. Having employed IVM to show this association between 
neutrophil infiltration and more marked organ damage, they were able to proceed with 
mechanistic studies. It was found that the DNA sensor TLR9 was upregulated on 
neutrophils during drug-induced injury, and blockage of DNA sensing (either by knockout 
of TLR9 or systemic DNASE1 treatment) rescued paracetamol-induced liver injury.429  
Bonder et al similarly investigated leukocyte signalling during drug-induced liver injury 
(DILI) using IVM.457 Administration of Con A causes acute hepatitis, largely mediated by 
T-lymphocytes. Con A treatment resulted in increased leukocyte rolling and adhesion (in 
exteriorized liver postsinusoidal vessels); mice with GFP-labelled T cells were used to 
show that within 4 hours of Con A administration, only 20% of the leukocytes interacting 
and adhering in postsinusoidal venules were T cells. In fact, Con A induced early hepatic 
recruitment of neutrophils, without which, the drug could not recruit CD4+ T lymphocytes 
to the liver, abrogating injury.457 Again, IVM permitted direct vision of these immune cells, 
with assessment of movement and adherence, and systematic selective depletion 
studies. This led to the novel realization that neutrophil recruitment is critical for the 
development of Con A-induced hepatitis, and that perhaps neutrophil activation may be 
important in patients with T cell-mediated liver diseases.457  
This approach was also utilized by the same group to identify adhesive mechanisms 
required for recruitment of CD4+ lymphocytes to liver sinusoids in the context of Con A-
induced liver injury.458 Here, endogenous leukocytes were visualized by trans-
illumination, whereas in vitro-differentiated T cells were labelled with rhodamine 6G ex 
vivo, and visualized by epi-illumination. Shear rates in postsinusoidal venules were 
quantified by measuring velocities of fluorescently-labelled lymphocytes, frame by frame. 
In vivo injection of specific antibodies led to the conclusions that CD4+ Th1 cells require 
α4β1-integrin for adhesion to liver sinusoidal vessels, whereas CD4+ Th2 cells need 
VAP-1. This work, for the first time, challenged the dogma that leukocyte-trapping within 
the liver during infection and inflammation was an unspecific, mechanical process, and 
demonstrated the importance of specific adhesion molecules, which could represent 
promising therapeutic targets.432,458  
In summary, IVM of paracetamol- and Con A-induced acute liver injury has already 
yielded insights into hepatocyte biology during injury, and been harnessed to test the 
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effect of specific pharmacological agents on liver damage. Perhaps most striking is the 
application of IVM to studying immune cell function, recruitment and signalling in this 
setting. Whilst the early stages of liver injury have proven relatively straightforward to 
study, experiments have been limited to several hours total imaging. Some progress has 
been made in terms of improving animal monitoring to allow longer sessions,433 however 
in vivo studies throughout the course of injury and repair are still lacking.  
 
Infection 
IVM of the liver is particularly suited to characterizing events occurring during the 
dissemination of pathogens via the bloodstream. Fluorescent labelling of immune cells 
and bacteria has allowed investigation of their interactions during infection, and 
mechanistic studies to visualize cellular movement in the vasculature and sinusoids in 
real-time. Even cellular morphology has provided new insights. KC, for example, were 
found to have numerous cell processes, extending into as many as five sinusoids, 
demonstrating their extensive filtering capacity.459 In this paper from Paul Kubes’ 
group,459 the critical role of KC in limiting bacterial dissemination (in this case the 
spirochete Borrelia burgdorferi) was elegantly presented using IVM. KC activity was 
compared and contrasted with a subset of natural killer T cells, referred to as ‘invariant 
natural killer T cells’ (iNKT cells). Interestingly, depletion of KC or iNKT in the context of 
B. burgdorferi infection resulted in different manifestations of loss of pathogen control. 
Depletion of KC by CLL treatment led to large numbers of GFP-expressing B. burgdorferi 
remaining in hepatic sinusoids 12 and 24 hours after injection. These spirochetes were 
freely translocating, unlike in untreated mice, in which they appeared immobilized after 
adhesion to KC. At 72 hours, a high frequency of B. burgdorferi organisms were 
observed in the blood and liver parenchyma, in the CLL-treated mice.459  
The role of iNKT cells was then assessed using Cd1d-/- mice. It had already been 
determined via IVM of the liver, that B. burgdorferi infection resulted in reduced crawling 
activity of iNKT cells, with subsequent arrest and clustering on KC, leading to IFN-γ 
production. It was therefore postulated that KC represent the main antigen presenting 
cells for iNKT in liver vasculature. In the absence of iNKT cells, a significant accumulation 
of B. burgdorferi occurred in joints, bladder and liver, but not in the blood. This suggested 
that iNKT cells could act to prevent the emigration of the microbes out of the 
vasculature.459 The authors concluded that absence of either KC or iNKT cells resulted 
in dissemination of B. burgdoferi, but whilst lack of the former resulted in massive 
bacteraemia, loss of the latter caused pathogen dissemination to other organisms such 
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as the blood. This systematic IVM-based approach to examining the function of different 
immune cells in response to a specific pathogen produced a plethora of information 
relating to cell-cell interactions, cell tracking and effect on bacterial load. Importantly, the 
data could be analysed with key contextual information such as details of the vascular 
microenvironment, further enhancing the yield from each experiment.  
The same group subsequently used a similar approach to characterise another novel 
interaction of KC, this time with platelets, during bacterial infection.460 Initially, platelets 
were shown to have continuous ‘touch and go’ activity within liver sinusoids, in mice, 
under basal conditions. Platelets labelled with anti-CD49b rapidly (<1 second) touched 
F4/80-labelled KC lining the sinusoids, via a GPIb-dependent mechanism. Upon 
infection with Bacillus cereus, platelet-depleted animals developed bacteraemia within 4 
hours, with 100% mortality. Using in vivo microscopy it was discovered that B. cereus 
trapping on KC occurred within seconds (in liver vasculature). The ‘touch and go’ activity 
of platelets then changed to sustained recruitment of platelets to the KC surface. The 
nature of this interaction was interrogated using high magnification and three-
dimensional reconstruction in real time; platelets were found to encase trapped B. 
cereus, on KC surface, within three minutes.460 This illustrates the potential for in vivo 
imaging to determine not only the nature of interactions between pathogens and immune 
cells, but also the actual time scale of key innate immune responses. Platelets were also 
shown to dock on KC following methicillin-resistant but not methicillin-sensitive 
Staphylococcus aureus infection, suggesting the platelet surveillance system may be 
specific to certain pathogens.460 
Information from IVM studies has also led to revelations in our understanding of how 
neutrophils are recruited during endotoxaemia, and how critical the vascular endothelium 
is in the inflammatory response to blood-borne microbes and their products. McDonald 
et al performed a series of experiments aiming to dissect out the role of hepatic vascular 
endothelium during endotoxaemia, particularly in relation to endothelial TLR4 activation 
and regulation of neutrophil recruitment.461 IVM was carried out on bone marrow 
chimeras and transgenic mice expressing TLR4 on selected cell populations, in the 
context of LPS treatment. It was demonstrated that LPS-induced TLR4 stimulation on 
vascular endothelium alone was enough to initiate neutrophil adhesion in hepatic 
sinusoids. They were also able to characterise a specific mechanism of neutrophil 
recruitment, showing the (interdependent) interaction between neutrophil CD44, 
endothelial hyaluronan and serum-derived hyaluronan-associated protein in this 
process. Overall, it was concluded that neutrophils accumulate in liver and lung 
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capillaries during endotoxaemia via active recruitment by non-leukocyte tissue resident 
‘sentinels’ rather than hyperactivation of circulating neutrophils by LPS.461  
The role of KC during other infections, including granuloma formation during 
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) infection, has also been examined 
with IVM.432 Whilst previous studies had investigated the static spatial localization of cells 
within mycobacteria-induced granulomas, little information was available on the dynamic 
cellular interactions within these immune structures. Egen et al used liver IVM throughout 
the granulomatous response to BCG infection, to look at host-pathogen interactions and 
the natural history of granuloma formation and dissolution.462 Use of genetically modified 
BCG (expressing RFP) and mice with eGFP-expressing KC allowed interrogation of 
events immediately following infection. Gene-targeted mice expressing eGFP under 
control of endogenous lysozyme M promoter (LysM-eGFP) and those expressing eGFP 
recombined into the major histocompatibility complex (MHC) class II I-A locus (MHCII-
eGFP) were used to identify KC during IVM.462 TPEF IVM was employed to demonstrate 
that within one minute of IV infection, BCG became associated with the fluorescent KC 
population. Bone marrow chimera mice were then used to show that KC persist following 
BCG infection and redistribute into granulomas. Interestingly, whilst the myeloid 
populations moved slowly within granulomas, activated CD4+ T cells entered and 
migrated rapidly around the myeloid cell network. T cells were very motile within 
granulomas, but tended to remain within the borders of the structure. This restriction 
appeared to be mediated mechanically by the myeloid cell border. These experiments 
led the authors to propose a scenario whereby a protective granuloma environment is 
created by TNFα-dependent maintenance of a static scaffold of myeloid cells, supporting 
the migration of motile effector T cells.462     
IVM during systemic bacteraemia has been utilized to describe the effects of specific 
immune cell products, such as neutrophil extracellular traps (NETs). Kolaczkowska et al 
extensively studied the formation and degradation of these neutrophil-derived NETs, 
which are composed of DNA associated with histones and proteases.463 Whilst NETs 
are able to trap and kill bacteria, they are also known to cause collateral tissue 
damage.464-467 IVM using spinning disk confocal microscopy of liver, during MRSA 
bacteraemia, demonstrated neutrophil-dependent NET formation within liver 
sinusoids.463 NET release was shown to correspond with liver injury, and inhibition of von 
Willebrand factor (which anchored NET components to the liver vasculature) significantly 
reduced liver damage. It was observed that DNase treatment did not affect liver damage 
in this model, and real-time in vivo imaging allowed elucidation of the reasons for this; 
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although DNase immediately dissolved extracellular DNA, other NET components 
(histones and neutrophil elastase) remained attached to sinusoids i.e. DNase did not 
fully eliminate NETs.463 These experiments identified potential limitations of DNase 
treatment (currently used in clinical practice) and it was postulated that inhibition of NET 
production could be beneficial. However, some of the challenges of in vivo imaging were 
also highlighted. For example, despite a number of different staining approaches, the 
authors were unable to image within necrotic areas. Hopefully, MP microscopy, with 
better laser penetration depths compared with confocal might overcome this problem. 
Furthermore, Sytox green was used to label extracellular DNA. However, on careful 
review of imaging, it was observed that a few KC and hepatocytes had taken up Sytox 
green, therefore it was essential that other NET components were concomitantly stained 
for (namely histones and neutrophil elastase) to ensure specificity for NET 
identification.463 This emphasizes the importance of validating staining techniques and 
recombination efficiency/specificity of fluorescent reporter-expressing transgenic lines, 
before drawing conclusions from in vivo imaging. 
IVM studies have also contributed to progress in our understanding of parasitic infections 
of the liver. In particular, Frevert et al were able to clarify the dynamics of the journey of 
malarial sporozoites from bloodstream to hepatocyte.468 It had previously been unclear 
whether Plasmodium sporozoites entered the liver by passing through KC, or if they 
crossed directly through fenestrations in sinusoidal endothelia.469,470 Frevert et al infected 
transgenic mice with Plasmodium berghie sporozoites by mosquito bite, then imaged 
exposed liver in vivo, by confocal and epifluorescence microscopy, up to depths of 50 
μm. Sporozoites were detected by expressing red or green fluorophores, and endothelia 
or KC were identified by GFP using Tie2-GFP or lys-EGFP-ki mice respectively.468 
Sporozoites were observed gliding along the sinusoidal cell layer, then crossing it 
through a KC. Having entered liver parenchyma, they were then seen transmigrating 
through hepatocytes, moving at faster velocity, and damaging subcellular architecture. 
Time-lapse imaging allowed quantification of migration time (up to 15 minutes) and the 
longest distance covered (400-500 μm).468 Despite shear forces of blood within vessels, 
the parasites were not detached from the sinusoidal cell wall, suggestion high affinity 
adhesion. Moreover, the parasites entered KC and hepatocytes with different patterns 
of motion, suggesting cell-specific invasion mechanisms. Plasmodium sporozoite 
invasion of hepatocytes had historically been problematic to study; these elegant IVM 




Further information regarding elimination of liver-stage malaria parasites has been 
derived from IVM studies, especially concerning CD8+ effector T cell function.471-473 
Cockburn et al used spinning disk confocal microscopy to image mice infected with GFP-
expressing Plasmodium yoelii sporozoites (i.e. naïve animals), or mice immunized 10 
days previously with P yoelii radiation-attenuated sporozoites.471 Phycoerythrin-
conjugated α-CD8 antibody-labelled CD8+ T cells were injected 24 hours after 
sporozoite injection. In the previously immunized mice, most parasites imaged were 
surrounded by clusters of CD8+ cells. Mathematical modelling of cluster formation 
suggested that the process was non-random. Both parasite-specific CD8+ T cells and 
similarly activated OT-1 cells (ie non-specific CD8+ T cells) were recruited to clusters 
around P yoelii infected hepatocytes. Again, timelapse imaging data allowed 
mathematical modelling of cluster formation, suggesting both cell types were recruited 
to clusters in a positive-feedback, density-dependent fashion.471 These observations 
were supported by a second study, using a slightly different model of protective immunity 
(again to the liver stage of malaria infection). Kimura et al472 generated recombinant 
Plasmodium berghei expressing a fusion protein of an ovalbumin epitope, and GFP, in 
the parasite cytoplasm. It was then demonstrated that the ovalbumin epitope was 
presented by infected hepatocytes, and became a target of specific CD8+ T cells (from 
T cell receptor transgenic mouse line OT-1) conferring protection from liver stage 
Plasmodium infection. IVM using TPEF allowed visualization of the interaction between 
CD8+ T cells and infected hepatocytes, again demonstrating OT-1 cell clustering and 
elimination of intrahepatic parasites.472  
Cockburn et al performed detailed imaging of the interaction between CD8+ T cells and 
Plasmodium-infected hepatocytes, in vivo, and were able to record parasite-killing in real 
time, for the first time.471 They challenged previous findings from in vitro studies, 
suggesting that CD8+ T cell-mediated killing was rapid, instead observing prolonged 
(four hours) associations between T cells and infected hepatocytes. They also described 
four different parasite ‘death phenotypes’ characterized by distinct modes of GFP loss 
(e.g. sudden loss of GFP versus progressive attrition). The authors expressed 
confidence that loss of parasite fluorescence represented loss of viability, having 
considered possible confounding factors.471 This illustrates another caveat of IVM, 
namely that care must be taken not to over-interpret a reduction in fluorescence from 
photobleaching or emigration from the field of view, as cell death.  
In a further publication from the Yui group, Akbari et al473 described an improved 
approach to fixing the liver, to facilitate MP IVM, focusing again on the interaction 
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between malaria parasites and antigen-specific CD8+ T cells during the liver-stage of 
malaria infection. They found inhaled isoflurane rather than injectable agents allowed 
better control of depth of anaesthesia. Avoidance of isoflurane overdose was 
recommended, as was relatively low concentration (1%) isoflurane use throughout 
surgery and the experiment. This served to prevent agonal breathing, which was 
associated with increased liver movements and image distortion. A portion of liver was 
exposed and fixed to gauze using adhesive glue. The liver was irrigated with PBS to 
avoid dehydration, and a coverslip applied, before imaging on a platform of the MP 
microscope. This allowed imaging for up to three hours before photobleaching. Whilst 
this approach only permitted relatively short imaging sessions, the optimization of 
anaesthesia described is particularly relevant, and becomes even more important for 
longer experiments, both in terms of image quality and animal welfare.  
Experimental Leishmania infection is another parasitic disease that has been employed 
in conjunction with in vivo IVM of the liver, to investigate KC and CD8+ T cell dynamics, 
in the context of granuloma formation. Beattie et al474 demonstrated how IVM could 
complement adoptive cell transfer and flow cytometry techniques, to obtain detailed 
information about the antigen-presenting process in parasitic infection. They were able 
to show for the first time, in situ, that KC act as targets for antigen recognition by 
granuloma-infiltrating CD8+ T cells.474 These experiments supported the findings from 
Egen et al, suggesting that granulomas are not simply static tissue structures, but 
comprise a complex dynamic microenvironment.425 
More recently the Leishmania model was used in a study to develop methods for imaging 
and measuring blood flow velocity within individual hepatic blood vessels, and 
quantitatively analyse the velocity of individual red blood cells (RBC).475 Dasari et al 
described two independent imaging methods for measuring RBC velocity and blood flow 
speed, which could then be used to correlate blood flow parameters with parasite 
multiplication within the liver.475 This technique could be applied in other infection and 
injury models, to gain valuable information about pathophysiological alterations in 
hepatic blood flow.  
 
Cancer and metastasis 
IVM techniques allow direct visualization of tumour cells interacting with their 
microenvironment, providing insights into the biological processes summarized by 
Hanahan and Weinbery as the ‘hallmarks of cancer’.476-478 These include, for example, 
tumour cell ability to migrate, metastasize and induce angiogenesis. The majority of IVM 
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cancer research (recently reviewed and summarized by Ellenbroek and van Rheenan478) 
comprises work using well-established optical windows, such as breast, skin and brain. 
Sophisticated experiments have shown not only the dynamics of migratory cells within 
tumours, but also, for example, the regulatory role of individual proteins in migration. 
Canel et al combined the use of dorsal skin windows with photobleaching, 
photoactivation and photoswitching, to quantitatively measure tumour cell movement, 
proliferation and protein dynamics, in squamous cell carcinoma cells in vivo within a 
tumour mass.479 Fluorescence of green-fluorescent-protein (GFP)-tagged E-cadherin 
was bleached in a specific area of tumour cells, and fluorescence recovery after 
bleaching (FRAP) was measured. Inhibition of focal adhesion kinase (FAK) increased 
the fluorescence recovery rate, demonstrating that FAK is a key regulator of E-cadherin 
activity.479,480 
The use of photoswitchable fluorophores has enabled study of the migration of large 
numbers of tumour cells over multiple imaging sessions.478 Kedrin et al expressed the 
photoswitchable protein Dendra2 in cells from the metastatic breast cancer line 
MTLn3.416 Dendra2 expression results in green fluorescence prior to photoswitching; 
exposure to blue light induces an irreversible red shift.481 Tumour cells were imaged 
through a mammary imaging window. Certain photoswitched regions demonstrated 
significant migration and invasion of the adjacent microenvironment. However there was 
limited migration in other regions, suggesting that the surrounding microenvironment 
influences cell behavior.416 
In the liver, IVM cancer models to date have largely been confined to studying colorectal 
cancer metastasis or HCC by imaging inoculated cancer cell lines.  
To improve our understanding of leukocyte recruitment and migration in HCC, Takeichi 
et al inoculated the Hep55.1C HCC cell line directly into the livers of transgenic mice 
(expressing eGFP-labelled leukocytes of either lymphoid or myeloid origin) via a midline 
incision.482 After 12-14 days, solid, vascularized tumours of up to 10mm had grown at 
the implantation site. For IVM, midline incision was performed, and tumours were 
identified macroscopically. The tumour-bearing liver lobe was exteriorized and imaged 
by confocal microscopy. From timelapse images, density of perfused blood vessels was 
measured (visualized by IV injection of TRITC-labelled albumin) in addition to density 
and velocity of migrating leukocytes. Analysis of blood vessel density showed that vessel 
distribution was heterogeneous within HCC tissue, with areas of high and low vessel 
density. Quantification of eGFP fluorescence demonstrated that peritumoural blood 
vessels were the main site of leukocyte recruitment, in comparison to intratumoural blood 
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vessels, where low extravasation rates of single leukocytes were seen. The density of 
lymphoid leukocytes within tumour tissues was higher than that of myeloid leukocytes, 
and most intratumoural leukocytes migrated randomly, and changed direction many 
times over 30 minutes (the length of the observation period). The authors concluded that 
infiltration of tumour tissue by lymphoid and myeloid leukocytes in this model 
represented a cellular immune response against HCC, which might be further studied to 
elucidate mechanisms of leukocyte recruitment in this liver tumour.482  
Tanaka et al investigated tumour angiogenesis in colorectal liver metastases in vivo, by 
inoculating red-fluorescent-protein (RFP)-expressing cell lines into the spleens of GFP 
nude mice, which then travelled to the liver.483 The liver was then exteriorized and fixed, 
and imaged by two-photon laser scanning microscopy. Tumour cell arrest/adhesion, 
tumour cell-induced platelet aggregation, tumour cell extravasation and phagocytosis by 
Kupffer cells was observed using timelapse and z-stack imaging techniques. Mice were 
imaged at three time points, and by eight weeks, dilated and tortuous blood vessels 
within liver metastatic nodules were seen. Imaging more frequently using this approach 
was limited by the development of fibrous adhesions between the abdominal wall and 
liver surface. It was acknowledged that recurrent exteriorization of the liver might also 
affect the physiological condition of the organ.483  
Ritsma et al pioneered the use of the AIW to demonstrate colorectal cancer metastasis 
formation in the liver, in real-time, over five days.424 They identified a ‘pre-
micrometastasis’ step, during which individual extravasated colorectal cancer tumour 
cells proliferate in the liver, and form a clone in which cells are highly motile, but lack 
contact with other tumour cells within the clone. When cell migration was inhibited in pre-
micrometastases, maturation to micrometastases was abrogated, resulting in reduced 
metastatic load.424 
To date, genetic or carcinogen-induced mouse models of HCC have not been imaged 
using the AIW technique; it is anticipated that this would be feasible, and coupled with 
MP microscopy, SHG and CARS, could yield a wealth of information regarding tumour 
biology, particularly with respect to angiogenesis and blood vessel function in this highly 
vascular tumour-type. Moreover, real-time imaging of the actions of anti-angiogenesis 
chemotherapy agents in this setting might prove illuminating in terms of understanding 




5.2 Hypothesis and aims 
It was hypothesized that IVM of mouse liver, using a MP microscope, could be 
performed via an AIW, allowing sequential imaging of biological processes over many 
days. Similarly, I hypothesized that HCC induced by perinatal DEN injection could be 
imaged similarly, by placing the AIW on tumour tissue.    
 
Aims 
 To develop IVM of the liver, via an abdominal window, with optimization of 
surgical and imaging techniques, to allow sequential imaging of the liver in the 
same animal over several weeks. 
 To optimize liver imaging of different fluorescent reporter mice strains ex vivo, 
including the use of SHG to visualize collagen, and CARS to demonstrate lipids, 
prior to live imaging. 
 To image fluorescent reporter mice strains in vivo, using a variety of different 
models of acute or chronic liver injury and regeneration 







Animals were housed in standard sterile conditions with free access to chow and water. 
All procedures were undertaken in accordance with the local ethical committee. Animals 
were between 12 and 20 weeks of age. All transgenic mouse crosses are described in 
the results section. All mice were maintained on a C57BL/6 background. Pdgfrb-Cre 
mice were a kind gift from Ralf Adams.328 These were crossed with Ai14 (B6;129S6-
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J)484 or mTmG (B6.129(Cg)-
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J)485 mice, obtained from Jackson 
Laboratories. Macgreen mice (B6N.Cg-Tg(Csf1r-EGFP)1Hume/J) were a kind gift from 
David Hume. Alb-Cre x confetti (albCre;Gt(ROSA)26Sortm1(CAG-Brainbow2.1)Cle/J) mice were 
obtained from the Jackson Laboratory.329,486,487 Genotyping was performed by 
polymerase chain reaction (PCR). For all IVM experiments, mice aged 10-14 weeks were 
used, to ensure optimal liver lobe size for AIW placement.  
To our knowledge, this is the first time the liver has been imaged in vivo through an AIW 
in the UK. A rigorous home office schedule was therefore adhered to, involving initial 
pilot experiments in which small numbers of animals were imaged under terminal 
anaesthesia. Once proof of principle was obtained that this was feasible and well-
tolerated, animals were recovered post-imaging, and underwent a further imaging 
session at a later date. Again, once this was achieved, longer term experiments were 
performed, in which animals were imaged up to two weeks after initial AIW implantation.  
 
Models of liver injury 
Acute liver injury was induced by injection of anti-Fas antibody (Jo-2). Animals were 
injected IP with 0.5μg/g body weight of Jo-2 (purified NA/LE hamster anti-mouse CD95, 
5544254, BD Bioscience, Franklin Lakes, NJ, USA) dissolved in sterile PBS. Where 
nuclei were labelled, the fluorescence nucleic acid stain Hoechst (33342, ThermoFisher 
Scientific, Walthm, MA, USA) was used. 2μg/g of Hoescht diluted in sterile PBS was 
injected IV, 30 minutes prior to culling, to allow incorporation into nuclei.  
Chronic liver injury was induced by CCL4. Mice received 0.25μl/g diluted in olive oil, 
twice weekly for six weeks. IP Injections were carried out using a 27g short needle and 
a Hamilton glass syringe.  
 
AIW implantation materials 
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Figure 5.4 shows the AIW computer-aided design (CAD) diagrams for the three different 
prototypes used throughout these experiments. Initial experiments utilized an AIW 
(modified very slightly from the specifications described by Ritsma et al in their Nature 
Protocols manuscript)421 consisting of a titanium ring with a 1.3mm groove and a glass 
coverslip (8mm diameter, 0.13-0.17mm thickness) fixed on top, by a removable circlip 
(Figure 5.4 A and E(i)). Titanium alloy was chosen so the AIWs could be sterilized and 
reused. It was also light and therefore well-tolerated, as well as being highly 
biocompatible, corrosion resistant and non-inflammatory.421 After surgical implantation 
of the ring (described below) a purse-string suture was employed to fix the AIW in place. 
This suture was concealed within the groove to prevent biting or pulling by the animals 
after recovery from surgery. For sequential imaging, the circlip design allowed removal 
of the coverslip and cleaning of any accumulated exudate beneath it, before replacement 
with a new coverslip. The van Rheenen group subsequently developed a larger ring with 
a smaller inlay to which the coverslip (12mm diameter, 0.16-0.19mm thickness) was 
glued (AIW-insert). This smaller AIW-insert fit into the main ring with a sliding 
mechanism, allowing removal with a custom-made tool (again to allow change of 
coverslip between imaging sessions); we were kindly permitted to use this design. Our 
group refined this further, by adding small grooves to the outside ring circumference (for 
better immobilization during imaging) and milling the underside of the ring to create a 
slant towards the aperture. This followed the curvature of the liver surface better, thereby 
minimizing the gap between the coverslip and the liver (manufactured by School of 
Engineering, University of Edinburgh). 
 
Ritsma et al reported the development of exudate below the glass coverslip, which could 
be problematic for long-term imaging. This prompted them to coat the glass coverslip 
with poly-L-lysine-g-poly(ethylene glycol) (PPL-g-PEG) to prevent the development of an 
inflammatory or immune response against it. Therefore all glass coverslips were 
immersed in PPL-g-PEG 0.1mg/ml -1 prior to use. To assemble the AIW-insert, a thin 
layer of cyanoacrylate glue was applied to the anterior surface, and the coverslip placed 
on top. Once dry, this was placed in 70% ethanol (vol/vol) for 30 minutes, then moved to 
a sterile laminar flow cabinet. PPL-g-PEG was then applied to the underside of the AIW-
insert, and left for one hour, before being gently washed off using sterile PBS. This was 





Figure 5.4 Abdominal imaging windows 
A CAD drawing of the first prototype titanium AIW. A glass coverslip was placed on the 
inner rim of the aperture, and secured with an overlying circlip. B CAD drawings of the 
van Rheenan AIW design with a larger aperture (i), and removable AIW-insert (ii). A 
custom-built tool for changing the AIW-insert was kindly supplied by the van Rheenan 
group (iii). C CAD drawings of our modified AIW design with grooves for better 
immobilization and domed underside. D (Left to right) photographs of AIW shown in B, 
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A and AIW for kidney imaging (CAD not shown). E (i) Still from video of well and active 
animal, 24 hours post-surgery. AIW pictured with circlip in situ. (ii) AIW from B prior to 







All instruments and AIW components were sterilized prior to surgery. Mice were 
anaesthetized by inhalation of 2% isofluorane and 2L/min oxygen flow, with induction in 
a Plexiglas chamber. Buprenorphine 0.1mg/kg SC was administered after induction of 
anaesthesia, for analgesic purposes. Anaesthesia was maintained by isofluorane 
inhalation through a mouthpiece, and hypothermia avoided by use of a warming pad 
throughout surgery. Lacrilube was applied to the eyes; abdominal hair was removed 
using commercially available cream and clippers. Skin was then disinfected with 
betadine. A midline laparotomy incision was made. Using standard aseptic surgical 
techniques, the caudal part of the sternum (xyphoid process) was clamped and removed, 
the liver mobilized and falciform ligament transected. In some cases, a cotton gauze roll 
was placed above the liver, under the diaphragm, aiming to cushion (and therefore 
minimize) movement artefact from respiration. A purse string suture was then placed, 
surrounding the incision. The left liver lobe was manipulated anteriorly through the 
incision, and the AIW glued to the liver surface. Once the glue had dried, the liver was 
returned intra-abdominally, and the skin and muscle layers eased into the AIW groove. 
The purse-string suture was tightened and tied off. Depending on the AIW prototype 
used, either the pre-assembled AIW-insert was then placed using the window tool 
(Figure 5.4 B) or the PPL-g-PEG coated coverslip was sited within the ring and held in 
place with a circlip. Post-operative fluids (25ml/kg saline) were administered SC at the 
end of the procedure, and a further SC dose of buprenorphine given if required 6-12 
hours later. Mice were monitored twice daily for the first 48 hours, then daily for pain and 






Figure 5.5 AIW surgical technique 
Sequential photos from preparation of the abdomen to securing AIW in place using a 





Imaging was performed using a custom-built microscope as described previously.488 
Briefly, a picoEmerald (APE) laser provided both a tuneable pump laser (720–990 nm, 
7 ps, 80 MHz repetition rate) and a spatially overlapped second beam termed the Stokes 
laser (1064, nm, 5–6 ps and 80 MHz repetition rate).  The laser was inserted into an 
Olympus FV1000 microscope coupled to an Olympus XLPL25XWMP N.A. 1.05 objective 
lens using a short-pass 690 nm dichroic mirror (Olympus). For general imaging the pump 
beam was tuned to 816.8 or 812.2 nm to generate CARS signals at 2845 cm-1 or 2930 
cm-1 respectively. The various emissions were filtered in the following fashion: SHG 
signals were filtered using the following series of filters: FF552-Di02, FF483/639-Di01 
and FF01-400/40. GFP two-photon fluorescence signals were filtered using filters: 
FF552-Di02, FF483/639-Di01 and FF510/84. RFP two-photon fluorescence signals were 
filtered using: FF552-Di02, and FF440/520-Di01 and HQ610/75m (Chroma). CARS 
signals were filtered using: FF552-Di02, and FF440/520-Di01 and ET687/95m (Chroma). 
For Confetti mice imaging the pump beam was tuned to 920.0 nm and the various 
fluorescences were filtered in the following fashion: CFP two-photon fluorescence was 
filtered using the following series of filters FF520-Di02, FF495-Di03 and FF01-466/40.  
GFP two-photon fluorescence signals were filtered using filters: FF520-Di02, FF495-
Di03 and FF01-504/12. YFP two-photon fluorescence signals were filtered using: FF520-
Di02, ET570lp (Chroma) and FF01-542/27. RFP two-photon fluorescence signals were 
filtered using FF520-Di02, ET570lp (Chroma) and FF01-605/15. All other filters were 
from Semrock.   
Animals were maintained under isofluorane anaesthesia, titrated to respiratory rate, 






Figure 5.6 Multiphoton microscope and IVM equipment 
Clockwise from left: custom-built MP microscope and imaging box. Animal anaesthetized 





Pdgfrb-Cre mice were crossed with mTmG reporter mice, to allow imaging of HSC under 
homeostatic conditions and following injury. mTmG reporter mice express membrane-
targeted tandem dimer tomato (TdTomato) prior to Cre-mediated excision and 
membrane-targeted green fluorescent protein (mGFP) after excision).485 Therefore, in 
these double-fluorescent reporter mice, all cells express membranous TdTomato (clearly 
outlining hepatic architecture) apart from HSC, which express mGFP. Pdgfrb-Cre mice 
were also crossed with Ai14 reporter mice (a single fluorescent reporter that expresses 
TdTomato after recombination).484 In these animals, HSC TdTomato fluorescence is 
cytoplasmic, clearly demonstrating HSC morphology. MacGreen mice were crossed with 
Alb-Cre animals, allowing visualization of liver macrophages in green. Alb-Cre x confetti 
mice were used in the HCC model. The confetti mouse uses the Brainbow-2.1 construct, 
in which two invertible units are positioned in tandem.487 Cre-mediated excision can 
therefore yield a total of four expression possibilities: RFP, yellow fluorescent protein 
(YFP), cyan or GFP. In Alb-Cre x confetti animals, hepatocytes stochastically express a 
fluorescent protein. In our experience, a proportion of cells express two fluorescent 
proteins, which may be explained by hepatocytes possessing multiple nuclei, resulting 
in more than one confetti construct per cell, or this may be secondary to Alb-Cre mice 
expressing Cre constitutively. We also observed minimal GFP reporting, which is 
consistent with the literature.   
For all reporter mice, fluorescent MP microscopy was first performed ex vivo, to optimise 
laser settings. Uninjured animals were culled, livers harvested and imaged immediately 
in a petri dish. Figure 5.7 shows preliminary ex vivo images of uninjured PDGFRβCre+/-
;mTmG liver.  
 
Figure 5.8 shows in vivo IVM of PDGFRβCre+/-;mTmG. Imaging was undertaken under 
terminal anaesthesia. High resolution images were obtained, over a period of one hour. 
Initially a tile was taken to see how the liver was fixed below the AIW, and to allow 
selection of areas to take Z stack images from.  
After establishing optimal laser settings for imaging the PDGFRβCre+/-;mTmG line, the 
same experiments were performed in a model of chronic liver injury. CCL4-treated mice 
were culled, and whole liver immediately imaged in a dish. Tiles and z stacks obtained 






Figure 5.7 Uninjured PDGFRβCre+/-;mTmG liver ex vivo 
A Uninjured PDGFRβCre+/-;mTmG mouse liver. Harvested whole liver imaged in a dish 
with MP microscope. Images taken at level of capsule and just below, with SHG 
demonstrating mature collagen fibrils (cyan, white arrows). HSC seen in green (green 
arrows) in close association with collagen. B Z stack images, from the same liver, starting 






nodular, and uneven, resulting in black ‘holes’ in the tile (Figure 5.9 A). Expansion of 
GFP reporting around blood vessels was observed, due to marked HSC activation in 
response to injury, which also corresponded with increased SHG signal from collagen 
deposition. These and in vivo images (Figure 5.10) illustrate the utility of this reporter to 
characterise HSC location and morphology in relation to scar formation and parenchymal 










Figure 5.8 Timelapse IVM of uninjured PDGFRβCre+/-;mTmG mouse liver under 
terminal anaesthesia 
Sequential stills from timelapse imaging of uninjured PDGFRβCre+/-;mTmG mouse liver 
under terminal anaesthesia. High resolution images were acquired over one hour. The 
mTmG reporter allowed characterisation of liver sinusoids and parenchymal architecture. 
All cell membranes (other than HSC, labelled with GFP) were labelled with RFP. It is 
hypothesised that this transgenic mouse might have some platelets labelled with GFP, 
(due to platelets transiently expressing PDGFR), which would account for small 
fluorescently labelled fragments flowing in large blood vessels. Work to determine the 






Figure 5.9 CCL4-injured PDGFRβCre+/-;mTmG ex vivo  
A (i) PDGFRβCre+/-;mTmG liver in a dish, after 4 weeks CCL4 treatment. Tile showing 
fibrotic nodular liver with HSC expansion around blood vessels and collagen deposition. 
(ii) Z stack image through same liver. B Higher magnification images of CCL4-treated 





Figure 5.10 Intravital imaging of CCL4-injured PDGFRβCre+/-;mTmG mice  
A (i) Image from chronic CCL4-injured PDGFRβCre+/-;mTmG mouse; timelapse in vivo 
imaging under terminal anaesthesia. (ii) CARS channel of the timelapse image, showing 
blood-flow through a vessel. B Sequential Z stack images (left to right) from the same 
mouse imaged in vivo, from capsule to liver parenchyma. Bottom panel shows 
corresponding CARS channel image.  
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Next, experiments were repeated using a model of acute liver injury, to examine 
activated HSC expansion and investigate the ability of CARS to show features of 
parenchymal damage. Images were taken four hours after IP injection of anti-Jo2 
antibody. Ex vivo images (Figure 5.11) show HSC accumulation in close association with 
the collagen-rich liver capsule. Parenchymal damage was visible with destruction of 
hepatocyte architecture, and disruption of RFP membranous fluorescence, which 
corresponded with areas of haemorrhage depicted by an increase in grey CARS signal. 
Furthermore, CARS demonstrated an increase in hepatocyte lipid droplet content (bright 
white dots) which is known to occur in acute injury. The quality of in vivo timelapse 
imaging using this model was limited by movement artefact from respiration (Figure 
5.12). This was potentially at least partly secondary to the severity of systemic illness in 
these animals, resulting in more gasping respiratory efforts. Subsequent in vivo imaging 
of acute liver injury was therefore largely focused on the paracetamol model, at well-
characterized doses, known to induce hepatic injury with minimal systemic upset. Where 
anti-Jo2 antibody was used, the slightly earlier time point of three hours post-injection 




Figure 5.11 Jo-2 antibody-injured PDGFRβCre+/-;mTmG liver ex vivo 
Whole liver harvested and imaged in a dish with MP microscope. Images from a single 
Z stack are shown, sequentially from liver capsule (top left) to deeper within parenchyma. 
Top panel shows fluorescent reporters and SHG; bottom panels show corresponding 
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CARS image. HSC expansion is visible following injury (green). Loss of hepatic 
architecture is seen with a paucity of red membranous fluorescence, particularly as depth 





Figure 5.12 Timelapse IVM of Jo-2 antibody-injured PDGFRβCre+/-;mTmG liver 






Having established that surgical abdominal window implantation and imaging under 
terminal anaesthesia was successful, we envisaged that longer imaging periods might 
be desirable to capture cellular events, for example HSC movement, hepatocyte division 
and hepatocyte necrosis. The PDGFRβCre+/-;Ai14 reporter mouse was used in this set 
of experiments. This mouse labels HSC with TdTomato fluorescence.  
Figure 5.14 shows consecutive stills from in vivo timelapse imaging of uninjured liver. 
Erythrocytes are seen clearly with strong CARS signal, in a large blood vessel. The liver 
was imaged for a total of three hours (all timelapse imaging) in the same field of vision. 
Although no specific HSC movements were visualized during this period, the cytoplasmic 
Ai14 fluorescence was extremely strong, and was not compromised by photobleaching, 
confirming the utility of this reporter for in vivo studies. The main limitation of this 
approach was intermittent loss of the water bubble between the microscope objective 
and the specimen, resulting in degradation of images and necessitating a pause to 
replenish the water bubble.  
Once the results of these experiments had been presented to the veterinary team, it was 
possible to proceed with experiments involving recovery after abdominal window 
surgery, rather than immediate imaging under terminal anaesthesia.   
 
In line with the suggested Home Office pilot studies, we assessed the effects (on animal 
welfare and imaging quality) of the mice having AIWs in for increasing lengths of time. 
Figure 5.16 shows timelapse IVM of PDGFRβCre+/-;Ai14 liver, in which the AIW was 
surgically placed two weeks previously. Animals (n=2) were allowed to recover after 
window surgery, and had free access to food and water. The AIW coverslip was changed 
under brief anaesthesia every 48-72 hours. At two weeks they received IP anti-Jo2 
antibody and were imaged three hours later. The resulting images remained of high 





Figure 5.13 PDGFRβCre+/-;Ai14 liver ex vivo 
Whole liver harvested and imaged in a dish with MP microscope. A Tile of uninjured liver 
showing relatively sparse HSC expressing cytoplasmic Td tomato B High magnification 
image of chronic CCL4-injured liver, at level of liver capsule (shown with cyan SHG) with 
high density of HSC. C Jo-2 antibody liver parenchyma (3 hours post-IP injection) 
showing marked HSC accumulation. D Jo-2 antibody-injured liver parenchyma with 








Figure 5.14 IVM of PDGFRβCre+/-;Ai14 mouse under terminal anaesthesia 
Sequential stills from timelapse imaging. Top panel shows fluorescent reporter and 




Figure 5.15 IVM of uninjured PDGFRβCre+/-;Ai14 liver capsule under terminal 
anaesthesia   
Sequential stills from timelapse. Collagen-rich capsule shown using SHG, with high 











Figure 5.16 IVM of Jo-2 antibody-injured PDGFRβCre+/-;Ai14 liver under terminal 
anaesthesia 
Sequential stills from timelapse imaging. Top panel shows fluorescent reporter; lower 
panel shows corresponding CARS image. Animals imaged two weeks after AIW surgery. 
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Aiming to image a single mouse multiple times throughout the hepatic regenerative 
process, the next experiment was designed to sequentially image macrophages and 
their spatial relationship to collagen scar. The CCL4 model of chronic liver injury was 
therefore used. Imaging of MacGreen mice was undertaken over consecutive days, 
following cessation of chronically-administered (twice weekly for four weeks) CCL4 
injections. In this experiment, animals underwent AIW surgery and in vivo imaging 48 
hours after their last CCL4 injection. They were allowed to recover after this first imaging 
session, then anaesthetized and imaged again the following day (Figure 5.17 A(i-iii)). In 
this preliminary experiment, the animals only underwent in vivo imaging on two days. 
However livers were also imaged ex vivo (48 hours and one week after the last CCL4 
injection); figure 5.7.11 B(i) shows a high density of macrophages around the collagen 
scar in the early time point. At one week, the macrophages appeared more uniformly 
distributed throughout the parenchyma. This highlights the utility of this approach for 
investigating immune cell migration during the fibrotic response.  
 
Finally, to assess the potential utility of our AIW system to image cellular processes 
during hepatocarcinogenesis, we performed IVM of DEN-induced HCC. Figure 5.18 
shows a macroscopic image of an HCC within a harvested liver. In this experiment, 
AlbCre+/-;Confetti mice were used, in which hepatocytes express RFP, GFP, cyan or YFP 
as detailed above. Initial ex vivo images taken using the MP microscope demonstrated 
a number of cells expressing fluorescent proteins, which morphologically looked more 
like HSC than hepatocytes. This was captured at high magnification and resolution 
(Figure 5.18 C) and it was postulated that this could represent epithelial-mesenchymal 
transition within the tumour. Other ex vivo images obtained showed large patches of 
fluorescent cells, although at times there was degradation of fluorescence raising the 
possibility of necrosis within the tumours affecting fluorophore expression. Figure 5.19 
demonstrates that it was possible to place an AIW on an area of HCC and perform IVM. 
The CARS images provide evidence that this technique could, for example, be used to 





Figure 5.17 Serial imaging of CCL4-injured MacGreen liver 
A (i) Still from timelapse, in vivo imaging, day 1 post-chronic CCL4 treatment. (ii) and 
(iii) Still from the same animal, imaged again in vivo the following day. B Ex vivo 
images of liver in a dish. Images reconstructed using imaris software. (i) Day 1 post-
chronic CCL4 treatment. Collagen scar (SHG) visible, with high macrophage density. 
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Lower panel image shows fat infiltration, assessed using CARS. (ii) Day 7 post-chronic 
CCL4 treatment. Macrophages appear more evenly spread throughout the parenchyma, 





Figure 5.18 MP microscopy of DEN-induced HCC ex vivo 
A Macroscopic image of HCC ex vivo B AlbCre+/-;Confetti liver in a dish, harvested 10 
months after DEN injection. High resolution image of liver tumour, including CARS 
channel showing fat droplets within the tumour. Yellow cells with apparent HSC 
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morphology likely represent EMT within the tumour. C Higher magnification image of 





Figure 5.19 IVM of DEN-induced HCC under terminal anaesthesia 
Sequential stills from timelapse of AlbCre+/-;Confetti liver imaged in vivo, 10 months after 




The experiments presented above demonstrate that it is feasible to image mouse liver 
in vivo, via an AIW, in a broad range of different liver injury models. An extensive range 
of fluorescent reporter mice were used, in order to allowing imaging of multiple hepatic 
cell lineages. This is, to our knowledge, the first time this method has been employed in 
the UK. We therefore had to perform a series of pilot experiments, to prove the surgery 
and imaging were well tolerated by the mice. For each reporter mouse strain we began 
with imaging liver ex vivo to optimize microscope settings for detection of the specific 
fluorescent report in that particular strain of mouse. We progressed to live imaging under 
terminal anaesthesia, imaging animals after having a window in for up to 2 weeks, and 
finally imaging on consecutive days. The results were then presented to the veterinary 
Home Office team. As the animals recovered from window surgery rapidly, and tolerated 
subsequent anaesthesia and imaging well, we then incorporated induction of acute liver 
injury into our protocols, namely paracetamol overdose or partial hepatectomy. The 
development and utilization of these IVM models will be discussed in the following 
chapter.  
Throughout these experiments, surgical and imaging techniques were further refined and 
optimised. I found that imaging quality was highly dependent on how successful AIW 
surgery was. This improved significantly with experience. Initially, there were two cases 
of wound dehiscence and therefore dislodgement of the AIW, necessitating culling of the 
animal. This was prevented by improvement in accurately sizing the laparotomy incision, 
and better placement of the purse string suture. Other than these initial complications 
relating to surgery, there were no problems with maintenance of the AIW in live animals; 
specifically the coverslips never cracked or dislodged in between imaging sessions, and 
no mice developed sepsis. Occasionally in early experiments, too little glue was used to 
fix the liver to the AIW, resulting in poor images. Achievement of a tight seal with tissue 
glue was imperative, to prevent introduction of fluid from the peritoneal cavity into the 
space below the coverslip, which restricted views and imaging quality. I also found that 
placing the AIW on the large left lobe of the liver (as opposed to the median lobe) 
minimized movement artefact. Pre-treatment of the coverslip with PEG solution prior to 
AIW placement was also critical to avoid thick biofilm development, rendering imaging 
impossible. For sequential imaging, the AIW design was modified to include a domed 
underside, for better apposition to the liver surface.  
During imaging, I found that low-flow anaesthesia helped reduce respiratory movement-
induced artefact, which was consistent with the findings of Akbari et al.473 In conjunction 
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with saline boluses at the start and end of imaging, the low-flow anaesthesia also aided 
recovery (typically animals were feeding and grooming within ten minutes of finishing 
imaging sessions). Fixation of the animal in the imaging box was also important in 
reducing movement artefact. Therefore, we designed an improved base plate for the 
box, which has a more secure fixation mechanism. 
Experiments in which the animals were maintained for a week or more with an AIW in 
situ allowed us to gain experience in deciding how often the coverslip requires to be 
changed during sequential IVM of the liver. We usually replaced the coverslip every 48-
72 hours as longer intervals resulted in the development of a thick biofilm that could not 
be safely removed. At the start of imaging, the liver was examined using epifluorescence. 
If views were poor, the coverslip was removed (under anaesthesia and using aseptic 
technique) and the exudate on the liver surface gently teased away with a needle and 
saline washes. There were some initial problems with haemorrhage during this 
procedure, but with increasing operator experience this was minimised.  
Timelapse imaging was often briefly limited by loss of the water droplet between the 
objective and the AIW. At times this occurred every five to ten minutes. This interval was 
lengthened by ensuring as tight a seal as possible (by optimising fixation of the animal 
with the imaging box) and by extra hair removal around the AIW (using hair removal 
cream as well as clippers) to prevent wicking away of the water droplet.  
Overall, I have shown here that intravital imaging of the liver can be performed, via an 
AIW, multiple times in the same animal. To the best of our knowledge, this is the first 
time this has been achieved in the UK. Use of specific fluorescent reporter mice, coupled 
with label-free microscopy techniques allows interrogation of different hepatic cell 
lineages and their interactions with other cell types and the microenvironment. I have 
extensively characterised a number of different transgenic reporter mice strains, 
particularly those in which HSC and hepatocytes express fluorescent proteins, to inform 
subsequent longer term experiments focusing on cellular behaviour during acute liver 
injury and regeneration.  
Furthermore, I have demonstrated that it is feasible to image DEN-induced HCC in vivo, 
via an AIW. As previously discussed, the DEN model is a well-established method of 
studying HCC. To the best of our knowledge, mature tumours from this model have not 
previously been imaged in vivo; this provides a novel opportunity to undertake 
experiments designed to unpick subtle differences in tumour biology and blood flow, that 
may only be detectable using an IVM system, and may also allow in-depth study of 
targeting and efficacy of novel chemotherapeutic agents, in the setting of HCC.  
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In summary, I have acquired significant experience in IVM, and have developed new 
protocols for real-time, sequential imaging of the mouse liver in a range of different injury 
models for the first time. The data presented serve as a strong platform on which to base 














Chapter 6: Intravital imaging of paracetamol-induced acute liver injury 
6.1 Introduction 
IVM experiments studying acute liver injury have, to date, been performed by 
exteriorization of the liver, or similar methods, allowing at most one or two short duration 
microscopy sessions. As discussed in the previous chapter, I hoped to develop a mouse 
model in which acute liver injury could be studied in vivo, sequentially, throughout the 
course of liver injury and repair. I was confident that the AIW approach would allow this; 
in particular, from my preliminary IVM experiments, I had established that crossing 
mTmG mice with cell specific promoters allowed clear identification of liver architecture, 
as well as cells of interest. In view of evidence suggesting LSEC take up paracetamol 
directly, I was also interested in using reporter mice in which I could image the 
microvasculature during liver injury, perhaps allowing quantification of angiogenesis 
around necrotic tissue. I therefore designed a series of experiments to first establish that 
the mice could tolerate acute liver injury and imaging following abdominal surgery, and 
then to confirm that parameters of damage and regeneration were similar with, and 
without, an AIW in situ. These will be presented in the following results section, along 
with subsequent sequential imaging experiments, using a number of different fluorescent 
reporter mice.  
 
6.2 Aims 
 To develop a protocol for sequential (daily) IVM of the liver, throughout the course 
of paracetamol-induced acute liver injury and recovery in the mouse 
 To characterise the inflammatory infiltrates and regenerative response in 
paracetamol-induced liver injury in mice, with and without, an AIW 
 To image fluorescent reporter mice strains in vivo, throughout the course of acute 
liver injury, aiming to capture images of the necrotic areas, surrounding 
vasculature and local blood flow.  
6.3 Materials and methods  
 
Animals 
Animal details are as previously stated (section 5.3). Additionally, for use in the following 
experiments, Cdh5-cre-ERT2 mice (Tg(Cdh5-cre/ERT2)1Rha)393 were crossed with 
Ai14 (B6;129S6-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J)484 or mTmG (B6.129(Cg)-
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J)485 mice, obtained from Jackson 
 
167
Laboratories. Cre recombinase was induced by tamoxifen injection. Tamoxifen was 
prepared in corn oil (20mg/ml) and given IP 100mg/kg daily for three days, followed by 
three days of rest, then daily for three days.  
Lastly, Pdgfrb-BAC-eGFP reporter mice (on a C57/Bl/6 background) were crossed with 
mTmG mice, and Cdh5Cre+/-;Ai14 mice. Pdgfrb-BAC-eGFP (Tg(Pdgfrb-
EGFP)JN169Gsat)234 animals express one copy of a BAC transgene expressing eGFP 
under the control of Pdgfrb regulatory elements.   
 
Immunohistochemistry on mouse liver specimens 
Paraffin-embedded sections were processed for immunohistochemistry as described 
previously. For BrdU staining, mice were injected with 100mg/kg BrdU (Roche 
10280879001, Sigma) IP, two hours before tissue harvesting. Tissue was fixed in 
methacarn prior to paraffin embedding. For BrdU IHC, briefly, tissue sections were 
deparaffinised, and exposed to 0.3% hydroxen peroxide in deionised water for 10 
minutes to block endogenous peroxidase. They were then treated with hydrochloric acid, 
and incubated with trypsin 0.1% for 20 minutes. Slides were washed with 0.1M sodium 
tetraborate decahydrate (Sigma S9640) and then PBS, before blocking with M.O.M. 
mouse Ig blocking reagent (Vector Laboratories, PK2200). The primary antibody, mouse 
anti-BrdU (Dako M0744) was applied (1:40 dilution in M.O.M diluent) for 30 minutes at 
room temperature. The secondary antibody was M.O.M. biotinylated anti-mouse IgG 
reagent, diluted 1:250 in M.O.M. diluent, and left for 10 minutes at room temperature. 
DAB reagent was then applied, followed by counterstaining with Harry’s Haematoxylin 
and dehydration through alcohols as previously described.  
 
For GR1 staining, 1:750 rat monoclonal anti-GR1 (RND Mab 1037) was used as the 
primary antibody (left overnight) and 1:1000 goat anti-rat biotinylated IgG, (mouse 
adsorbed, Vector 1928) was the secondary antibody (incubated for 30 minutes at room 
temperature). No antigen retrieval step was required in this protocol.  
 
Image analysis of immunostained sections 
Microscopic examination of tissue specimens and digital image analysis was performed 
as described in section 2.4.3. Quantification of regeneration index was performed by 
direct cell counting (of BrdU positive hepatocytes, and total number of hepatocytes) from 
20 consecutively selected high-powered fields (x20 magnification) from each liver 
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section. Hepatocyte regeneration index was calculated by: BrdU positive 
hepatocytes/total number of hepatocytes x 100.  
Twenty consecutive high-powered fields from each GR1-stained liver section were also 
acquired. Number of GR1-positive cells (with characteristic neutrophil morphology) was 
counted for each high-powered field, and an average number of positive cells/field 
calculated for each liver.  
 
Induction of liver injury 
For experiments investigating the effect of AIW insertion on paracetamol-induced liver 
injury, animals underwent AIW implantation surgery (as described in section 5.3). The 
night after surgery, they were allowed to recover, with food and water provided ad libitum. 
The following evening, they were fasted for 12-16 hours, then injected with 300mg/kg IP 
paracetamol. Control animals did not undergo AIW insertion, but were fasted at the same 
time, and received the same dose of paracetamol. Animals were then culled at either 24 
hours, 48 hours, or one week. One lobe from each liver was fixed in 10% formalin. For 
BrdU staining, one lobe was fixed in methacarn.  
Serum was stored at -80°C. ALT and other liver function test analyses were performed 
as described in section 4.5 
For sequential imaging, (Figure 6.1), animals underwent AIW implantation surgery, then 
allowed to recover overnight. The following evening they were fasted for 12-16 hours, 
then underwent baseline imaging under general anaesthetic. Imaging sessions lasted 
up to one hour. Animals were given supplementary IP saline at the start of imaging, then 
were injected IP with 300mg/kg paracetamol at the end of the imaging session. 
Subsequent imaging sessions were performed 24 hours later, up to a maximum of three 












6.3 Characterisation of injury and inflammatory infiltrate following paracetamol 
administration, with and without abdominal window 
In these experiments, animals with, and without an AIW received 300mg/kg paracetamol 
after an overnight fast. Animals were harvested at 24 hours, 48 hours, or one week, and 
markers of injury, HSC (PDGFβ), neutrophils (GR1) and regeneration (BrdU) were 
quantified.  
 
Severity of paracetamol-induced liver injury is similar in animals with an AIW, to 
non-operated controls 
Figure 6.2 shows liver function tests and quantification of injury at each time point. At 24 
hours, (n=6 in each group) mean percentage necrosis was 45.75 + 4.80 in controls, and 
45.25 + 3.10 in AIW animals, which was not significantly different (p=0.93). Similarly, at 
48 hours, (n=4 in each group) mean percentage necrosis was not significantly different 
between groups (24.65 + 5.89 in controls, 27.46 + 5.25 with AIW, p=0.73). At one week, 
liver architecture had recovered, and there were no clear areas of necrosis to quantify. 
This was consistent with ALT levels, which had also returned to normal (27 + 2.61 vs 
28.5 + 6.51, p=0.84).  
Serum ALT at 24 hours was 5248 + 856 in controls, and 4745 + 952.8 in the AIW group 
(no difference, p=0.70). At 48 hours serum ALT had dropped to 472.5 + 180.3 in controls, 
and 293.5 + 49.16 in window mice. This was not significantly different (p=0.70, n=4 in 
each group).  
Other liver function tests were all comparable at each time point, apart from ALP at 48 
hours, which was higher in controls than AIW mice (175.3 + 14.59 vs 108 + 7.62, 
p=0.007). This is of uncertain significance.  
 
Hepatic regeneration following paracetamol-induced liver injury is similar in 
animals with an AIW, to non-operated controls 
BrdU-incorporation was quantified at 24 and 48 hours (Figure 6.3). At 24 hours, 
percentage BrdU-positive hepatocytes was 0.36 + 0.12 in controls, and 0.83 + 0.50 in 
AIW animals, p=0.34, n=6 in each group. At 48 hours, this had increased to 5.85 + 1.46 
in controls and 7.47 + 2.29 in AIW mice (p=0.57, n=4 in each group).  
Liver to body weight ratio was also similar at one week, suggesting liver regeneration is 






Figure 6.2 Paracetamol-induced acute liver injury with and without an AIW in situ 
A Comparison of liver histology (H and E) between animals with an AIW and non-
operated controls, following 300mg/kg IP paracetamol, at (i) 24 hours, (ii) 48 hours, and 
(iii) 1 week; (x5 magnification). B Graph showing percentage necrosis at 24 and 48 hours 
post-paracetamol, for AIW and control animals (n=6 in each group at 24 hours, n=4 in 
each group at 48 hours and 1 week). Graph below shows there was no difference in 
liver:body weight ratio at 1 week (n=4 in each group). C Graphs showing similar serum 
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bilirubin and liver enzyme levels at 24 hours, 48 hours and 1 week, in animals with an 





Figure 6.3 The hepatic regenerative response following paracetamol-induced 
acute liver injury, with and without an AIW in situ 
 A Comparison of BrdU staining positivity between animals with an AIW and non- 
operated controls, following 300mg/kg IP paracetamol at (i) 24 (n=6 each group) 
and (ii) 48 hours (n=4 in each group); x20 magnification. B Graph showing percentage 
BrdU positivity at 24 and 48 hours post-paracetamol.   
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6.4 Characterisation of quiescent and activated HSC and neutrophil infiltrate 
following paracetamol-induced acute liver injury in animals with an AIW, and non-
operated controls 
PDGFRβ staining positivity was calculated at 24 hours, 48 hours and one week following 
paracetamol-induced liver injury (Figure 6.4). At 24 hours, percentage staining positivity 
per low-powered photomicrographic field was 4.21 + 0.39 in controls, and 5.32 + 0.66 in 
AIW animals (p=0.20, n=5 controls, n=6 AIW). At 48 hours this had risen to 11.66 + 2.68 
and 9.26 + 1.32 in controls and AIW mice respectively. This was not significantly 
different, p= 0.45 (n=4 in each group). By one week, PDGFRβ percentage positivity had 
reduced to 7.16 + 0.78 in controls, and 5.81 + 1.25 in the AIW group, which was again 
not significant, p=0.38 (n=4 controls, n=3 AIW group).  
 
GR1 staining positivity was also calculated at 24 hours, 48 hours and one week following 
paracetamol-induced liver injury (Figure 6.5). At 24 hours, mean number of GR1-positive 
cells per high-powered field was 13.14 + 1.13 in controls, compared with 20.24 + 3.68 in 
AIW animals. This was significantly different (p=0.003, n=6 controls, n=5 AIW group). By 
48 hours this difference had disappeared; GR1 positivity had reduced to 11.41 + 2.21 in 







Figure 6.4 PDGFRβ staining positivity following paracetamol-induced acute liver 
injury, with and without an AIW in situ 
A Comparison of PDGFRβ staining positivity between animals with an AIW and  
non-operated controls, following 300mg/kg IP paracetamol at (i) 24 hours (n=5 
controls, n=6 AIW) (ii) 48 hours (n=4 in each group) and (iii) 1 week (n=4 controls and 
n=3 AIW). x5 magnification. B Graph showing percentage PDGFRβ staining positivity, 




Figure 6.5 GR1 staining positivity following paracetamol-induced acute liver 
injury, with and without an AIW in situ  
A Comparison of GR1 staining positivity between animals with an AIW and non-operated 
controls, following 300mg/kg IP paracetamol at (i) 24 hours (n=6 each group) (ii) 48 
hours (n=4 in each group) and (iii) 1week (n=4 in each group). x20 magnification. B 
Graph showing number of GR1 positive cells per high-powered field (HPF), for AIW and 
control animals, at 24 hours, 48 hours and 1 week.   
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6.5 Sequential daily imaging of paracetamol-induced acute liver injury 
 
Paracetamol-injured Cdh5Cre+/-;Ai14 liver ex vivo 
In Cdh5-Cre mice crossed with Ai14 reporter mice, LSEC express TdTomato. Initially, 
imaging after paracetamol-induced liver injuy was performed ex vivo. Whole liver was 
imaged in a dish, to optimise MP microscope settings, and characterise the appearance 
of necrotic areas with this reporter. Figure 6.6 shows uninjured and injured liver 
specimens. There was more autofluorescence in necrotic areas (seen in green in Figure 
6.6 B (i)) and I originally hypothesised that this could be used for daily quantification of 
the necrotic area. However, significant background levels of hepatic autofluorescence 
meant that it was not possible to clearly distinguish between areas of injury and normal 
tissue. This transgenic mouse strain did, however, label LSEC extremely efficiently, 
which would be adequate for quantitative analysis of the vascular networks (Figure 6.6 
B (ii) around areas of necrosis.  
 
IVM of paracetamol-injured Cdh5Cre+/-;Ai14 liver  
In the following experiment (Figure 6.7) animals underwent AIW implantation, followed 
by IP paracetamol (300mg/kg) as per Figure 6.1. IVM was performed daily for three days. 
At each imaging timepoint, a tiled multisite image was acquired, as well as several Z 
stacks. 24 hours post-paracetamol, Z stacks were obtained from areas that appeared 
necrotic (referring back to the multisite tile to identify regions of interest). Figure 6.7 
shows images taken at baseline and 24 hours after paracetamol. High magnification 
CARS images show centrilobular hepatocyte disruption post-injury.  
 
Figure 6.8 shows timelapse IVM under anaesthesia, from a Cdh5Cre+/-;Ai14 animal, 24 
hours post-paracetamol. Here, an area of necrosis was initially identified from a multisite 
tile; a single high magnification image was then obtained, confirming there was some 
hepatocyte damage using CARS. A timelapse of the area was then performed, over three 
minutes. Blood vessel outline could be clearly seen with this Cdh5Cre+/-;Ai14 reporter, 




Figure 6.6 Paracetamol-injured and uninjured Cdh5Cre+/-;Ai14 liver ex vivo 
A Multisite tiled images of (i) uninjured and (ii) 24 hours post paracetamol-injured 
(350mg/kg) liver. B (i) Image from Z stack through necrotic area in paracetamol-injured 
liver (imaged in a dish). (ii) Reconstructed vascular network, from a small section of the 





Figure 6.7 Serial IVM of Cdh5Cre+/-;Ai14 mouse at baseline and 24 hours post-
paracetamol, under anaesthesia 
A Multisite tile of baseline (i) and injured (ii) liver, taken under anaesthesia. B Image 
taken from Z stack through liver (under anaesthesia) from (i) uninjured liver and (ii) 24 
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hours post-paracetamol, in an area of necrosis. Top panel shows CARS image, with 
hepatocyte damage visible in (ii). Lower panel shows corresponding red channel 





Figure 6.8 Timelapse IVM of Cdh5Cre+/-;Ai14 mouse 24 hours post-paracetamol, 
under anaesthesia 
A Single high magnification image of area of hepatocyte necrosis (RFP and CARS 
channel shown). B Sequential stills from timelapse imaging of same area over three 




IVM of paracetamol-injured Cdh5Cre+/-Ai14;PDGFRβ-BAC-eGFP liver 
Serial IVM before and after paracetamol-induced acute liver injury was also performed 
in Cdh5PBAG animals. In this fluorescent reporter mouse strain, LSEC are labelled red 
with Td tomato, and HSC are labelled with GFP. Figure 6.9 A shows multisite tiles from 
the same animal, taken by IVM under anaesthesia, (i) at baseline, (ii) 24 hours post-
paracetamol and (iii) 48 hours post-paracetamol. This reporter strain allowed 
interrogation of HSC spatial relationship to LSEC (Figure 6.9 B and C).  
 
IVM of paracetamol-injured Cdh5Cre+/-;mTmG liver 
Finally, serial IVM was performed on paracetamol-injured Cdh5Cre+/-;mTmG animals. 
Here, LSEC are labelled with GFP, and all other cells express membranous RFP. Figure 
6.10 A shows multisite tiles taken at 24 and 48 hours post-paracetamol. Figure 6.10 B 





Figure 6.9 Serial IVM of Cdh5+/-Ai14;PDGFRβ-BAC-eGFP mouse, performed under 
anaesthesia, before and after paracetamol-induced acute liver injury 
A Multisite tiled images taken (i) at baseline, (ii) 24 hours post-paracetamol (300mg/kg) 
and (iii) 48 hours post-paracetamol. B 3D reconstructed image (generated from a Z stack 
using Imaris software), showing HSC and LSEC orientation.  
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C Sequential stills from a high magnification timelapse, showing blood flowing through a 





Figure 6.10 Serial IVM of Cdh5Cre+/-;mTmG mouse, under anaesthesia, following 
paracetamol-induced acute liver injury 
A Multisite tiles taken (i) 24 hours and (ii) 48 hours post-paracetamol induced acute liver 
injury (300mg/kg). B Single images taken from three separate Z stacks, acquired from 





The serial IVM experiments presented above confirm that it is possible to perform daily, 
live imaging on a mouse undergoing paracetamol-induced liver injury. I initially 
completed a set of experiments investigating parameters of injury, regeneration and 
inflammation, in animals undergoing paracetamol-induced liver injury, with and without 
an AIW. This was to ensure that the window itself or abdominal surgery did not 
significantly affect hepatic damage, regeneration or inflammation in this model. Injury 
was assessed by quantification of necrotic area on H and E liver sections, and ALT. This 
was similar in both groups at 24 hours, 48 hours and one week. The only liver enzyme 
difference observed was in ALP, which was significantly lower in control animals at 48 
hours. This relevance of this is uncertain, and unlikely to represent a major clinical effect. 
Regeneration, as assessed by BrdU staining and liver:body weight ratio at one week, 
was similar in both groups. PDGFRβ staining was also similar in each group. At 24 hours 
post-paracetamol, the neutrophil marker GR1 was slightly higher in the AIW group than 
controls. This is unsurprising, and may represent part of the acute response to abdominal 
surgery. Interestingly this effect had dissipated by 48 hours, and did not seem to affect 
injury or repair. Future work to fully characterise the inflammatory infiltrate in this setting 
could include assessment of macrophage presence at the different timepoints, by F4/80 
immunohistochemistry. 
 At a dose of 300mg/kg, mice tolerated liver injury and daily imaging sessions (performed 
for up to three days). Imaging sessions typically lasted up to an hour, but it is anticipated 
that longer sessions could be performed if necessary, with intermittent saline boluses 
given SC, to replace insensible fluid losses. As previously, liver from a Cdh5+/-;Ai14 
reporter mouse was initially imaged ex vivo, to optimize the microscope settings for 
imaging, and obtain preliminary pictures of paracetamol damage in this strain. These 
confirmed that recombination was good, and that images were adequate for performing 
downstream analysis of the microvasculature using Imaris software.  
After several serial IVM experiments using different reporter strains, it was established 
that imaging quality was mostly dependent on surgical factors and movement artefact 
from respiration. This improved with increasing experience and use of low-flow 
anaesthesia. Usually, six mice underwent AIW surgery at the start of a week-long 
experiment. This number was to ensure that there were sufficient animals available to 
trial red blood cell labelling, which was being optimized. Furthermore, occasionally the 
glue seal between the liver surface and the AIW was slightly suboptimal, meaning that 
images were slanted, and quality was not maintained throughout the week. At most 
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imaging sessions, the AIW insert was removed, and the liver surface flushed with saline. 
The coverslip was replaced, preventing significant biofilm development. Operating on six 
animals at the start provided a good sample size to obtain serial images and test IVM 
techniques such as red blood cell labelling.  
Future work with this model includes optimising image analysis, to fully harness the 
potential of the different transgenic reporter mice strains. In particular, animals with 
LSEC fluorescent reporting are excellently suited to the quantification of vascular 
networks, sequentially during liver injury and repair. Improved AIW and imaging platform 
designs are expected to further increase the quality of in vivo imaging. It is hoped that 
this in vivo approach to studying acute liver injury can now be successfully applied to 
other models, such as partial hepatectomy, allowing comparison of different pathological 





This research project began with an investigation into the role of αv integrins in a mouse 
model of HCC. It is proposed that loss of αv integrins on HSC or hepatocytes does not 
affect hepatocarcinogenesis in the DEN mouse model of HCC. This was an unexpected 
finding, but perhaps reflects the complexity of TGF-β effects in tumourigenesis. 
Evaluation in a cirrhotic model of HCC would complement these experiments.  
The role of αv and β8 integrins on HSC and hepatocytes were then investigated in the 
context of paracetamol-induced acute liver injury. Integrin loss on HSC or hepatocytes 
did not confer protection in this model. During these experiments I gained valuable 
expertise in the paracetamol model, and was able to contribute animal data to the work 
of other researchers, resulting in publication. 
The key output from this research project, however, has been the development of IVM 
of the liver, and the design and implementation of a new protocol for daily in vivo imaging 
of paracetamol-induced acute liver injury. To our knowledge, this is the first time IVM of 
mouse liver using an AIW has been performed in the UK, and the first time acute liver 
injury has been imaged daily in vivo through a window. Similarly, I have shown that it is 
feasible to image HCC in this fashion. Together with other members of Neil Henderson’s 
lab, we have developed and optimised protocols for in vivo imaging; this is currently 
approaching a point at which we can begin to answer questions about injury and repair. 
For example, whilst targeted inhibition of integrins on HSC did not confer protection in 
paracetamol hepatotoxicity, I was interested in whether depletion of HSC throughout the 
course of acute liver injury might influence hepatic injury or regeneration. Using an IVM 
approach, and genetic targeting of HSC, sequential imaging throughout paracetamol-
induced liver injury could allow detailed investigation of this research question, with 
quantification of interactions between different cells, and interrogation of interactions with 
the microenvironment, made possible by cell-specific fluorescent reporting and label-free 
imaging techniques.  
Ultimately, however, we aim to publish our findings from our use of serial IVM in two 
different models of acute liver injury. Accordingly, results from sequential in vivo imaging 
of both paracetamol overdose and partial hepatectomy will be presented. This will be 
performed in transgenic mice in which hepatocytes express a distinct fluorophore 
depending on which stage of the cell cycle they are in, allowing assessment of 
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